---
document_datetime: 2023-11-30 12:00:01
document_pages: 163
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/zynrelef-epar-public-assessment-report_en.pdf
document_name: zynrelef-epar-public-assessment-report_en.pdf
version: success
processing_time: 109.2017328
conversion_datetime: 2025-12-21 20:21:57.355664
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

23 July 2020 EMA/CHMP/450646/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report ZYNRELEF International non-proprietary name: bupivacaine / meloxicam Procedure No. EMEA/H/C/005205/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

Official address

Domenico Scarlattilaan 6

Address for visits and deliveries

●

1083 HS Amsterdam

●

The Netherlands

Refer to www.ema.europa.eu/how-to-find-us

Send us a question

Go to www.ema.europa.eu/contact

Telephone

+31 (0)88 781 6000

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................6                                                          |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6      |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................7               |                                                                                                          |
| 2. Scientific discussion                                                                                                   | ................................................................................8 authorised             |
| 2.1. Problem statement                                                                                                     | ...............................................................................................8         |
| 2.1.1. Disease or condition...........................................................................................8    |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                        | ....................................................................................................8    |
| 2.1.3. Aetiology and pathogenesis                                                                                          | ................................................................................9                        |
| 2.1.4. Clinical presentation...........................................................................................9   |                                                                                                          |
| 2.1.5. Management...................................................................................................10     |                                                                                                          |
| 2.2. Quality aspects                                                                                                       | ..................................................................................................12     |
| 2.2.1. Introduction....................................................................................................12  |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................12     |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                          | ................................................................................15                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................22                       |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects longer                                           | ......................22                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................22                     |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                  | ............................................................................................23           |
| 2.3.1. Introduction....................................................................................................23  |                                                                                                          |
| 2.3.2. Pharmacology .................................................................................................23    |                                                                                                          |
| 2.3.3. Pharmacokinetics.............................................................................................31 no  |                                                                                                          |
| 2.3.4. Toxicology                                                                                                          | ......................................................................................................33 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                           | .........................................................35                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................36          |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................39            |                                                                                                          |
| 2.4. Clinical aspects ..................................................................................................39 |                                                                                                          |
| 2.4.1. Introduction....................................................................................................39  |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................42     |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................49        |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................55 product    |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................57 Medicinal   |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                     | ..................................................................................................57     |
| 2.5.1. Dose response study(ies)                                                                                            | .................................................................................59                      |
| 2.5.2. Main study(ies)                                                                                                     | ...............................................................................................74        |
| 2.5.3. Discussion on clinical efficacy..........................................................................           | 126                                                                                                      |
| 2.5.4. Conclusions on the clinical efficacy...................................................................             | 131                                                                                                      |
| 2.6. Clinical safety                                                                                                       | .................................................................................................. 131   |
| 2.6.1. Discussion on clinical safety ............................................................................          | 148                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................             | 152                                                                                                      |
| 2.7. Pharmacovigilance............................................................................................         | 154                                                                                                      |
| 2.8. Product information ..........................................................................................        | 155                                                                                                      |
| 2.8.1. User consultation...........................................................................................        | 155                                                                                                      |
| 2.8.2. Labelling exemptions                                                                                                | ..................................................................................... 155                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AP135  Triethylene glycol poly(orthoester) excipient

AP

Applicant's Part (or Open Part) of a ASMF

AS

Active substance

API Active Pharmaceutical Ingredient AR Assessment Report ASM Active Substance Manufacturer ASMF Active Substance Master File = Drug Master File BCS Biopharmaceutics Classification System CEP Certificate of Suitability of the EP CHMP   Committee for Medicinal Products for Human use CMA CVMP Committee for Medicinal Products for Veterinary use CFU Colony Forming Units CMS Concerned Member State CoA Certificate of Analysis Critical process parameter CQA Critical Quality Attribute CRS Chemical Reference Substance (official standard) DMSO  Dimethyl sulfoxide DoE Design of experiments DP Decentralised (Application) Procedure DPM Drug Product Manufacturer DPMT   N,N-dimethyl-p-toluidine DSC Differential Scanning Calorimetry EDQM  European Directorate for the Quality of Medicines EC European Commission EP European Pharmacopoeia EU European Union FDA Food and Drug Administration FMEA   Failure mode effects analysis FPM Finished Product Manufacturer FT-IR Fourier Transform Infrared Spectroscopy GC Gas Chromatography GC-MS  Gas chromatography mass spectrometry GMP Good Manufacturing Practice GPC Gel permeation chromatography GVS Gravimetric vapour sorption HDPE High Density Polyethylene HPLC    High performance liquid chromatography HRMS   High resolution mass spectrometry IC        Ion chromatography ICP-OES Inductively coupled plasma-optical emission spectroscopy ICH      International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use IPC In-process control ICP-MS Inductively coupled plasma mass spectrometry IR Infrared IU International Units IUPAC  International Union of Pure and Applied Chemistry IVR In vitro release KF Karl Fischer titration LC Label claim LCMS   Liquid chromatography mass spectrometry Low density polyethylene LLA Luer lock applicator Medicinal product no longer authorised

Critical Material Attributes

CPP

LDPE

LOD

Loss on drying

LDPE

Low Density Polyethylene

LMW     Low molecular weight

LOA

Letter of Access

LoD

Limit of Detection

LOQ

Limit of Quantitation

<div style=\"page-break-after: always\"></div>

<!-- image -->

LoQ List of Questions LT Less than MA Marketing Authorisation MAH Marketing Authorisation holder MMA Methylmethacrylate MMD Molecular mass distribution Mn Number average molecular weight MS Mass Spectrometry Mw Weight average molecular weight ND Not detected NLT Not less than NMR Nuclear Magnetic Resonance NMT Not more than NOR Normal Operating Range OMCL Official  Medicines  Control Laboratories OOS Out of Specifications PAR Proven Acceptable Range PBS Phosphate buffered saline PDE Permitted Daily Exposure PDI Polydispersity index PE Polyethylene Ph. Eur.European Pharmacopoeia PIL Patient Information Leaflet PP Polypropylene QbD Quality by design QC Quality Control QOS Quality Overall Summary QP Qualified person QTPP Quality target product profile QWP Quality Working Party RH Relative Humidity RMS Reference Member State RP Restricted Part (or Closed Part) of an ASMF RRT Relative retention time RSD Relative standard deviation SmPC Summary of Product Characteristics TGA Thermo-Gravimetric Analysis THF Tétrahydrofurane TLC Thin layer chromatography TSE Transmissible Spongiform Encephalopathy TTC Threshold of toxicological concern USP United States Pharmacopoeia USP/NF United States Pharmacopoeia/National Formulary UV Ultraviolet XR(P)D X-Ray (Powder) Diffraction Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

<!-- image -->

The applicant received the following Scientific advice on the development relevant for the indication subject to the present application:

The applicant Heron Therapeutics B.V. submitted on 8 March 2019 an application for marketing authorisation to the European Medicines Agency (EMA) for Zynrelef, through the centralised procedure under Article 3 (2) (b) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 15 November 2018. The eligibility to the centralised procedure under Article 3(2)(b) of Regulation (EC) No 726/2004 was based on demonstration of significant scientific innovation. The applicant applied for the following indication: Zynrelef is indicated in adults for application into the surgical site to reduce postoperative pain for 72 hours. The legal basis for this application refers to: Article 10(b) of Directive 2001/83/EC - relating to applications for fixed combination products. The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0013/2019 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP (EMEA-002246-PIP01) was not yet completed as some measures were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. Scientific advice Medicinal product no longer authorised

| Date         | Reference                     | SAWP co-ordinators                 |
|--------------|-------------------------------|------------------------------------|
| 20 July 2017 | EMEA/H/SA/3574/1/2017/SME/III | Walter Janssens , Marion Haberkamp |

<div style=\"page-break-after: always\"></div>

The Scientific advice pertained to the following aspects:

- Adequacy of the non-clinical package to support the safety of HTX-011 for the proposed Phase 3 local administration studies in visceral and somatic models.

| The application was received by the EMA on                                                                                        | 8 March 2019     |
|-----------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                          | 28 March 2019    |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on no                                                 | 1 July 2019      |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                 | 18 June 2019     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                               | 5 July 2019      |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on product                   | 25 July 2019     |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                               | 23 December 2019 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on Medicinal | 03 February 2020 |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                          | 13 February 2020 |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                         | 27 February 2020 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                   | 29 March 2020    |
| The Rapporteurs circulated the Joint Assessment Report on the                                                                     | 20 April 2020    |

· Adequacy of the available hepatic impairment clinical data for bupivacaine and meloxicam; the available renal impairment data for bupivacaine and meloxicam are sufficient; that renal impairment studies with HTX-011 are not required and that drug-drug interaction (DDI) studies with HTX-011 are not required for the planned MAA. · Design and adequacy inclusion/exclusion criteria and primary endpoint, statistical plan for the clinical efficacy study Phase 3 studies in visceral (herniorrhaphy) and somatic (bunionectomy) models to support MAA. · Design and adequacy of safety data base to support the MAA. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Alexandre Moreau Co-Rapporteur: Natalja Karpova The appointed co-rapporteur had no such prominent role in Scientific advice relevant for the indication subject to the present application. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| responses to the List of Outstanding Issues to all CHMP members on                                                                                                                       |               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| The CHMP agreed on a second list of outstanding issues in writing and in Oral explanation to be sent to the applicant on                                                                 | 30 April 2020 |
| The applicant submitted the responses to the second CHMP List of Outstanding Issues on                                                                                                   | 22 June 2020  |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                  | 20 July 2020  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Zynrelef on | 23 July 2020  |

Postoperative pain remains an important problem  despite notable advances  in the scientific understanding of pain in recent decades. It has been suggested that less than half of patients who undergo surgery report adequate postoperative pain relief (Apfebaum 2003). Following surgery, 65% of patients  experience  moderate-to-severe  pain.  Following  discharge,  46%  of  patients  still  suffer  from moderate-to-severe  pain, and  pain  remains  the  leading  cause  of  unanticipated  hospital  readmission following surgery. A review of data on postoperative pain on the first day following surgery in 105 German

The applicant submitted the responses to the second CHMP List of Outstanding Issues on 22 June 2020 The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on 20 July 2020 The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Zynrelef on 23 July 2020 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Pain is defined by the International Association for the Study of Pain (IASP) as ''an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such  damage'.  Pain  can  be  described  as  acute  or  chronic  according  to  its  duration.  Acute  pain  is considered adaptive, in that it has a warning function. It is of short duration (generally up to a few weeks)  and  declines  with  the  healing  of  the  underlying  injury  or  disease.  Pain  after  surgery  is  a predictable part of the postoperative experience (Apfelbaum 2003). However, like all pain, postoperative pain is complex and multidimensional. Up to 70% of patients have moderate to severe pain after surgery, and the most severe pain occurs within the first 72 hours. 2.1.2. Epidemiology Pain is one of the most widespread conditions affecting patient health and quality-of-life. Postoperative pain, one of the most serious forms of acute pain, remains an area of particularly high unmet medical need. A study of 56 World Health Organization member states estimated that annually 234.2 million major surgical operations take place worldwide. This translates into about one surgery each year for every 25 people (Chapman 2013). Surgery induces important disturbances in body homeostasis such as hypercatabolism, hypercoagulability, and inflammation, leading to a series of symptoms and signs such as  hypoxaemia,  pain,  nausea,  vomiting,  ileus,  sleep  disturbances,  and  fatigue,  and  complications including  pneumonia  and  myocardial  infarction  (Bonnet  2005).  Postoperative  pain  is  often  the predominant symptom (Bonnet 2005). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

hospitals, 2 found that high pain scores can result from almost all surgical procedures, including those that appear minimally traumatic (Chapman 2013). However, it also has been reported that orthopaedic surgeries are among the major generators of intense postoperative pain (Chapman 2013).

Importantly, poor management of postoperative acute pain may lead to the development of chronic pain. This occurs in 10%-50% of patients after various common operations (Khelet 2006; Meissner 2015). Once pain has become chronic, it is generally regarded as maladaptive and difficult to treat as patients' response to currently available treatments is highly variable. Multiple  and  complex  mechanisms are frequently involved, including somatic, psychological and socioeconomic factors. Associated disorders such as depression, anxiety and sleep disturbances may have an additional impact (Guideline on the clinical development of medicinal products intended for the treatment of pain; EMA/CHMP/970057/2011). Prevention of chronic postsurgical pain involves risk factors detection and evaluation, appropriate anesthetic support and effective postoperative pain management. Intensity of acute postoperative pain correlates with the risk of developing a persistent pain state (Khelet 2006). 2.1.3. Aetiology and pathogenesis According to IASP website, acute pain after surgery has a distinct pathophysiology that reflects peripheral and central sensitization as well as humoral factors contributing to pain at rest and during movement. Surgical tissue trauma leads to nociceptor activation and sensitization. As a result, individuals suffer ongoing pain at rest and increased responses to stimuli at the site of injury. Different surgical procedures involve distinct organs and specific tissue within and adjacent to them, creating a variety of patterns of nociceptor  sensitization  and  differences  in  the  quality,  location,  and  intensity  of  postoperative  pain. Mediators  released  locally  and  systemically  during  and  after  surgery  that  contribute  to  nociceptor sensitization include: prostaglandins, interleukins, cytokins and neurotrophins. Decreased tissue pH and oxygen tension, and increased lactate concentration, persist at the surgical site for several days. These responses  may  contribute  to  peripheral  sensitization  and  spontaneous  pain  behaviour  following  an incision. Nerves may be injured during surgery and hence discharge spontaneously. Spontaneous action potentials in damaged nerves may account for qualitative features of neuropathic pain that may be present early in the postoperative period and can evolve into chronic neuropathic pain. Noxious input during  and  after  surgery  can  enhance  the  responses  of  nociceptive  neurons  in  the  CNS  (central sensitization) thereby amplifying pain intensity. The magnitude of central sensitization depends on many factors, including the location of the operative site and the extent of the injury. Postoperative pain may originate in skin, or deeper somatic and visceral structures. It can be divided into nociceptive somatic (from skin, muscles, bones), nociceptive visceral (from organs of the thoracic and  abdominal  cavity),  and  neuropathic  (caused  by  damage  to  neural  structures).  Usually  it  is  a combination of several types of pain. 2.1.4. Clinical presentation Acute  pain  is  an  unpleasant  sensory,  emotional  and  mental  sensation  (experience)  associated  with vegetative signs, psychological response and changes in behaviour. Medicinal product no longer authorised

Proper diagnosis of the type and intensity of pain is crucial for an adequate and targeted treatment of acute pain. It requires professional approach in terms of expertise, psychology, and ethics. The patient should feel sufficient empathy on the part of health care professionals. The examination of acute pain should include medical history, physical examination, and specific evaluation of pain.

Pain is an individual and subjective experience, influenced by various physiological and psychological factors, education, prognosis, sleep deprivation, race, gender, and environmental influences. Objective

<div style=\"page-break-after: always\"></div>

methods of measuring pain are used more in experimental medicine, and, above all, in chronic pain management (algometer, tail flick test, plantar test, changes in the level of ROS, cholesterol or blood glucose levels). Measuring physiological changes (heart rhythm), response to stress (plasma cortisol), or changes in behaviour (facial expression) can provide important information on the intensity of pain. Other methods of measuring pain are subjective.

Patients taking opioids still frequently experience episodes of moderate to severe pain in the first 72 hours after surgery (Apfelbaum 2003). Systemic paracetamol or systemic NSAIDs are also used as part of multimodal therapy in the post-operative setting, often at high daily doses, and are associated with the risk of liver toxicity or renal, gastrointestinal and cardiovascular toxicity, respectively.

The most widely used method of numerical assessment of pain intensity is the visual analogue scale (VAS), where patients specify the intensity of pain by indicating a point along a continuous horizontal line,  with numbers from 0 to 10 on the other side. In Numeric Rating Scale (NRS) the patient uses numbers to quantify the intensity of pain - 0 means no pain and 10 corresponds to the worst pain imaginable. In the elderly, NRS is superior to VAS, as these patients understand the numerical scale better. An alternative to numerical scale may be an expanding color circle sector or Faces Pain Scale, which shows facial expressions ranging from the state of well-being to worst pain possible. Acute pain should be routinely monitored in intensive care as well. 2.1.5. Management The options for pain management are classified on the basis of the administration routes, mechanisms of action, and types of drugs. Oral, intravenous (IV), intramuscular, subcutaneous, rectal, transdermal, intrathecal,  and  epidural  routes  are  the  common  routes  of  administration.  Other  promising  options include neuronal blocks such as neuraxial blocks and peripheral nerve blocks. Some of the advanced techniques for pain management include epidural analgesia (which is efficacious but difficult to manage because it involves the administration of peripheral nerve blocks via catheters) and extended-duration analgesia (which can be administered at home). The aim of analgesic protocols is not only to reduce pain intensity but also to decrease the incidence of side-effects  from  analgesic  agents  and  to  improve  patient  comfort  (Bonnet  2005).  Although  opioids remain an important component in managing severe postsurgical pain, their use as the single therapeutic entity causes significant problems such as ventilatory impairment, sedation, nausea and vomiting, and delayed  recovery  of  bowel  function.  These  adverse  effects  endanger  patient  safety  and/or  impair recovery and rehabilitation and thereby delay discharge from hospital. Postoperative pain management practice guidelines and clinical studies endorse the use of a multimodal or balanced approach defined as the use of multiple antinociceptive agents (two or more drugs) with different mechanisms of action. That is, pain is best managed using a combination of methods including regional anesthetic and analgesic techniques  (e.g.,  nerve  blocks,  local  wound  infiltrations,  epidural  catheters)  along  with  systemically administered  drugs  (Schurr  2004).  Generally,  a  systemic  opioid  is  complemented  by  one  or  more adjuvant agents (Meissner 2015). According to IASP and European Pain Federation (EFIC) websites, Systemic analgesics with proven or potential efficacy as components of multimodal analgesia used to treat  postsurgical  pain  include:  paracetamol,  non-selective  nonsteroidal  anti-inflammatory  drugs (NSAIDs)  and  selective cyclooxygenase-2  inhibitors (COX-2),  N-methyl-D-aspartate  antagonists (ketamine), alpha-2 adrenergic agonists (clonidine, dexmedetomidine), alpha-2-delta receptor modulators (gabapentin, pregabalin), systemic local anesthetics and corticosteroids. Nefopam have also been reported to reduce opioid demand when combined with i.v. morphine PCA (Bonnet 2005). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Postoperative pain management with locoregional anesthesia techniques is a highly effective solution. According to many studies, these methods are more effective (lower pain score) and at the same time reduce the incidence of adverse effects associated with systemic analgesics.

Local anesthetics can be used in various ways depending on anatomical location and desired effect: -Infiltration/field block: multiple injections of a local anesthetic are performed around the wound, surgical site, or tissue plain to produce local analgesia; -Nerve block: nerves in a specific area are targeted with an injection using ultrasound, nerve stimulation, or anatomical guidance. Bupivacaine HCl is the current standard of care for post-surgical analgesia as one of the long-acting local anaesthetics, but even so it has a limited duration of action after local administration, usually reported as less than 8-12 hours (MARCAIN SmPC 2016). Alternative  local  anaesthetic  treatment  options  are  needed  as  part  of  multimodal  therapy  to  better manage post-surgical pain that offer extended duration and greater magnitude of analgesic effects. The recognised  advantages  of  multimodal  analgesia  are  the  following:  improved  analgesia,  reduced opioids requirements and reduced adverse effects of opioids. The  exact  components  of  effective  multimodal  therapy  vary  depending  on  the  patient,  setting,  and surgical procedure. Clinical practice guidelines on the management of postoperative pain have been published in the USA (Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical  practice  guideline  from  the  American  Pain  Society,  the  American  Society  of  Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia,  Executive  Committee,  and  Administrative  Council.  J  Pain  2016;17:131-57).  In  Europe, recommendations for specific procedures for postoperative pain management are for example proposed by  the  European  Society  of  Regional  Anaesthesia  &amp;  Pain  Therapy  and  published  on  its  website (https://esraeurope.org/prospect/). Improved  postsurgical  or  acute  pain  management  contributes  to  better  healing,  faster  patient mobilization, shortened hospital stays, and reduced healthcare costs. Nevertheless, each technique has its own limitations, and none can achieve complete postoperative pain control. For instance, analgesic techniques  such  as  infiltration  of  the  incision  with  local  anaesthetic  solution  are  associated  with  a morphine-sparing effect that is limited to a few hours (Bonnet 2005). Current modalities of postoperative analgesia include surgical site administration and/or nerve block with local  anaesthetics  combined  with  the  systemic  administration  of  analgesics  (multimodal  therapy). Multimodal therapy usually includes opioid medications, which have considerable drawbacks including time  and  resources  required  for  monitoring  opioid-related  side  effects.  A  reduction  in  the  use  of postoperative  opioids  is  desirable  to  decrease  the  incidence  and  severity  of  opioid-induced  adverse effects,  such  as  respiratory  depression,  nausea,  vomiting,  constipation,  somnolence,  pruritus,  and urinary retention. About the product Medicinal product no longer authorised

Zynrelef has been formulated as prolonged-release wound solutions (60 mg / 1.8 mg, 200 mg / 6 mg and 400 mg / 12 mg). The active substances of Zynrelef are bupivacaine and meloxicam, local anaesthesia medicines (amides). Bupivacaine works as a local anaesthetic and meloxicam enhances the efficacy of bupivacaine.

<div style=\"page-break-after: always\"></div>

## Type of Application and aspects on development

This application has been submitted under Article 10(b) of Directive 2001/83/EC, as amended - relating to applications for new fixed combination products.

<!-- image -->

2.2. Quality aspects 2.2.1. Introduction The finished product is presented as prolonged-release wound solution containing (60 mg + 1.8 mg) / 2.3 mL,  (200 mg + 6 mg) / 7 mL, and (400 mg + 12 mg) / 14 mL of bupivacaine and meloxicam respectively as active substances. Each mL of solution contains 29.25 mg of bupivacaine and 0.88 mg of meloxicam. Other ingredients are: DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer, triacetin, dimethyl sulfoxide, and maleic acid. The product is available: 60 mg bupivacaine/1.8 mg meloxicam: one 10 mL Type I glass vial, 1 vented vial spike, one 3 mL Luer lock syringe, and 1 Luer lock applicator. 200 mg bupivacaine/6 mg meloxicam: one 10 mL Type I glass vial, 1 vented vial spike, one 12 mL Luer lock syringe, and 1 Luer lock applicator. 400 mg bupivacaine/12 mg meloxicam: one 20 mL Type I glass vial, 1 vented vial spike, two 12 mL Luer lock syringes, and 2 Luer lock applicators. 2.2.2. Active Substance Bupivacaine General information The chemical name of the active substance is ( RS )-1-butylN -(2,6-dimethylphenyl)piperidine-2carboxamide corresponding to the molecular formula C18H28N2O. It has a molecular weight of 288.43 g/mol and the following structure: Medicinal product no longer authorised

Figure 1: Active substance structure

<!-- image -->

The chemical structure of active substance was elucidated by a combination of mass spectrometry, NMR spectroscopy, IR spectroscopy, UV-Vis spectroscopy, elemental analysis (CHN) and specific optical

<div style=\"page-break-after: always\"></div>

rotation. The solid-state properties of the active substance were measured by melting point, DSC and TGA.

The active substance is a non-hygroscopic white or off-white crystalline powder, crystals or granules. It is soluble in methanol, ethanol and dichloromethane and insoluble in water.

Bupivacaine exhibits stereoisomerism due to the presence of one chiral centre and is manufactured as a racemic mixture. This is routinely controlled in the specifications. Polymorphism has been observed for the active substance. Two different crystal forms (form 1 and form 2) of bupivacaine base were  observed  during development  and  scale-up. These are clearly distinguishable by IR, XRPD and melting point analysis. Form 1 is thermodynamically stable and does not convert to another form during storage. Form 2 was formed at lab scale when the active substance was crystallized from a different solvent and could not be replicated. The melting point is part of the release analysis of bupivacaine base assuring control of formation of Polymorph 1. Manufacture, characterisation and process controls Two manufacturers of bupivacaine were initially proposed, but following questions raised by CHMP, one of the active substance manufacturers was withdrawn. Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory. Bupivacaine is synthesized in three main steps using well defined starting materials with acceptable specifications. The choice of proposed starting material is based on ICH Q11 principles. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. The active substance is packaged in double polyethylene bags, which complies with the EC directive 2023/2006 EC and EC 10/2011 as amended. Specification The bupivacaine active substance specification includes tests for appearance, identification (IR), optical rotation (Ph. Eur.),  loss on drying (Ph. Eur.), bacterial endotoxins (Ph. Eur.), microbiological limits (Ph. Eur.), assay (HPLC), impurities (HPLC), residue of ignition (Ph. Eur.), residual solvents (GC), and water content (KF). The specifications of the impurities are set according to the requirements in ICH Q3B. The impurity profile is based on the monograph of bupivacaine HCl in Ph Eur. The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for impurities testing has been presented. Medicinal product no longer authorised

Batch analysis data (3 commercial scale batches) of the active substance are provided. The results are within the specifications and consistent from batch to batch.

<div style=\"page-break-after: always\"></div>

## Stability

Stability data from 6 commercial scale batches of active substance from the proposed manufacturer stored in the intended commercial package for up to 60 months under long term conditions (25ºC / 60% RH) , for up to 12 months under intermediate conditions (30°C/65 %RH and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. Photostability testing following the ICH guideline Q1B was performed on one batch. One batch of the active substance was stored under stress conditions: high temperature (60°C), high humidity, pH, oxidative degradation (H2O2), and 40ºC / 75% RH for oxidation study.

<!-- image -->

The following parameters were tested : appearance, identity, water, chromatographic purity, assay, 2,6-Xylidine, and XRDP. The analytical methods used were the same as for release (except for XRDP, which is not part of the release specification) and were stability indicating. All tested parameters were within the specifications under long term, accelerated, photostability, and stress conditions. From forced degradation study a formation of 2,6-xylidine has been observed in the light study. The storage conditions should thus include ' Protect against light'. Bupivacaine base is stable under the conditions investigated and no storage instructions are required. The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 48 months protected against light in the proposed container. Meloxicam General information The chemical name of meloxicam is 4-Hydroxy-2-methylN -(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2 H -1λ ⁶ ,2-benzothiazine-3-carboxamide  corresponding  to  the  molecular  formula  C14H13N3O4S2.  It  has  a molecular weight of 351.40 g/mol and the following structure: Figure 2: Active substance structure The active substance meloxicam is described in the Ph.Eur. monograph 01/2017:2373. The manufacturer of the active substance has been granted a Certificate of Suitability of the European Pharmacopoeia (CEP) for meloxicam which has been provided within the current Marketing Authorisation Application. Medicinal product no longer authorised

Information regarding structure and characteristics is provided in the CEP.

Meloxicam is a pale yellow powder practically insoluble in water, soluble in dimethylformamide, very slightly soluble in ethanol.

<div style=\"page-break-after: always\"></div>

Meloxicam has a non-chiral molecular structure.

Polymorphism has been observed for meloxicam. Meloxicam is manufactured as a thermodynamically stable crystalline polymorphic Form I .

<!-- image -->

The  aim  of  the  pharmaceutical  development  was  to  develop  a  prolonged-release  formulation  for application to a surgical site. It is intended to be applied as a single-dose administration without a needle to coat the affected tissue before the end of surgery and wound closure. The product has been developed to  address  the  unmet  medical  need  for  a  longer-lasting  postoperative  analgesic  that  provides  more effective, sustained pain relief.

Manufacture, characterisation and process controls Two manufacturers of meloxicam were initially proposed by the applicant, but following questions raised by CHMP, one of the active substance manufacturers was withdrawn. The relevant information has been assessed by the EDQM before issuing the Certificate of Suitability. The characterisation of the impurities is in accordance with the Ph. Eur. monograph and the EU guideline on chemistry of new active substances. The active substance is packaged in double polyethylene bags placed in a polyethylene container. Quality and suitability of the primary packaging has been evaluated and considered satisfactory by EDQM. Specification The meloxicam release and shelf-life release include appropriate tests and limits for description (visual), identification (IR, HPLC), assay (HPLC and titration), degradation products (HPLC), loss on drying, residue on ignition, residual solvents and microbiological quality (Ph. Eur.). Satisfactory information regarding the reference standards used for identification, impurities and bacterial endotoxins testing has been presented. The control tests were carried out to comply with the specifications and test methods of the Ph. Eur. monograph. Additional specifications have been set for bacterial endotoxins and microbial limits. All additional analytical methods have been adequately validated and described according to ICH Q2. Stability The stability data have been evaluated by the EDQM. The following re-rest period is mentioned in the CEP: 3 years if stored in double polyethylene bags placed in a polyethylene container. 2.2.3. Finished Medicinal Product Description of the product and Pharmaceutical development The finished product is a prolonged-release (also known as extended release) solution containing a fixed-dose combination of bupivacaine and meloxicam that is intended for single-dose local administration into the surgical site. The finished product is supplied as 4.6 mL and 10 mL presentations filled in a 10 mL vial and an 18.6 mL presentation filled in a 20 mL vial. Medicinal product no longer authorised

The  finished  product  is  a  fixed-ratio  combination  product  that  contains  two  active  substances: bupivacaine base and meloxicam, incorporated in a proprietary polymer (AP135).

<div style=\"page-break-after: always\"></div>

Bupivacaine and meloxicam both exist in multiple polymorphic forms. Based on fact that both active substances are completely dissolved during the manufacturing process, it is concluded that polymorphism will not affect finished product properties. For the same reason particle size distribution and re-dispersion will not affect finished product properties. The effects due to pH are not applicable in a non-aqueous formulation.

The compatibility of bupivacaine and meloxicam with each other and with the excipients was evaluated in several forced degradation studies of the finished product. The finished product was exposed to elevated temperature (70°C, ~72 h), and the related substances that were generated were evaluated. There was no degradation of bupivacaine nor were any bupivacaine related substances generated, indicating that the active substances are compatible with one another and bupivacaine is compatible with the excipients.

During the manufacture of the finished product, the active substances are first dissolved in dimethyl sulfoxide (DMSO). Therefore, their solubility in mixtures of DMSO and triacetin was investigated at 25°C and 65°C. The concentration of bupivacaine in DMSO during the dissolution step is above its solubility in room temperature. Once fully  formulated  with  AP135,  bupivacaine  remains  in  solution,  even  during storage  at  5°C  indicating  AP135  plays  a  role  in  solubilizing  the  active  substance.  The  amount  of meloxicam is well below its solubility in DMSO. All  excipients  are  well  known  pharmaceutical ingredients and their quality is compliant with Ph. Eur standards except for DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer which is novel excipient used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report. The viscosity of DMSO-only formulations was too high, so triacetin, an aprotic short chain triglyceride, was  added  to  further  reduce  the  viscosity  and  facilitate  the  administration  and  processing  of  the formulation. DETOSU/triethylene  glycol/triethylene  glycol  polyglycolide  copolymer  is  a  highly  viscous  polymeric excipient that provides the slow diffusional release of the active substances over approximately 3 days. After the active substances are released, the polymer undergoes hydrolysis in the aqueous environment leading to small water-soluble products that are rapidly cleared from the body. No other excipient was tested during the pharmaceutical development to achieve a prolonged release. The choice of this excipient was justified by the fact that 'in the case of a viscous polyorthoester, active ingredients are dissolved in the formulation to form a solution with the polymer and solvent excipients and released after administration by diffusion from the depot. Because the mechanism of release is diffusion, the release of active ingredients begins immediately after administration of the formulated drug product. By selecting the appropriate polyorthester polymer compositions, short-term, controlled release over a few days can be achieved. Other commonly used classes of drug delivery polymers, for example poly (ε -caprolactone), poly (lactide acid), and poly (lactic-co-glycolic acid) degrade by bulk erosion and by hydrolysis. As these polymers break down, the encapsulated active ingredient is released. This release mechanism results in a lag phase (ie, the active ingredient is not released for a period of time after administration) during which the polymer must sufficiently hydrolyze to allow the release of active ingredients. A formulation with a lag phase would have an early gap in analgesia. Additionally, erosion of poly (ε -caprolactone), poly (lactide acid), and poly (lactic-co-glycolic acid) polymers is slow, therefore making it impractical to formulate relatively short-release periods on the order of days (3 to 7 days)'. Satisfactory information on manufacture, characterization, control, and stability of this novel excipient has been provided. Formulation development focused on viscosity, dose volume, and achieving sustained simultaneous release of both active ingredients, bupivacaine and meloxicam, while maintaining bupivacaine plasma maximum observed concentration (Cmax) as low as possible. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Initial efforts evaluated the possibility of formulating bupivacaine HCl, but the salt had unacceptably low solubility in solvent excipients that could be used with DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer. Therefore, the finished product is formulated with bupivacaine base that acts as a 'proton sink', becoming protonated as moisture enters the formulation after administration, and therefore reducing the concentration of protons available to hydrolyze the orthoester and controlling the rate of release. In fact, the use of bupivacaine HCl in the formulation, even if it was soluble, would accelerate the rate of DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer hydrolysis.

In early formulation development, occasional crystallization of the bupivacaine was observed. The addition of an organic acid as a stabilizing agent to prevent crystallization in the formulation was evaluated. The hypothesis was that a small amount of protonated bupivacaine would interfere with the formation of bupivacaine crystals, as it is structurally similar but positively charged, thus disrupting the molecular order needed for crystallization. Of the organic acids screened, only maleic acid was shown to prevent crystallization of bupivacaine in the formulation . After exploration of the excipient ranges, a formulation with an approximately 20-fold lower viscosity than the initial formulation, was developed with half the concentrations of active substances to further increase the volume. This second formulation allowed for easier administration and a sufficient volume to cover large surgical areas. However, the Cmax observed was higher than from the initial formulation indicating a more rapid release of the active substances from the second formulation. Based on the higher observed Cmax, this formulation was discontinued from further clinical evaluation. In order to achieve a more favorable pharmacokinetic (PK) profile of bupivacaine similar to that from the initial formulation, a third formulation was developed to contain the same percentage by weight of the 2 active substances as the second formulation with the excipient levels adjusted to provide slower release in vivo . While the viscosity of this third formulation was slightly higher than in the second formulation, the PK profile for the active ingredients was similar to that of the initial formulation. Therefore, this formulation was selected for phase 2b and phase 3 clinical trials and commercial use. A customized IVR ( in vitro release) method was developed based on a forced-air incubator with rotating platform which provided better reproducibility than employing a USP Type 2 apparatus. The customized method consists of placing a depot of finished product in a cylindrical well, with fixed dimensions, that is drilled in a polyoxymethylene insert. The insert is placed at the bottom of a 10-ounce polypropylene specimen container, and phosphate-buffered saline (PBS) is added. The container is closed and placed on  the  rotating  platform  of  a  forced-air  incubator  calibrated  to  maintain  37°C  ±  0.5°C.  At  this temperature, &gt; 85% release of both actives is achieved consistently by 72 h, similar to the in vivo release profile. Aliquots are withdrawn from a set position within each container at specified timepoints using a manual pipette. These aliquots are analysed for both meloxicam and bupivacaine contents by a validated HPLC assay. The depot size is 200 mg to improve reproducibility, the rotation speed of the incubator platform is 120 rpm for improved mixing, which led to IVR method with good precision and discriminatory power. A risk assessment of the manufacturing process was conducted to identify critical process steps with corresponding parameters whose variability may potentially have an impact on critical quality attributes (CQAs) of the finished product and should be monitored or controlled to assure the process produces product of desired quality. The risk ranking considered severity, probability and detectability (failure mode and effect analysis (FMEA)).  Parameters receiving a risk priority rating high were determined to be critical process parameters. Medicinal product no longer authorised

The finished product quality target product profile (QTPP) was prospectively developed to define design criteria and to form the basis for development of the finished product CQAs. Refer to Table 1 for the QTPP elements, targets, and justifications.

<div style=\"page-break-after: always\"></div>

Table 1: Finished Product Quality Target Product Profile

<!-- image -->

The finished product is packed in Type I vials which are co-packaged with medical devices intended for the preparation and administration of the finished product. These are a vented vial spike (VVS), which is used to remove the finished product from the vial directly into a syringe, a 3 mL or 12 mL polypropylene Luer lock syringe, and a Luer lock applicator (LLA) which is attached to the syringe for the administration of the product. The medical devices are CE marked. Because the finished product is a viscous solution, the vial is filled with some excess volume that cannot be removed due to hold-up in the vial and device components. Hold-up weights for the syringe and LLA were determined to allow further calculation of the minimal fill volume/weight required for specific doses.

The proposed commercial manufacturing process parameter ranges for the 50 kg commercial scale were based on evaluation of results from scale-up development studies (0.5 kg laboratory-scale and 20 kg pilot-scale),  the  manufacture  of  registration  batches  and  process  validation  data.  The  proposed commercial production process utilizes critical process parameters (CPPs) that are identical to the CPPs used for production of pivotal clinical and registration batches. The  finished  product  cannot  be  terminally  sterilized  by  heat  since  meloxicam  degrades  at  high temperatures, nor can it be terminally sterilized by radiation since bupivacaine and meloxicam degrade when irradiated. The finished product is therefore sterilized by sterile filtration. In the sterile filtration process, the formulated bulk product from the mixing vessel is sterile filtered through two 0.2 μm nylon filters in series by nitrogen pressure into a st erile fill vessel. Throughout the sterile filtration process, due to the sensitivity of DETOSU/triethyleneglycol/triethylene glycol polyglycolide copolymer and the formulation to hydrolysis, moisture is minimized by dry gas blow down and nitrogen purge of equipment before and during use. Extractables and leachables from the container closure system were evaluated in three studies with different solvents (nitric acid, 10% DMSO, hexane, isopropyl alcohol and cyclohexane). The observed levels of extractables/leachables were determined to be safe. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Dose of Zynrelef required depends upon the surgical area of tissue to be treated. Nominal doses based on the formulation and a density of 1.17 g/mL are shown in table below. The nominal volumes shown do not include any hold-up.

| Table 2   |
|-----------|

Table 2 The actual volume delivered will be the volume withdrawn minus the hold-up volume in the LLA and the syringe. Therefore, to determine the volume of drug product that must be withdrawn from a vial to deliver the appropriate dose of the formulation, the hold-up in the syringe(s) and LLA(s) was added to the target dose volume. Furthermore, hold-up in vials was added to determine total minimum weight that needs to be filled into vials. Compatibility studies between the medical devices used for the preparation and administration of the formulation and the finished product were performed by incubating them for varying lengths of time and assessing physical changes in the components as well as the physico-chemical properties of the exposed finished  product.  Components were exposed to finished product for at least 2 times the anticipated maximum contact time indicated in the SmPC. The product was evaluated for changes in drug content and leachables; in addition, the product was stored for up to 72 hours in syringes and evaluated for changes  in  viscosity,  molecular  mass  determination  (MMD),  and  in  vitro  release  (IVR)  as  well. Conversely, the device components were inspected visually for any changes in shape, color, or integrity that may have been associated with exposure to the formulation. There were no detectable observed changes in any of the parameters tested at any time-point. The compatibility of the finished product with surgical materials was assessed in vitro. Commonly used types of silicone sheets for breast implants, bone cements, metal alloys used in replacement joints, surgical mesh, sutures, and povidone-iodine solution were evaluated to determine either the effect of finished product on the mechanical properties of the material, or the effect of the material on the integrity of the drug product, or both. No major effects were observed when the finished product was in contact with surgical materials Manufacture of the product and process controls The finished product is manufactured by one manufacturing site. The manufacturing process consists of 6 main steps: addition of DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer, active substance solution preparation, bulk finished product preparation, sterile filtration, aseptic vial filling, and secondary packaging. The process is considered to be a nonstandard manufacturing process. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

A  prospective  approach  was  used  for  validation  of  the  finished  product  manufacturing  process. Information and experience gained during process development and registration batches production at the  commercial  scale  were  used  to  support  the  design  of  the  commercial  finished  product  process validation (PPQ). Three commercial scale batches were manufactured to complete the PPQ requirements for  each  intended  commercial  fill  volume.  Validation  of  the  labelling  and  secondary  packaging  was completed  after  demonstrating  that  3  consecutive  batches  meet  pre-defined  criteria.  The  same manufacturing process, equipment, and facilities used for PPQ will be used for commercial manufacture. It has been demonstrated that the manufacturing process is capable of producing the finished product of  intended  quality  in  a  reproducible  manner.  The  in-process  controls  are  adequate  for  this  type  of pharmaceutical form.

Control of the triacetin content is accomplished by testing viscosity, IVR, and DMSO content of the finished product. Triacetin constitutes 25.0% of the formulation. A change in the ratio between polymer, DMSO, and triacetin would be observed in viscosity results and IVR release results. Therefore, it is acceptable to omit direct measurement of triacetin content from the finished product specification.

Product specification The  finished  product  release  specifications  include  appropriate  tests  for  this  kind  of  dosage  form: appearance (visual), dynamic viscosity (Ph. Eur.), water content (KF), molecular mass distribution (GPC), particulate  matter  (light  obscuration),  identification  of  bupivacaine  and  meloxicam  (HPLC,  HILIC), bupivacaine assay (HPLC), bupivacaine related substances (HPLC), bupivacaine dose uniformity (Ph. Eur.), meloxicam assay (HPLC), meloxicam related substances (HPLC), meloxicam dose uniformity (Ph. Eur.), in vitro release (HPLC),  ethylene glycol, diethylene glycol, and dimethyl sulfoxide (GC), triethylene glycol (GC), container closure integrity (dye ingress), bacteria endotoxins (Ph. Eur.), sterility (Ph. Eur.), and extractable volume (Ph. Eur.). Ethylene glycol (EG) and diethylene glycol (DEG) are organic impurities potentially present in the DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer. They are   tested at release and also monitored on stability, although there are no data to indicate that they are degradation products of formulation components. The proposed specification limit for EG is below the permissible daily exposure (PDE) in ICH Q3C(R6). The proposed specification limit for DEG content is supported by results of toxicity study described in scientific literature. Paediatric dosing will be individualized on a weight basis and proportional to adult dosing. Therefore, these acceptance criteria are also suitable for paediatric use. Triethylene glycol (TEG) is a monomer used in the manufacture of DETOSU/triethylene glycol/triethylene glycol polyglycolide copolymer. Residual monomer is potentially present in the polymer and may also form  in  the  finished  product  as  a  hydrolytic  degradation  product.  TEG  is  monitored  on  release  and stability. TEG, after administration of the formulation in vivo, is released into systemic circulation during polymer hydrolysis and is rapidly excreted. Thus, limits for TEG are set based upon the expected range in production of the copolymer plus the small amounts expected to be generated during storage, and not its toxicological properties. Control of the polymer content is accomplished by testing the viscosity and MMD of the finished product. Viscosity testing ensures the performance of the product, and Mn and Mw confirm the presence of the polymer. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Specific gravity was characterized during product development, and routine control is not considered necessary as the dynamic viscosity controls for appropriate concentration of excipients that determine the specific gravity.

A risk assessment for potential elemental impurities was completed in accordance with ICH Guideline Q3D on Elemental Impurities. Potential sources of elemental impurities evaluated consist of the active substances, excipients, and purified water used in product manufacturing, the finished product manufacturing and packaging equipment used in the finished product production process, as well as the container-closure systems. Based on this assessment, none of the potential sources would introduce elemental impurities into the finished product at levels that exceed the respective ICH Q3D control thresholds. This supports the conclusion that the finished product manufactured using the currently approved procedures, methods, and materials, at the current manufacturing site, meets the ICH Q3D elemental impurity requirements for a parenteral product. In the context of the on-going review under Article 5(3) of Regulation (EC) No 726/2004 related to the potential presence of nitrosamine impurities in human medicinal products the applicant was requested by CHMP to review his product for potential presence of nitrosamine impurities and to conduct a risk evaluation/risk  assessment  as  appropriate.    Risk  assessments  from  the  suppliers  of  the  active substances, excipients and finished product manufacturer were provided. Based on the risk assessments provided, the risk of nitrosamine contamination is considered low. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for identification, assay, related substances MMD and viscosity testing has been presented. Batch analysis results are provided for 6 commercial batches of 10- and 20-mL vials confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification. The finished product is released on the market based on the above release specifications, through traditional final product release testing Stability of the product Stability data from 3 commercial scale batches of the 60 mg/1.8 mg, 3 commercial scale batches   of the 200 mg/6 mg presentations and 4 commercial scale batches of the 400 mg/12 mg presentation of finished product stored for up to 36 months under long term conditions (5ºC, 25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing. Stability data from 2 commercial scale batches of 300 mg/9 mg product presentation, which is not currently planned for commercialization, stored for up to 24 months under long term conditions (5ºC, 25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided as supportive information. Medicinal product no longer authorised

Samples were tested for appearance, dynamic viscosity, molecular mass distribution, particulate matter, identification of bupivacaine and meloxicam, bupivacaine and meloxicam assay, bupivacaine and meloxicam related substances, meloxicam dose uniformity, ethylene glycol, diethylene glycol, dimethyl sulfoxide (DMSO), triethylene glycol, in vitro release (IVR) for bupivacaine and meloxicam, container closure integrity, bacterial endotoxin and sterility. The analytical procedures used are stability indicating.

<div style=\"page-break-after: always\"></div>

The  physicochemical  and  microbiological  characteristics  of  the  finished  product  remained  within  the proposed shelf-life specification criteria when stored at long term conditions.

Samples stored at the accelerated storage conditions showed changes expected from an accelerated storage condition. The changes observed are consistent with results seen in samples stored at long term storage conditions.

The stability data for the sideways and upright vial orientations showed that vial orientation made no difference in the product quality. Additionally, stability data from development stability studies with the product presentation of 400 mg/12 mg in a 20 mL vial showed that the desiccant and the Mylar pouch did not have an impact on product quality. In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New  Drug  Substances  and  Products.  According  to  the  photostability  results  a  decreasing  trend  for meloxicam potency, and an increasing trend for meloxicam and bupivacaine related substances have been observed. Therefore, vials should be protected from light and a secondary packaging which provides acceptable protection from UV and visible light was proposed. A thermal cycling study was conducted to investigate the effects of freeze/thaw cycles on the stability of the finished product. The samples were exposed to a total 72-hour study with cycling occurring during each 24-hour period from -20°C ± 5°C to 40°C/75% RH. All results remained within the proposed commercial specification. Based on available stability data, the proposed shelf-life of 24 moths and do not store above 25°C. Store in the original package in order to protect from light and moisture. This medicinal product should only be prepared immediately prior to use as stated in the SmPC (section 6.3). 2.2.4. Discussion on chemical, pharmaceutical and biological aspects Information on development, manufacture and control of the active substances and the finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. The applicant has applied QbD principles in the development of the finished product and their manufacturing process. However, no design space was claimed for the manufacturing process of the finished product. 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. 2.2.6. Recommendation(s) for future quality development Not applicable. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The active ingredients in HTX-011-56, bupivacaine and meloxicam, are well known. Thus, the focus of the assessment was the combination of bupivacaine and meloxicam in the extended-release formulation. 2.3.2. Pharmacology Primary pharmacodynamic studies Study 33-12 The primary aim of the study was to evaluate the analgesic activity of Bupivacaine prepared in unique formulations (HTX02-01 and HTX07-03) with a potential prolonged activity. Bupivacaine was dosed using 2  different  routes  of  administration:  instilling  (into  the  wound  space)  and  intra-lesionally  (into  the margins of the open wound). Instilling administration of HTX02-01 was more active than intra wound administration. HTX02-01 and HTX07-03 had prolonged effect following single administration just before wound closure. Study 33-13 The aim of the study was to assess the nociceptive activity of various formulations in postoperative pain model in pigs. Treatments with HTX07-1233158; HTX11-1233155 and HTX16-1233159 were active in relieving post operating sensitivity for 6 days. Treatment with HTX11-1233155 was active in completely inhibiting  post-operative  nociception.  Treatment  with  HTX12-1233153  (containing  diclofenac)  might have an effect on changing the suture property causing suture fragile. Study 33-14 The aim of the study was to assess the nociceptive activity of various test item formulations in postoperative pain model in pigs using 2 different methods for test item introduction and different compounds combinations.  Treatment with  various  combination of  bupivacaine  and  meloxicam  suggests that  the effect  of  bupivacaine  as  analgesic  agent  is  more  crucial  in  the  mixture  than  meloxicam  in  the concentration  ranges  tested.  The  results  show  that  the  maximum  effect  of  this  mixture  is  already achieved  using  the  combination  of  100mg/gm  bupivacaine  +  7.5mg/gm  meloxicam.  Comparison between 2 methods of test item introduction suggests that, in this model, the most effective method of administration is by injection under the skin as opposed to laying the test item directly onto the wound bed. Study 33-24 The aim of the study was to assess the analgesic effect of 5 formulations in the postoperative pain model. Treatment with bupivacaine and meloxicam was more active than the treatment with meloxicam alone. Treatment with bupivacaine and meloxicam at a volume of 3.4 ml was more active than treatment with half concentration or half volume (1.7 ml) suggesting a dose related effect. Treatment with the same bupivacaine and meloxicam concentration using DMSO is more active than using NMP carrier. Medicinal product no longer authorised

## Study 33-29

This study was conducted to evaluate the activity of 3 compounds in POP model in the pigs. Treatment with HTX-011-056 resulted in the most prolonged analgesic effect. Treatment with either HTX-011-49,

<div style=\"page-break-after: always\"></div>

HTX-011-19 or HTX-011-56 were active in significantly increasing the withdrawal threshold. On study days 3-5, only treatment with HTX-011-056 reached significance vs. saline (15.00±0.00g vs. 4.50±0.50 g for saline group on day 5; p&lt;0.05). These data suggest that treatment with HTX-011 formulation was active  in  increasing  mechanical  withdrawal  threshold.  Treatment  with  HTX-011-56  had  the  most prolonged activity.

<!-- image -->

The objective of this study was to investigate the effects of a sustained release formulation of bupivacaine and meloxicam (HTX-011-056) or saline on incisional pH in the pig. A pig incisional model was developed to assess pH changes in a surgical incision. pH measurements were collected in the tissues surrounding a surgical incision made on the dorsum of the pig. In saline treated or sham control incisions, a decrease in pH occurred soon after the incision was made, and the lower pH was maintained for at least 48 hours. Treatment  of  incisions  with  HTX-011-056  created  an  environment  surrounding  incision  allowing  for incisional pH to return to a normal pH (baseline) within 24 hours.

Study 33-61 This  study  was  conducted  to  evaluate  the  activity  of  3  formulations  in  POP  model  in  the  pigs.  All compounds  contained  bupivacaine  at  a  concentration  of  2.5%w/w  with  different  concentration  of meloxicam. HTX-11-056 contained the highest concentration of meloxicam (0.075% w/w) compared to HTX-011-062 (0.038% w/w) and HTX-011-063 (0.019% w/w). Treatment with HTX-011-056 resulted in the most prolonged analgesic effect and was more effective than HTX-011-062 or HTX-011-063 with no difference between HTX-011-062 and HTX-011-063. These data suggest that treatment with HTX-011 formulation  was  active  in  increasing  mechanical  withdrawal  threshold  and  had  the  most  prolonged analgesic efficacy. Reducing the concentration of meloxicam below 0.075% w/w significantly affected the analgesic effect of the HTX-011 formulations. Study 33-68 This study was conducted to evaluate the activity of 3 formulations in POP model in the pigs formulated with 2.5% w/w bupivacaine and with different concentrations of meloxicam: HTX-011-56 (0.075% w/w); HTX- 011-072 (0.1125% w/w); and HTX-011-074 (0.15% w/w). The activity of these formulations was compared to the activity of combined injections of Bupivacaine and Eloxijet (Groups 1 and 2). The effect of  treatment  with  HTX-011-056 (Group 3) or HTX-011-074 (Group 5) was superior to the effect of treatment with Bupivacaine and Eloxijet even when Eloxiject was dosed at a higher dose (6 mg; Group 2). HTX-011-074 was superior to HTX-011-56 and HTX-011-072 in specific time points. Coadministration of bupivacaine HCl and meloxicam (Eloxijet) solutions showed an analgesic effect, which was significantly lower when compared to HTX-011-056. Increasing the concentration of meloxicam from 0.075% w/w to 0.15% w/w (HTX-011-074) significantly increased the analgesic effect when compared to HTX-011-056. Study 33-71 This study was conducted to evaluate the activity of HTX-002-013 in combination with systematically administered  meloxicam  (Eloxiject)  in  POP  model  in  the  pigs.  Additional  aim  was  to  compare  the combination  activity  with  HTX-011-074  and  HTX-032-001.  No  statistical  difference  was  found  when comparing the activity of HTX-002-013/Eloxiject 6mg (Group 3) with that of HTX-002-013/Eloxiject 3mg (Group 2). Systemic administration of meloxicam (6 mg) with HTX-002-013 (2.5% w/w bupivacaine only formulation) increased the analgesic effect of HTX-002-013 on Days 1 and 2 with no difference on Day 3 to Day 6. Effect of HTX-032-001, a formulation with both bupivacaine (0.5% w/w) and meloxicam (0.15% w/w) was no different that HTX-002-013. HTX-011-074 (2.5% w/w bupivacaine and 0.15% w/w meloxicam) was significantly more effective that HTX-002-13 with and without systemically administered meloxicam (6 mg) and HTX-032-001. The most active formulation was HTX-011-074. Study 33-87 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Results analysis

## a) Assessment of the analgesic efficacy of an extended-release formulation of bupivacaine alone and liposomal bupivacaine (Study 33-12, Study 33-14).

<!-- image -->

Moreover, no information regarding local concentrations and kinetic of release from HTX-002-01 and Exparel are available and due to the difference of nature between the two products (liposome vs polymer) the use of Exparel is questionable. The applicant answered that differences observed regarding PK profile are related to the kinetic release of BPV and the amount of BPV released at the site of administration is similar between HTX-002-01 and Exparel. In addition, it appears in Fig 3 that a full analgesia is observed 1hr post dose with HTX-002-01 whereas an efficiency of only 20% is observed with Exparel at the same timepoint. It appears also from Fig 3 that analgesic effect with HTX-002-01 drops from 5 to 96 hrs, however superiority vs Exparel is not demonstrated at that timepoint. Superiority of HTX-002-01 over Exparel has been observed until 72 hrs. Nevertheless, it is difficult to conclude that the superiority is correlated with the nature of the product of the highest total BPV concentration. In addition, it is not clear whether or not the full analgesia observed at 1hr is due to a burst release of BPV from HTX-00201. Overall, plasma concentrations observed in BPV only describe systemic exposure and cannot describe the release of the chemical substance from its support and the mean residence time. It is not possible

BPV contained in their design polymer offers a higher efficacy at all the timepoints in comparison with liposomal BPV such as Exparel ® . It was concluded that 'administration of HTX-002-01 resulted in a greater  analgesic  effect  compared  with  liposomal  bupivacaine  through  144  hours  (see  Fig  3).  The analgesic effect diminished for HTX-002-01 from 48 to 96 hours and for liposomal bupivacaine from 24 hours'. Figure 3: Analgesic Effect of an Extended-Release Formulation of Bupivacaine Alone and Liposomal Bupivacaine Conclusions made by the applicant are questionable since the applicant has not selected Exparel with the highest dosage. Indeed, a formulation with 266 mg of BPV in Exparel would have been a better comparator since the analgesic effect relies on BPV and therefore local available concentrations may deeply affect the scores obtained. Therefore, the applicant was asked to discuss why Exparel with the lowest concentration (106.4 mg) in BPV was chosen as the comparator. The applicant has underlined that  the  purposes  of  studies  with  HTX-002-001  (extended-release  formulation  of  BPV)  and  Exparel (liposomal BPV) were not to demonstrate superiority of HTX-002-001 over Exparel. Doses selected were based on time of release and length of the incision. It is agreed that loss of analgesia is expected after time, however it is not clearly understandable how strong analgesia with HTX-002-01 (BPV only) could occur after 1 hr post incision and drug administration. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

to correlate what is observed in systemic (quick massive release in BPV?) moreover the applicant has stated that measurement of the local tissue concentration of bupivacaine following administration of HTX-002-01 (extended-release formulation of bupivacaine) or Exparel (liposomal bupivacaine) is not possible.

<!-- image -->

In addition, a further increase in analgesia was observed at 144 hrs whereas no return was observed for Exparel and the applicant did conclude: 'As inflammation subsides with time, the pH at the incision returns  to  physiologic  pH  and  more  bupivacaine  in  the  un-ionized  lipid-soluble  form  is  available  to penetrate the nerve membrane. This could explain the return of the analgesic effect of HTX- 002-01 at around 120 hours.'  In theory similar finding could be observed if sufficient local concentration of BPV is available whatever the origin of the product. Overall superiority of HTX-002-01 over Exparel (106.4 mg) is only partially demonstrated although the highest efficacy for Exparel was observed only between 3-5 hrs. b) Assessment of the analgesic efficacy of the extended-release combination formulation of bupivacaine and meloxicam (Study 33-12, Study 33-13, Study 33-14). The reduced sensitivity in the VF test was expressed as an increase in the withdrawal force and therefore reflecting the analgesic effect of the test article. The applicant has highlighted that compared to saline and as expected a significant beneficial effect  following  instilling  dosing  of  various  extended-release formulations, containing ropivacaine or BPV, versus vehicle was observed during the study. Best scores were obtained after 6 days for G5 and G6, however score obtained in G6 should be tempered based on the presence of buprenorphine (analgesic effect). The applicant has stated that 'Meloxicam demonstrated the optimal profile of potency (to allow a practical dose for incorporation in the matrix) and other physicochemical properties, such as solubility, for use in combination  with  bupivacaine  formulated  with  the  TEG-POE  polymer.'  However,  there  is  no  clear demonstration how MLX was the perfect candidate compare with other NSAID and since local pH variation is the key factor why a standard pH modulator has not been used. In other words, there is no proper demonstration that MLX acts as an active substance, in that case MLX would be equivalent to an excipient and the product may not rely on the EMA/CHMP/158268/2017 guideline on fixed combination medical. The applicant has compared the analgesic potency of HTX-002-01 (BPV 316 mg), HTX-011-03 (BPV 351 mg / MLX 81.9 mg) and Exparel (BPV 106.4 mg) over saline test article. Saline, HTX-002-01, and HTX011-03 were administered by instillation, and liposomal bupivacaine was administered by injection in each side of the wound. Increasing analgesia scores of the various test articles are reported in Fig 4. HTX-002-01 is an extended-release formulation of bupivacaine alone designed to release bupivacaine for  144  hours.  HTX-011-03  is  an  extended-release  combination  formulation  of  bupivacaine  and meloxicam designed to release bupivacaine and meloxicam for 144 hours. Liposomal bupivacaine was designed to release bupivacaine for up to 96 hours. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 4: Analgesic effect of an extended-release combination formulation of bupivacaine and meloxicam, extended-release formulation of bupivacaine alone, and liposomal bupivacaine

<!-- image -->

The choice of the concentration of BPV in Exparel is questionable in order to compare the nociceptive activity of various formulations in this animal model. Scores obtained for HTX-002-01 and Exparel have been  previously  discussed.  From  Fig  4  it  appears  that  full  analgesia  was  obtained  from  1hr  pots administration till 144 hrs without any drop of the effect. These results seem to demonstrate that addition of MLX to BPV led to a higher effect or did maintain the effect at the same level for a long period. Therefore,  from  that  aspect  potency  of  HTX-011-03  &gt;  HTX-002-01  &gt;  Exparel  and  has  shown  a 'synergistic  activity'  of  the  combination.  As  previously  hypothesized,  full  analgesia  at  1hr  pots administration is the result of a 'burst effect' releasing locally BPV. Nevertheless, the full potency for HTX-011-03 observed during almost all the timepoints is questionable since it is not known if that potency is directly linked to the 'synergistic activity' or related to the high dose level of MLX involved. Thus, the choice of a high dose in MLX (81.9 mg) is debatable since this dose is by far superior to the highest dose used in humans (15 mg/day). 81.9 mg in MLX for a mini pig of 40 kg would correspond to a human dose of 116 mg based on a human of 60 kg. Overall, superiority of HTX-011-03 over HTX-002-01 is only partially demonstrated. The applicant was asked to discuss the rationale for the dose selection in MLX used in HTX-011-03. The applicant did justify the use of a high dose of MLX in the context of sustainedrelease. This was considered acceptable. Nevertheless, there is no indication based on PK data that the effective  daily  release  of  MLX  and  how  closed  it  is  to  the  maximum  daily  oral  dose  in  humans  (15 mg/day). It is not clear why a strong analgesia is observed so quickly whatever the formulation used and  less  is  known  regarding  the  minimum  effective  local  concentration  in  BPV  (released  from  the polymer) to have a pharmacological effect on pain release. In addition, it is observed that combination with MLX results in higher efficacy. c)  Administration  of  bupivacaine  and  meloxicam  in  the  extended-release  combination formulation results in a greater analgesic efficacy than bupivacaine alone or meloxicam alone in the extended-release formulations (Study 33-12, Study 33-14 and 33-24). Treatment with bupivacaine and meloxicam was more active than the treatment with meloxicam alone. Treatment with bupivacaine and meloxicam at a volume of 3.4 ml was more active than treatment with half concentration or half volume (1.7 ml) suggesting a dose related effect. Medicinal product no longer authorised

Treatment with the same bupivacaine and meloxicam concentration using DMSO is more active than using NMP carrier.

Based  on  results  obtained  from  studies  33-12,  33-14  and  33-24,  the  applicant  has  compared  the analgesic effects of HTX-002-01 (BPV 316 mg), HTX-011-10 ( BPV 234 mg / MLX 8.9 mg), HTX-009-003

<div style=\"page-break-after: always\"></div>

(MLX 3 mg) and liposomal BPV Exparel (106.4 mg).  HTX-002-01 is an extended-release formulation of BPV alone designed to release BPV for 144 hours. HTX-009-03 is an extended-release formulation of MLX  alone  designed  to  release  MLX  for  72  hours.  HTX-011-10  is  an  extended-release  combination formulation of BPV and MLX designed to release BPV and MLX for 72 hours. Liposomal bupivacaine was designed to release BPV for up to 96 hours.

<!-- image -->

Overall, it can be concluded that local administration of extended-release formulation of BPV and MLX (HTX-011-10) was more efficient than extended-release formulation of BPV (HTX-002-01) between 2448 hrs with the same tendency up to 72 hrs. Therefore, MLX seemed to prolong the analgesic efficacy of BPV after 24 hrs. Based on these results and scores obtained up to 24 hrs pots incision, it appears that release of BPV and MLX or time residency at the local site of administration were different. A question was raised if there a real extended-release for both substances or if real extended-release is observed solely  for  MLX.  The  applicant  has  answered that the same TEG-POE polymer is used to achieve the

Figure 5: Analgesic effect of extended-release formulations of bupivacaine alone or meloxicam alone, extended-release combination formulation of bupivacaine and meloxicam, or liposomal bupivacaine The  applicant  stated  that  'local  administration  of  an  extended-release  combination  formulation  of bupivacaine  and  meloxicam  results  in  greater  and  longer  analgesic  efficacy  compared  with  local administration of extended-release formulations of each individual active ingredient alone.' The choice of the concentration of BPV in Exparel is questionable in order to compare the nociceptive activity of various formulations in this animal model. From Fig 5 it appears that similar efficacy between HTX-002-01 and HTX-011-10 is observed at 3-5 hrs post incision corresponding to the maximum efficacy of Exparel with an overall lower effect compared with those from HTX-002-01 and HTX-011-10. Analgesic effect of HTX-002-01 dropped after 24 hrs whereas analgesic effect reached its maximum for HTX-01110.  Therefore,  superiority  of  HTX-011-10  over  HTX-002-01  was  demonstrated  between  24-48  hrs. Nevertheless, based on the high SD observed at 72 hrs for HTX-011-10, superiority of HTX-011-10 over HTX-002-01 was less pronounced. Since HTX-002-01 was designed to release BPV for 144 hrs and HTX011-10 was designed to release BPV and MLX for 72 hours, it would have been interesting to follow the analgesic  effect  over  144  hrs.  Regarding  HTX-009-03,  analgesia  scores  were  the  lowest  observed throughout all the time-period demonstrating that MLX alone was not sufficient to provide a satisfying analgesic effect. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

extended release in all HTX-002 and HTX-011 (and HTX-009, meloxicam only) formulations tested in nonclinical  and  clinical  studies  including  HTX-011-56,  the  intended  commercial formulation tested in Phase  2b  and  Phase  3  clinical  studies.  PK  and/or  in  vitro  release  (IVR)  profiles  have  been  used  to demonstrate the extended release of bupivacaine and meloxicam from HTX-011 and bupivacaine from HTX-002 for several formulations as well as meloxicam from HTX-009. Applicant's response underlined that both polymers were not designed to release BPV over the same length period. The applicant has acknowledged that although no PK data are available for HTW-011-10, IVR profile was submitted of both active  ingredients  BPV  and  MLX.  The  applicant  has  considered  similar  profiles  for  both  compounds nevertheless the extended release for MLX appeared more delayed in comparison with BPV. Whereas the applicant  has  considered  that  BPV  PK  profile  is  not  modified  by  MLX  presence  (see  Figure  5),  both polymers were not designed to release BPV over the same period. Based on Figure 5, it cannot be concluded that difference in PK profile between BPV and MLX is due to MLX clearance. Indeed, it appears that MLX release seems to be delayed but it is unknown how valuable could be the in vitro/in vivo correlation. In addition, as previously mentioned, real description of the PK profile of Zynrelef is difficult to  figure  out  since  only  a  part  of  the  process  is  observed  (after  systemic  passage).  In  conclusion, extended release is observed for BPV and MLX, however PK profile cannot be considered similar and MLX's  release  from  the  matrix  appears  more  delayed.  Uncertainties  remain  regarding  the  whole  PK process and no translation to Human can be drawn. Superiority of BPV: MLX extended-release over BPV only extended-release is significant between 24-48 hrs post incision. d) Determination of the lowest effective Meloxicam: Bupivacaine ratio in an extended-release formulation In Study 33-61, treatment with HTX-011-056 has resulted in the most prolonged analgesic effect and was more effective than HTX-011-062 or HTX-011-063 (no difference between HTX-011-062 and HTX011-063). All compounds contained BPV at a concentration of 2.5%w/w with different concentration of MLX. HTX-11-056 contained the highest concentration of MLX (0.075% w/w) compared to HTX-011-062 (0.038% w/w) and HTX-011-063 (0.019% w/w). Therefore, Study 33-61 has highlighted that a dose increase in MLX will enhance efficacy. In addition, increase in MLX concentration has also been associated with a raise in efficacy at Day 4 with a maximum observed at Day 5 for HTX-011-56 in comparison with HTX-011-062  and  HTX-011-063.  The  applicant  was  expected  to  explain  why  HTX-011-56  profile  is different after Day 4 whereas similarity was observed for HTX-011-62 and HTX-011-63. The applicant did justify discrepancies due to abnormal response from Animal 28. The answer provided was endorsed. In Study 33-68: · Superiority of treatment was observed with HTX-011-056 (Group 3) or HTX-011-074 (Group 5) vs Bupivacaine and Eloxijet even when Eloxiject was dosed at a higher dose (6 mg; Group 2). Coadministration of bupivacaine HCl and meloxicam (Eloxijet) solutions showed an analgesic effect, which significantly lower, when compared to HTX-011-056. Increasing the concentration of  meloxicam  from  0.075%  w/w  to  0.15%  w/w  (HTX-011-074)  significantly  increased  the analgesic effect when compared to HTX-011-056. It appears that superiority of HTX-011-074 was  observed  over  HTX-011-56  and  HTX-011-072  in  specific  time  points.  Therefore,  the applicant was expected to discuss why formulation HTX-011-074 was not selected as the final formulation instead of HTX-011-56. The applicant justifies the development of HTX-011-56 based on its lowest effective MLX:BPV ratio in the extended-release combination formulation. This is acknowledged, also in light of the results obtained in clinical studies. Medicinal product no longer authorised

No dose-response relationship (trend of effect of HTX-011-072 always reduced compared to HTX-01156) in the mean von Frey force required for withdrawal. A question was raised on how this be justified in light of the rationale proposed behind the use of such combination therapy. The applicant presented the relationship between the average von Frey withdrawal force and the MLX:BPV ratio. A clear dose

<div style=\"page-break-after: always\"></div>

(MLX:BPV ratio) response with increasing amounts of meloxicam can be extrapolated. These data further justify the choice of developing HTX-011-56, which presents the lowest effective MLX:BPV ratio in the extended-release combination formulation.

e)  Systemic  administration  of  meloxicam  does  not  enhance  analgesic  efficacy  of  locally administered bupivacaine alone in the extended-release formulation Conclusion of the applicant claiming superiority of HTX-011-56 over HTX-002-13 could be accepted until 24 hrs and after 48 hrs even though high variability has been observed. Returns in analgesia profile is observed but this phenomenon was not explained. f)  Determination  of  a  potential  mechanism  by  which  meloxicam  enhances  the  analgesic efficacy of bupivacaine Study 33-87 should be considered as the key study to justify the use of MLX regarding the effect on pH variation. A drop of pH was only observed on the intra-dermal area whereas no drop was observed on the intra-incisional area. In addition, discrepancy is observed wherein raise in pH is observed when HTX011-56 is used. Indeed, if a raise in pH is observed after a drop due to incision, it would have been observed at the intradermal interface, therefore the raise described would correspond to the intradermal part. However, HTX-011-56 would be applied below the skin incision (intra-incisional) where no drop in pH was observed therefore the use of MLX as pH modulator is confusing and should be discussed by the applicant. The applicant has stated that: ' the Agency ' s interpretation of Figure 2 in Study Report 3387 is correct: a drop in the pH was observed in the intradermal tissues surrounding the incision and not inside the intraincisional pocket formed by the incision. The pH in the intraincisional pocket does not decrease  because  the  mechanism  of  pH  drop  (vasoconstriction  and  infiltration  and  activation  of neutrophils)  occurs  within  the  tissues  (details  are  described  in  the  response  to  the  Major  Objection #264) '. The applicant has acknowledged that Section 2.6.2.2.1.3 and related descriptions in the text are not clear. Rise in the pH is observed in the intradermal tissues surrounding the incision due to MLX presence via diffusion. However, less is known regarding local concentrations in MLX and time residency at this interface and no reply would be given by the applicant and therefore the issue was not pursued. In addition, PK results generated in pigs have shown a similar PK profile between BPV and MLX, whereas significant differences were observed in dogs and rats species. Secondary pharmacodynamic studies No secondary pharmacology studies were conducted. Safety pharmacology programme The applicant conducted hERG test with MLX that was in principle not in accordance with the regulatory standards. However, IC20 inhibition of hERG would correspond to a circulation concentration in MLX of 10 000 ng/mL whereas Cmax observed at the MHRD (BPV 400 mg/ MLX 12 mg) was measured between 270-527 ng/mL. Moreover, Cmax values are 4-fold lower than the mean Cmax measured with the lowest approved oral dose of MLX (MOBIC 7.5 mg/day), no effects on ECGs were observed during repeateddose toxicity  studies  and no  effect  on  QT  was  observed  in  clinic.  Overall,  the  effects  on  CV  can  be considered as potentially low. Medicinal product no longer authorised

## Pharmacodynamic drug interactions

No pharmacodynamic drug interactions studies were conducted.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacokinetics

The following studies were conducted:

- 2 absorption studies with HTX-011-56 in rats (study 33-79) and dogs (33-36).

<!-- image -->

<!-- image -->

· 1 excretion study with HTX-011-56 in minipigs (study 33-77). · 1 PK drug interaction study with HTX-011-56 and lidocaine in minipigs (33-78). · 2 other PK studies with bupivacaine alone and meloxicam alone in extended-release formulations in dogs (study 33-47 and study 33-69). In the absorption studies, exposure to bupivacaine and meloxicam following administration of HTX-01156 was assessed in rats and dogs following a single subcutaneous administration. In Study 33-79 male and female rats (9/sex/group) were administered as a single SC dose HTX-011-56 at a low (25 mg/kg bupivacaine and 0.75 mg/kg meloxicam) or a high (50 mg/kg bupivacaine and 1.5 mg/kg meloxicam) dose level. Table 3: Mean PK parameters for bupivacaine and meloxicam in SD rats following a single SC administration of HTX-011-56 (Study 33-79) a  Not calculated due to insufficient number of samples. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 6: Mean concentration-time profiles of bupivacaine and meloxicam in SD rats following a single SC administration of HTX-011-56 (Study 33-79)

<!-- image -->

In Study 33-36, male and female Beagle dogs (5/sex/group) were administered a single SC dose of HTX011-56 (6.96 mg/kg bupivacaine and 0.209 mg/kg meloxicam for males and 6.66 mg/kg bupivacaine and 0.200 mg/kg meloxicam for females). The objectives of the Study 33-77 were to measure levels of the primary hydrolysis products triethylene glycol (TEG), pentaerythritol monopropionate (PEMPA), pentaerythritol (PE), the metabolite triethylene glycol monocarboxylic acid (TEG acid), bupivacaine (BPV), and meloxicam (MLX) in the plasma, milk, and urine of nursing sows following a SC dose of HTX-011-56 within 48 hours of farrowing, and to measure levels of TEG, PEMPA, PE, TEG acid, BPV, and MLX in the plasma, and urine of piglets following dosing to the sows. The aim of Study 33-78 was to determine the PK profiles of BPV and MLX after a single administration of HTX-011 to a 5 cm incision with or without lidocaine in naïve male Yucatan minipigs (12 animals: 3 / group). Lidocaine co-administration with HTX-011-56 did not result in any significant modification of the individual PK parameters of BPV and MLX. In Study 33-47 (Study Report 33-47), male and female dogs (5/sex/group) were administered a single SC  dose  of  bupivacaine  alone  in  an  extended-release  formulation  HTX-002-13  wherein  HTX-002-13 contains the same amount of bupivacaine as HTX-011-56. In Study 33-69 (Study Report 33-69), male and female dogs (5/sex/group) were administered a single SC dose of meloxicam alone in an extended-release formulation (HTX-009-05). HTX-009-05 contains the same amount of meloxicam as HTX-011-56. Medicinal product no longer authorised

The  distribution  and  excretion  of  the  TEG-POE  polymer  in  HTX-011-56  were  evaluated  during  the development  of  United  States  (US)-approved  parenteral  product,  SUSTOL ®   (granisetron)  extendedrelease injection, for subcutaneous use. SUSTOL is formulated with vehicle, APF18A, which is composed of 80% TEG-POE polymer and 20% methoxypolyethylene glycol (MPEG)-550.

<div style=\"page-break-after: always\"></div>

In the development of SUSTOL, the TEG-POE polymer was assessed following SC local administration consistent with the Food and Drug Administration (FDA) Guidance for Industry on Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (May 2005) and Committee for Medicinal Products for Human Use (CHMP) Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product (EMEA/CHMP/QWP/396951/2006, June 2007).

To assess the distribution and excretion of the TEG-POE polymer in APF18A, the TEG moiety was randomly labeled throughout the molecule. Thus, the results of these assessments provide information on the distribution and excretion of the TEG-POE polymer in HTX-011-56. 2.3.4. Toxicology Single dose toxicity Single dose toxicity studies did not reveal any systemic toxicity. No deaths were recorded, no effect on food consumption, body weight, urinalysis parameters, on coagulation, on haematological parameters… were observed. The main observed effects were localised at the injection site and clinical signs observed consist  mainly  in  crust,  lesions,  and  skin  discoloration.  Microscopic  findings  at  the  dosing  site corresponded to minimal to moderate SC necrosis, inflammation, oedema, epidermal erosive/ulcerative inflammation. Overall, all the test articles were well tolerated and TK analysis have highlighted exposure to all tested animals. Repeat dose toxicity Repeated-dose toxicity studies with up to a 15-day observation period were conducted in SD rats or beagle  dogs  with  the  aim  to  assess  systemic  and  local  toxicity  of  HTX-011-56  under  exaggerated conditions. No mortalities were observed during both studies and no findings suggestive of systemic toxicity.  In  rats  (study  33-85),  similar  non-adverse  inflammatory  findings  were  observed  following administration  of  HTX-024-02  or  HTX-011-56  at  the  dosing  sites  as  in  the  single-dose  studies nevertheless incidence and severity were higher compared to single dose toxicity studies. Full recovery of the inflammatory changes was almost observed at the end of the observation period. In dogs (study 33-86), adverse findings were observed in animals (except saline group). In animals administered HTX024-02, moderate to severe oedema and hypoactivity, dermal scabs, and swollen sites were present and serosanguinous fluid at the dosing sites of some animals were noticed. Decreases in body weights and changes in clinical pathology parameters were linked with acute inflammatory reaction to HTX-024-02. Based on these events, dose volume for HTX-024-02 was decreased from 1 mL/kg to 0.5 mL/kg. Overall, HTX-011-56 was well tolerated and no systemic toxicity was observed. Supportive data with TEG-POE polymer Nonclinical  toxicology  studies  of  APF18A  were  conducted  in  the  development  of  the  US-approved parenteral product, SUSTOL. Because APF18A is composed of 80% TEG-POE polymer, the nonclinical toxicology studies conducted with APF18A administered SC are relevant to the assessment of safety of the TEG-POE polymer in HTX-011-56. The TEG-POE polymer has been qualified in: Medicinal product no longer authorised

- 2 GLP repeated-dose toxicity studies in rats and dogs;
- 2 GLP in vitro genotoxicity studies + 1 GLP in vivo genotoxicity study in rats

<div style=\"page-break-after: always\"></div>

- 4 GLP Segments 1 through 3 reproductive and developmental toxicity studies in rats and rabbits that evaluated APF18A.

The  results  of  the  repeated-dose  studies  of  APF18A  were  consistent  with  those  conducted  in  the development of HTX-011-56.

<!-- image -->

Single SC administration of HTX-011-56 in a surgical bone defect model was clinically well-tolerated. No differences in bone in-growth or regeneration of the adipose and hematopoietic tissue when compared to untreated or saline-treated limbs. The NOEL was set to 45.4 mg/kg BPV with 1.37 mg/kg MLX.

· No systemic toxicity. · At the dosing sites, transient inflammatory changes. · No genotoxic potential · No reproductive and developmental toxicity of the TEG-POE polymer. Genotoxicity An Ames test was conducted in accordance with OECD guideline with a product derived form HTX-01115 wherein relative BPV and MLX concentrations are higher, 4-fold and 20-fold respectively. In presence and/or absence or S9 metabolic activation system no significant increase in the number of revertant colonies was observed and therefore it was concluded that HTX-011-15 was not genotoxic and by analogy HTX-011-56 as well. In addition, the applicant has submitted results of genotoxicity studies conducted on APF18A polymer that should support the use of the TEG-POE polymer in HTX-011-56. Applicant was expected to discuss why the standard genotoxicity test battery is not needed. Applicant's response was based on previous results regarding BPV and MLX. Concerning the evaluation of the genotoxic potential of TEG-POE, the applicant relied on in vitro data (mutagenicity item) and in vivo data (rat µnucleus). Moreover, the applicant has justified the lack of standard genotoxicity test battery for HTX-011-56 since an Ames test was performed with HTX-011-15 which contains higher concentrations of MLX, BPV and TEG-POE.  In  addition,  genotoxicity  testing  was  in  line  with  CHMP  Guideline  for  the  non-clinical development of fixed combinations of medicinal products (CHMP/SWP/258498/05; January 2008) and ICH M3(R2). Carcinogenicity No carcinogenicity studies were conducted. Reproduction Toxicity Reproductive and developmental toxicity studies were not conducted. Relevant data is already available from  product  information  for  already  approved  medicinal  products  containing  bupivacaine  and meloxicam. Local Tolerance Local tolerance was assessed in 6 GLP studies Study 33-83 Medicinal product no longer authorised

## Study 33-80

<div style=\"page-break-after: always\"></div>

Findings  observed  (surgical  site  skin  bruising,  discoloration,  swelling)  were  procedure-related  and moderate erythema and oedema were observed on the surgical site. No differences between control and test  groups  for  any  of  the  three  types  of  meshes,  were  observed.    No  treatment-related  biological changes  for  any  of  the  three  types  of  mesh  implantation.  All  pathology  findings  were  comparable regardless of the type of surgical mesh. This study has demonstrated that single administration of HTX011-56 with implantation of surgical meshes Gore-Tex, polypropylene, or polyester was biocompatible and tolerable. No adverse impact on the integrity of the tested meshes after implantation up to 14 days were noted.

Study 33-41 No increase in incidence or severity of the dermal and/or subcutaneous changes indicative of normal and comparable reparative process at incision sites after administration of all three tested items compared to the control (saline and vehicle) and comparator (HTX-002-014). No difference in healing between test items and the comparator and the changes observed were considered to be related to the normal process of healing. Study 33-54 BPV/ MLX induced a slightly increased incidence of the findings but these changes were apparent at a low incidence. Minimal differences of incidence and severity of the dermal and/or subcutaneous changes were observed across all controls, BPV and MLX incision sites indicative of comparable reparation. Study 33-42 Single administration of HTX-024-001 Vehicle Control, HTX-002-14, HTX-011-49, or HTX-011-56 as a brachial plexus block in dogs was well tolerated with no adverse findings evident 3 or 14 days following administration. Study 33-63 Perineural administration to male beagle dogs of HTX-011-056 and bupivacaine HCl (reference) for 3 consecutive days, were well tolerated. Anaesthetic properties of HTX-011-056 were demonstrated, but there was no indication of prolonged effects when compared to bupivacaine HCl. There were no gross or microscopic changes related to HTX-011-056 or bupivacaine HCl were noticed. Higher Clast confirmed the extended kinetics of HTX-011-056 when compared to bupivacaine HCl. 2.3.5. Ecotoxicity/environmental risk assessment The applicant has submitted a justification for the absence of a complete Environmental Risk Assessment (ERA) for bupivacaine in the marketing authorization application (MAA) for Zynrelef (bupivacaine and meloxicam)  prolonged-release  wound  solution.  A  separate  ERA  document  has  been  prepared  for meloxicam. The justification for the absence of a complete ERA for bupivacaine is on the basis that it is already utilized in a variety of approved drug products and Zynrelef is intended to replace the use of already existing bupivacaine-containing drugs at a same or lower dosage, thereby not significantly increasing the overall environmental exposure of the active ingredient, bupivacaine. The absence of significant increase  of  the  environmental  exposure  is  furthermore  demonstrated  by  comparing  the  recent bupivacaine EU consumption data with the expected production volume for Zynrelef. Medicinal product no longer authorised

From meloxicam ERA assessment it appears that the logDow value of meloxicam is below 3 (i.e., logDow = 1.6 at pH 5, 0.1 at pH 7 and -0.5 at pH 9). Therefore, it is not identified as a PBT or a vPvB substance.

<div style=\"page-break-after: always\"></div>

The Phase I PECSW of meloxicam (0.00049 μg/L) does not exceed the action limit of 0.01 μg/L, and meloxicam is not expected to affect the reproduction of vertebrate or lower animals at concentrations lower than the action limit of 0.01 μg/L. A Phase II environmental fate and effects assessment is thus not triggered.

<!-- image -->

2.3.6. Discussion on non-clinical aspects The applicant has submitted a pharmacological package based on experiments performed in piglets wherein POP in pigs was chosen as the animal model. POP in pigs is a usual model and therefore it is acceptable  to  demonstrate  the  POC  of  HTX-011-56  in  this  model.  The  aim  of  these  studies  was  to demonstrate the analgesic efficacy of locally administrated extended-release formulation of BPV and MLX. Main claim of efficacy is based on the use of low dose of MLX in the formulation in order to normalize the local pH of the acid environment (caused by the incision) and therefore modify the ratio between ionized: un-ionized form of BPV. Only the un-ionized form is able to penetrate into the nerves and thereby enabling analgesic activity. Overall, the elements presented to support the POC needed clarifications since some discrepancies have been noticed in the interpretation of the studies conducted. Indeed, the main question mark relies on the pH variation at the site of administration wherein from data submitted no pH drop was observed in study 33-87 and therefore the necessity of use of MLX was questioned. Prior to that, the applicant has attempted to demonstrate the superiority of an extended formulation of BPV  alone  (HTX-002-1)  over  liposomal  BPV,  but  the  choice  of  that  comparator  in  terms  of  BPV concentrations was not optimal. Thus, overall superiority of HTX-002 could be considered as partially demonstrated. The applicant has studied the analgesic efficacy of the extended-release combination formulation of BPV and MLX in studies 33-12, 33-13 and 33-14. The results generated demonstrate that that addition of MLX to BPV led to a higher effect or did maintain the effect at the same level for a long period. Therefore, from  that  aspect  potency  of  HTX-011-03  &gt;  HTX-002-01  (BPV  only)&gt;  Exparel  and  has  shown  a 'synergistic activity' of the combination. Nevertheless, since very high concentration of MLX was used in HTX-011-03, these results have to be tempered. Local administration of extended-release formulation of BPV and MLX (HTX-011-10) was more efficient than extended-release formulation of BPV (HTX-002-01) between 24-48 hrs with the same tendency up to 72 hrs. Regarding HTX-009-03, analgesia scores were the lowest observed throughout all the timeperiod demonstrating that MLX alone was not sufficient to provide a satisfying analgesic effect. Overall, MLX seems to prolong the analgesic efficacy of BPV after 24 hrs. Based on these results and scores obtained up to 24 hrs. post-incision, it appears that release of BPV and MLX or time residency at the local site of administration were different. The applicant has highlighted that systemic administration of MLX does not enhance analgesic efficacy of locally administrated BPV alone in the extended-release formulation. Indeed, superiority of HTX-01156 over HTX-002-13 could be accepted until 24 hrs and after 48hrs even though high variability has been observed. PK  profile  of  HTX-011-56  has  been  investigated  throughout  PK  studies  of  various  extended-release formulations  in  rat  and  dog  species.  Although  the  PK  development  program  is  consequent  many uncertainties remain and lack of some studies have not been justified by the applicant. Medicinal product no longer authorised

The CHMP did not require any new animal studies since it appears from the dossier that no correlation can be drawn between animal PK vs Human PK. In addition, it can also be said that no correlation can be made between in vitro release and in vivo PK.

<div style=\"page-break-after: always\"></div>

Uncertainties remain due to the lack of the knowledge of local concentration in BPV and MLX and the effect  observed.  It  is  acknowledged  that  an  extended  release  is  observed  for  the  two  substances, however the regimen of delivery from the polymer seems different based on systemic levels. Indeed, BPV is massively and rapidly released from the polymeric support whereas MLX's release is slower and with a lower intensity. Therefore, based on concentrations, efficacy observed during pharmacological studies is difficult to be properly understood.

The  applicant  did  not  conduct  any  study  regarding  distribution  of  HTX-011-56  based  on  structure similarity with the polymer used in SUSTOL. Nevertheless, those two polymers are not 100% identical and less is known regarding the impact of bupivacaine and meloxicam in distribution. Moreover, data provided by the applicant revealed that the distribution study seems to have been performed with the unloaded polymer i.e.  without  the  active  substance.  However,  based  on  the  presented  results,  it  is expected that the highest mean concentration of HTX-011-56 would be observed at the injection site. In addition, presence of the two active substances may have an impact on the overall physico-chemical parameters of the polymer and therefore distribution may be modified. Thus, the applicant had to justify the lack of distribution studies with HTX-011-56. The applicant has submitted a justification for the lack of distribution studies with HTX-011-56 in line with the provisions of article 10b of Directive 2001/83/EC.

In study 33-79, the applicant did conclude that no sex differences were observed for BPV, however high variation in Tmax value measured for BPV (25 mg/kg) is observed between male (6 hrs) and female (30 min) rats. The same tendency is observed with the highest dose in BPV (50 mg/kg). Moreover, it appears that Tmax and T1/2 for BPV and MLX in rats are different whatever the sex chosen whereas similarity was observed for both substances in pigs (study 33-87). In addition, from Study Report 33-79 mean concentration-time profiles are different in terms of curve shape between BPV and MLX. Therefore, the applicant was expected to discuss the difference observed in curve shape and possible relationship with extended release. The applicant underlines that inter-animal variability and sample assay variability can result in differences in mean Tmax and attributed to the plateau in BPV observed until 12 hrs post dose. This information did not appear in PK profile presented for BPV in study 33-79. A similar answer was given  for  MLX  based  on  limited  number  of  sampling  time  points  in  the  terminal  phase  and  this  is acknowledged. MLX t1/2 value presented in the dog PK study (study 33-36) has shown high variability with an important SD, therefore mean-concentration time profiles for MLX (study 33-36) are of weak interest since it is based on pool values with a high SD. Therefore, information generated during PK studies  are  not  very  supportive.  The  applicant  considered  that  'curve  shapes'  of  bupivacaine  and meloxicam in rats in study 33-79 appear different because the clearance is very different for these compounds. Although the applicant relied on IVR study to ascertain that BPV and MLXD release are equivalent and differences observed in the curve shapes in rats study are related to different kinetic of clearance. Nevertheless, in vivo results in animals have shown difference in terms of PK profile therefore IVR cannot be considered as supportive to describe similarity of release between the two substances and no in vitro/in vivo correlation can be drawn. As observed in study 33-79, it has been observed during study 33-36 that PK profiles for BPV and MLX are different in dog species (study 33-36) with curve shapes 'similar' in rats and dogs, however no sex difference was observed. Based on observed Tmax and T1/2 higher for MLX vs BPV, the applicant was expected to discuss why these results are not observed in pig species and which animal species is the most relevant to Human in terms of PK properties. The applicant identifies the rat species as being the most relevant to humans in terms of PK properties. This is substantiated from the data obtained from the  applicants'  own  studies  as  well  as  literature  reports.  The  applicant  has  discussed  further  the differences  on  Tmax  and  T1/2  that  are  higher  for  meloxicam  vs  bupivacaine  in  different  species. Differences in the meloxicam PK curves between pigs and rats and dogs are due to the faster clearance of  meloxicam  in  pigs  ([Pig  (mature;  ~220  kg)  CL=  0.72  mL/min/kg  vs  Dog  (~12  kg)  CL=  0.15 mL/min/kg]; Busch 1998, Pairis-Garcia 2015). The issue was considered as resolved. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Zynrelef is a medicinal product containing active substances used in the composition of other authorised medicinal products but not hitherto used in combination for therapeutic purposes. Taking the above into consideration, Directive 2001/83/EC codifies that results of new pre-clinical tests or new clinical trials relating to that combination shall be provided in a stand-alone new marketing authorization application (article  8(3)),  however,  it  shall  not  be  necessary  to  provide  scientific  references  relating  to  each individual active substance. The applicant also referred to study 24-21 that evaluated the distribution and excretion of the TEG-POE polymer used in HTX 011 56 and discusses that polymer remains at the administration site until it is hydrolysed. While study Report 24-21, indicates that the administration site has the highest concentration of polymer at 24 hours postdose, before significant hydrolysis occurs, which is the same with HTX-011-56. The applicant concludes that although the active ingredients have an impact on their release rate from the formulation, they do not impact the physico-chemical properties of the TEG-POE polymer. Taking all the arguments put forward on the lack of distribution studies with HTX-011-56, the applicant's justification is upheld.

Study 33-78 has demonstrated that Lidocaine co-administration with HTX-011-56 did not result in any significant modification of the individual PK parameters of BPV and MLX. In study 33-47, based on the PK results the applicant has demonstrated that presence of MLX into the polymer does not modify PK properties of BPV since similarity PK profile was observed for BPV in the two extended-release formulations HTX-011-56 and HTX-002-13 (BPV only). In study 33-69, based on the PK results the applicant has highlighted that presence of BPV seems to interact with PK profile of MLX. It appears that in the extended-release formulation containing only MLX i.e. HTX-009-05, MLX is absorbed faster as shown by earlier Tmax and a higher Cmax. This aspect is in opposition  to  what  was  observed  previously.  Thus,  the  applicant  was  expected  to  discuss  why  BPV presence modifies PK profile of MLX whereas MLX has no effect on BPV PK properties. The applicant has acknowledged that MLX is absorbed faster from HTX-009-05 (MLX only) than HTX-011-56 (BPV and MLX co-formulation). Although PK profiles seemed different, AUCs observed in MLX (for the same loading) were on the same range. The applicant did conclude that no metabolic-drug interaction was observed and this position is endorsed. Regarding the release from the polymeric support, the applicant has agreed that differences observed are related to the formulation. Applicant's demonstration relies on the hydrolysis of the polymer moiety that requires protons to be engaged. Since BPV base was integrated into the polymer, the applicant has indicated  that  protonation  of  BPV  would  result  in  protecting  the  polymeric  moiety  from  degradation (throughout hydrolysis process) and therefore MLX's release, wherein no BPV is added into the polymer, would be shorter.  Based  on  IVR  data  of  MLX  from  HTX-009-05  and  HTX-011-56,  the  applicant  has concluded that extended-release of MLX in HTX-009-05 occurred over 48 hrs. vs 72 hrs. in presence of BPV. Therefore, it was concluded that the difference in MLX PK profile was due to the difference of the formulation and not any biological interactions between BPV and MLX. This explanation could not be fully endorsed.  Indeed,  it  is  acknowledged  that  extended-released  is  observed  for  the  two  compounds, however differences were observed during in vitro studies and PK in vivo studies (study 33-79, study 33-36…). From the IVR of BPV and MLX in HTX-011-10, it appears that competition in terms of release from the polymeric support is observed in favour of BPV. The kinetic of release of BPV is faster in the first 24 hrs. for BPV in comparison with MLX. This phenomenon is supported by mean BPV concentration observed in vivo PK studies wherein a massive release is observed quickly. These aspects demonstrate that MLX's release from the polymeric support is not governed by BPV protonation, preventing hydrolysis of the polymer. Otherwise, MLX's release would be faster than BPV after the deposit. Therefore, the release from the polymeric is based on a diffusion-related process in favour of BPV. Indeed, in vivo animal  PK  studies  have  underlined  that  extended-release  was  observed  for  both  substances, nevertheless  this  extended-release  is  sustained  with  low  BPV  concentrations  whereas  higher  MLX's concentrations are observed. Thus based on these animals it can only be concluded that a massive burst Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

release in BPV is observed rapidly and remaining concentrations are released slowly over the time-period. In the other hand, MLX's PK profile in animals is more common to a classical extended release. Efficacy observed during pharmacology studies is finally difficult to interpret based on animal PK profile since it appears that BPV seems to be rapidly found in plasma (high concentrations) and it is not known which is the lowest local concentration sufficient in BPV in order to a pharmacological effect occurs. Shift in MLX's release is in favour of sustaining the effect of BPV, however there is not a full understanding of the mechanism based on pharmacology and PK studies. Thus, PK data cannot explain what is observed and no translation to Human can be made in terms of PK.

| Study No.            | Study Design and Population                                                      | Treatments (N)a                                                                 |
|----------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Phase 1              |                                                                                  |                                                                                 |
| 02 (The Netherlands) | Open-label, saline placebo-controlled, single-ascending dose, PK, safety, and PD | • HTX-011-19: 100 mg/3 mg (N=11), 200 mg/6 mg (N=5), or 400 mg/12 mg (N=11) via |

Overall, the applicant believes that study 24-21 provides sufficient information on the distribution of the TEG-POE moiety in HTX-011-56. Nevertheless, as previously mentioned behaviour of the fully loaded polymer (with the two active substances) may differ from APF18A polymer. No nonclinical pharmacodynamics drug interaction studies were conducted with HTX-011-56. PD drug interactions  of  BPV  and  MLX  alone  are  known  and  therefore  information  in  drug  PD  interactions  is available from clinical experience. Anaesthetics are known to have the potential to enhance the CNS toxicity (respiratory depression) of concomitantly applied opioids (e.g. Becker DE: Adverse drug reactions in dental practice. Anaesth Prog 2014, 61:26-34). Therefore, the applicant provided a thorough discussion concerning the CNS safety of bupivacaine/opioid combinations on basis of published non-clinical data to provide a justification for the absence of own non-clinical interaction studies on this issue. The impurity levels in the batches of drug product used in the nonclinical safety (and clinical) studies were generally very low or not detected. Impurities levels have been treated in accordance with current guidelines and the presented limits are acceptable. 2.3.7. Conclusion on the non-clinical aspects The non-clinical dossier is sufficient to support Marketing Authorisation Application for Zynrelef. 2.4. Clinical aspects 2.4.1. Introduction GCP The Clinical trials were performed in accordance with GCP as claimed by the applicant. The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC. · Tabular overview of clinical studies Table 4: Overview of HTX-011 clinical studies Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Section 2.7.2.2.1.1.1                    | study of 2 earlier HTX-011 formulations in healthy adult volunteers                                                                            | subcutaneous injection • HTX-011-49: 100 mg/3 mg (N=5) or 200 mg/6 mg (N=5) via subcutaneous injection • Saline placebo via subcutaneous                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 102 (US) Section 2.7.2.2.1.1.2           | Phase 1, PK, safety, tolerability in healthy Volunteers                                                                                        | • HTX-011-56 400 mg/12 mg via subcutaneous injection (N=10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Phase 2a                                 | Phase 2a                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 202 (US) Section 2.7.2.2.1.1.3           | Randomized, blinded, placebo- and active-controlled safety, efficacy, and PK study in subjects who underwent herniorrhaphy product no          | injection (N=9) • HTX-011-56 200 mg/6 mg via instillation (N=16) or injection (N=16) • HTX-011-56 300 mg/9 mg via instillation (N=16) • HTX-011-56 400 mg/12 mg via instillation (N=21), injection (N=14), or combination of injection and instillation (N=48) • HTX-002 200 mg via instillation (N=12) or injection (N=9) • HTX-002 400 mg via instillation (N=15) or injection (N=15) • HTX-009 12 mg via combination of injection and instillation (N=12) • HTX-011-19 200 mg/6 mg via injection (N=19) or instillation (N=16) • HTX-011-19 400 mg/12 mg via injection (N=17), instillation (N=20), or combination of injection and instillation (N=17) • HTX-011-49 200 mg/6 mg via injection (N=20) • HTX-011-49 400 mg/12 mg via injection (N=19) • Saline placebo via injection or combination of injection and instillation (N=103) • Bupivacaine HCl 0.25% 75 mg longer authorised |
| 203 (US) Section 2.7.2.2.1.1.4 Medicinal | Randomized, blinded, placebo- and activen controlled safety, efficacy, and PK study in subjects who underwent mini- or complete abdominoplasty | via injection (N=32) Mini-abdominoplasty • HTX-011-56 200 mg/6 mg via injection (N=10) • HTX-011-56 400 mg/12 mg via injection (N=11) or combination of injection and instillation (N=17) • HTX-011-56 600 mg/18 mg via injection (N=10) • HTX-002 400 mg via combination of injection and instillation (N=17) • HTX-011-49 200 mg/6 mg via injection (N=20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                    |                                                                                                                                                     | • Saline placebo via injection (N=63) Complete abdominoplasty • HTX-011-56 300 mg/9 mg via combination of injection and instillation (N=35) • HTX-011-56 400 mg/12 mg via instillation (N=17) or combination of injection and instillation (N=24) • Saline placebo via injection (N=32) • Bupivacaine HCl 0.25% 100 mg via injection (N=17) authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 208 (US) Section 2.7.2.2.1.1.5                     | Randomized, blinded, placebo- and active- controlled safety, efficacy, and PK study in subjects who underwent bunionectomy product no               | • HTX-011-56 30 mg/0.9 mg via injection using Mayo block (N=18) • HTX-011-56 60 mg/1.8 mg via instillation (N=17), injection (N=17), or injection using Mayo block (N=18) • HTX-011-56 120 mg/3.6 mg via instillation (N=37), injection (N=19), or injection using Mayo block (N=18) • HTX-011-56 200 mg/6 mg via injection (N=15) or injection using Mayo block (N=15) • HTX-002 60 mg via injection (N=12) or injection using Mayo block (N=11) • HTX-002 120 mg via injection (N=15) or injection using Mayo block (N=15) • HTX-002 200 mg via injection (N=6) or injection using Mayo block (N=5) • HTX-009 3.6 mg via injection (N=15) or injection using a Mayo block (N=14)HTX-011-49 200 mg/6 mg via injection (N=16) or injection using Mayo block (N=16) • Saline placebo via injection or injection using a Mayo block (N=104) • Bupivacaine HCl 0.5% 50 mg via injection or injection using a longer |
| Phase 2b                                           |                                                                                                                                                     | Mayo block (N=25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 209 (US) Module 2, Section 2.7.3.2.2.1.3 Medicinal | Phase 2b, randomized, double blind, placebo- and active controlled efficacy, safety, and PK study in subjects who underwent total knee arthroplasty | Cohort 1: • HTX-011-56 200 mg/6 mg via periarticular instillation (N=20) • HTX-011-56 200 mg/6 mg via a combination of periarticular injection and instillation (N=20) • Saline placebo via periarticular injection (N=11) • Bupivacaine HCl 0.25% 125 mg via periarticular injection (N=10) Cohort 2: • HTX-011-56 400 mg/12 mg via                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                     |                                                                                                                                                      | periarticular instillation and ropivacaine 50 mg via periarticular injection (N=56) • HTX-011-56 400 mg/12 mg via periarticular instillation (N=53) • Saline placebo via periarticular injection (N=53) • Bupivacaine HCl 0.25% 125 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 211 (US) Module 2, Section 2.7.3.2.2.2.1            | Phase 2b, randomized, double blind, placebo- and active controlled efficacy, safety, and PK study in subjects who underwent augmentation mammoplasty | via periarticular injection (N=55) • HTX-011-56 60 mg/1.8 mg via bilateral ultrasound-guided lateral and medial pectoral nerve block (N=12) • HTX-011-56 120 mg/3.6 mg via bilateral ultrasound-guided lateral and medial pectoral nerve block (N=26) • HTX-011-56 240 mg/7.2 mg via bilateral ultrasound-guided lateral and medial pectoral nerve block (N=24) • HTX-011-56 400 mg/12 mg via bilateral ultrasound-guided lateral and medial pectoral nerve block (N=47) • HTX-011-56 400 mg/12 mg via instillation (N=49) • Saline placebo via bilateral ultrasound-guided lateral and medial pectoral nerve block (N=41) • Bupivacaine HCl 0.25% 50 mg via bilateral ultrasound-guided lateral and medial pectoral nerve block (N=41) longer authorised |
| Phase 3                                             |                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 301 (US) Module 2, Section 2.7.3.2.2.1.1            | Phase 3, randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study in subjects who underwent bunionectomy product no   | • HTX-011-56 60 mg/1.8 mg via instillation (N=157) • Saline placebo via instillation (N=101) • Bupivacaine HCl 0.5% 50 mg via injection (N=154)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 302 (US and Europe) Module 2, Section 2.7.3.2.2.1.2 | Phase 3, randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study in subjects who underwent herniorrhaphy             | • HTX-011-56 300 mg/9 mg via instillation (N=161) • Saline placebo via instillation (N=82) • Bupivacaine HCl 0.25% 75 mg via injection (N=173)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

Bupivacaine and meloxicam are approved in several regions and have a long history of clinical use. Bupivacaine  is  a  local  anesthetic  and  meloxicam  a  nonsteroidal  anti-inflammatory  drug  (NSAID). Inclusion  of  low-dose  meloxicam  in  HTX-011  reduces  local  inflammation  caused  by  surgery  and normalizes the local pH, which is supposed to enhance bupivacaine penetration into nerves, thereby potentiating bupivacaine analgesic effect.

HTX-011-056 is a solution that is formulated in a proprietary Tri(ethylene glycol)-based poly(orthoester) polymer  (TEG-POE  polymer),  termed  Biochronomer®.  For  the  TEG-POE  polymer,  which  have  been

<div style=\"page-break-after: always\"></div>

previously used for another product SUSTOL (granisetron) for which the FDA have granted a MA, two studies using human biomaterial were provided in this dossier (Study 34-14 and Study 33-04) which have evaluated the water-soluble end products from the hydrolysis of TEG-POE in human plasma and have characterized TEG-POE metabolites using cryopreserved human hepatocytes.

| longer   |
|----------|
| no       |

The clinical pharmacology investigations has been performed in healthy volunteers (HV) first then in patients and consisted of two Phase I in HV, three Phase 2a, two Phase 2b and two Phase III studies, as shown in Table 6. In addition, preliminary results from an ongoing Phase 4 study are provided to support bridging of the proposed HTX-011 formulation vs the bupivacaine reference medicine. Full PK profiling has been performed in all the studies. Five PK modeling analyses were conducted to support the clinical pharmacology of HTX-011 as shown below. Table 5: PK modeling studies Absorption HTX-011  and  bupivacaine HCl have  been  investigated in various soft tissue (herniorrhaphy, augmentation mammoplasty) and bony (bunionectomy, TKA) surgical models covering a range of sizes and  vascularity.  In  addition  to  several  surgical  models,  different  HTX-011  formulation  containing bupivacaine and meloxicam (HTX-011-019, HTX-011-049 and HTX-011-056) or bupivacaine alone (HTX002) or meloxicam alone (HTX-009), and different route of administration (SC injection, instillation or combination)  were  investigated.  Table  6  provides  a  summary  of  bupivacaine  and  meloxicam  PK parameters  following  administration  of  HTX-011-056  via  instillation.  Figure  7  and  Figure  8  present concentration time-profiles of bupivacaine and meloxicam respectively. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 6: Summary of PK parameters for bupivacaine and meloxicam following a single dose of HTX-011-056 via instillation

<!-- image -->

<!-- image -->

Figure 7: Mean PK profiles for bupivacaine following instillation of HTX-011-056 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 8: Mean PK profiles for meloxicam following instillation of HTX-011-056

<!-- image -->

## · Metabolism

From the extended release formulation at 24h median % cumulative bupivacaine released ranged from 36.2  %  to  45.3%  (Bunionectomy  to  TKA)  whereas  for  meloxicam  at  24h,  median  %  cumulative bupivacaine released ranged from 22.3 % to 30.1% (Bunionectomy to TKA). Distribution The applicant relied upon the prescribing information from MARCAINE and MOBIC where estimated Vd were  73  L  and  11  L  respectively  for  bupivacaine  and  meloxicam  after  IV  administration  in  healthy volunteers. Elimination · Excretion Following instillation of HTX-011-056, the mean terminal half-life of bupivacaine, and across surgery type, ranged from 9.11 h to 14 h (herniorrhaphy to bunionectomy). For mammoplasty terminal half-life ranged from 14.4 h to 21.8h. Following instillation of HTX-011-056, the mean terminal half-life of meloxicam, and across surgery type, ranged from 17.8 h to 28.8 h (herniorrhaphy to bunionectomy). The excretion of water-soluble end products was evaluated in Study 102 following a single administration of HTX-011 400 mg/12 mg via subcutaneous injections. Approximately 83.6% and 92.0% of total PE (PE plus PEMPA) and total TEG (TEG plus TEG acid), respectively, were excreted in urine, indicating that urinary  excretion  is  the  major  elimination  pathway  for  these  TEG-POE-derived  water-soluble  end products and metabolites. Medicinal product no longer authorised

For  bupivacaine  and  meloxicam,  the  applicant  rely  upon  the  prescribing  information  for  approved MARCAINE and bupivacaine solution for injection (MARCAINE USIP 2015, Bupivacaine Injection SmPC 2017); and MOBIC and meloxicam solution for injection (MOBIC Tablets USPI 2016, Meloxicam Injection

<div style=\"page-break-after: always\"></div>

SmPC 2017). After bupivacaine and meloxicam have been released form HTX-011 and are absorbed systematically,  the  metabolism  is  expected  to  be  the  same  as  for  bupivacaine  and  meloxicam  oral formulations.

<!-- image -->

However, dose linearity have not been formally demonstrated with the claimed administration technique and across the surgery types. This is particularly highlighted in Table 10, where dose proportionality is unlikely.

For TEG-POE polymer, the metabolism has been investigated in 2 human biomaterials studies (Studies 34-14 and 33-04) and 1 Phase 1 clinical study. Studies 34-14 and 33-04 were performed during the MAA of another product, FDA-approved SUSTOL which is formulated with vehicle, APF18A, which is composed of  80%  TEG-POE  polymer  (SUSTOL  USPI  2017).  TEG-POE  undergoes  hydrolysis  to  TEG,  GA,  and pentaerythritol dipropionate that is then enzymatically hydrolyzed to PEMPA and PA. Figure 9: Hydrolysis pathway of TEG-POE (AP135) Polymer Dose proportionality According to the applicant, Bupivacaine mean Cmax for HTX-011 in the Phase 2 and Phase 3 studies increased linearly  for  doses  ranging  from  30  mg/0.9  mg  to  400  mg/12  mg  across  multiple  surgical procedures (R2=0.8581), regardless of vascularity of the surgical site or method of administration. The same trend was observed for AUC (R2=0.9627). Similarly to bupivacaine, meloxicam mean Cmax and AUC increased linearly for doses ranging from 30 mg/0.9 mg to 400 mg/12 mg, regardless of the surgical site or method of administration. Medicinal product no longer authorised

## Time dependency

Time-dependency has not been formally investigated since the drug product would be administered once.

<div style=\"page-break-after: always\"></div>

## Intra- and inter-individual variability

Results from the PPK analysis show that IIV for bupivacaine was particularly high 70.7% and 116% respectively for CL/F and Vc/F. For meloxicam IIV was also particularly high 69.8 % and 84.6 % for CL/F and Vc/F respectively.

Pharmacokinetics in target population The developed PPK models appear to adequately characterize the PK of bupivacaine and meloxicam, however a critical issue with regard to the estimate value of the apparent distribution volume for both compounds suggest a refinement of the PPK model. Nevertheless such refinement remain not needed as unreliable Vds do not have an influence on the absorption phase, which is the process of interest. Special Populations Impaired renal function Bupivacaine-Meloxicam No  formal  study  was  performed  to  investigate  impaired  renal  function  on  PK  of  bupivacaine  and meloxicam. Based on the results from the PPK of bupivacaine and meloxicam, creatinine was not tested as a covariate since according to the applicant no graphical trend was observed (ETA-PK vs creatinine). In the studied population mean observed creatinine was 73.9 µM (range: 38.9-147 µM). No eGFR was estimated. The applicant rely upon the prescribing information for approved products. After bupivacaine and meloxicam have been released form HTX-011 and are absorbed systematically, the effects of renal impairment are expected to be the same as for bupivacaine and meloxicam oral formulations. TEG-POE polymer The effects of renal impairment on the PK of water-soluble end products of TEG-POE (PEMPA, PE, TEG and TEG-acid) from HTX-011 was investigated using PK modelling with PK data from Study 102. Study 102 was a Phase I, single-center, single dose in healthy volunteers. Two PPK models were developed, one for PE and PEMPA and one for TEG and TEG acid using PK plasma and urine samples. PEMPA and PE PPK model Simulation of HTX-011 polymer hydrolysis products (PEMPA, PE, TEG and TEG acid) were performed in 1000 adult subjects per renal impairment groups using the developed final PPK.  Results of this analysis show that, there are minimal differences in PEMPA Cmax and AUCinf between the renal impairment groups. In female the Cmax is 20% and AUCinf 10% greater than male. For PE,as renal function become worse, PE Cmax and AUCinf increase from 20% to 175% (mild to severe vs normal). And For TEG and TEG acid impaired renal function have a minor effect of PK exposure metrics of both. Impaired hepatic function No  formal  study  was  performed  to  investigate  impaired  hepatic  function  on  PK  of  bupivacaine  and meloxicam. Based on the results from the PPK of bupivacaine and meloxicam, Albumin, ALP, ALT, AST, bilirubin were not tested as covariates since according to the applicant no graphical trend was observed. (ETA-PK vs hepatic function covariates). In the studied population mean observed albumin was 42.7 g/L (29.5-52.1 g/L), mean ALP was 73.1 U/L (14-167 U/L), mean ALT was 21.4 U/L (5-125 U/L), mean AST was 21.1 U/L (8-77 U/L), mean bilirubin was 8.75 µM (1.03-39.3µM) and were similar across the different surgical procedure. Medicinal product no longer authorised

The applicant rely upon the prescribing information approved for approved products. After bupivacaine and meloxicam have been released form HTX-011 and are absorbed systematically, the effects of hepatic impairment are expected to be the same as for bupivacaine and meloxicam oral formulations.

<div style=\"page-break-after: always\"></div>

However, since bupivacaine is known to be highly metabolized by liver enzymes and can cause toxicities in patients with liver impairment due to a reduction in clearance, the effects of hepatic impairment on the PK of bupivacaine from HTX-011 have been investigated using PK modelling based on PK data from Study 202. Results of this analysis indicated that hepatic impairment have a modest impact on the Cmax of bupivacaine, ranging from 4.8% to 12.5% for injection and instillation respectively.

Weight Weight was found to have a significant effect on Vp/F of bupivacaine and on Vc/F of meloxicam. Gender, race, age Based on the results from the PPK models for bupivacaine and meloxicam, gender, race or age have no effect on the PK of both bupivacaine and meloxicam, since no graphical trend was observed. Interactions No DDI studies were conducted with HTX-011. At the proposed recommended highest dose of HTX-011, mean plasma Cmax of bupivacaine and meloxicam from HTX-011 have been shown to be lower than those of approved bupivacaine and meloxicam products, respectively, within the proposed recommended doses. The likelihood of a DDI between bupivacaine and meloxicam in HTX-011 is low based on an evaluation of in vitro data of the disposition of each drug reported in published literature as well as clinical data from HTX-011 studies showing no clinically meaningful changes in PK exposure between each active ingredient administered alone (ie, HTX-002 or HTX-009) or together in HTX-011. Exposure relevant for safety evaluation Model-based simulation of bupivacaine Cmax Bupivacaine concentration profiles were simulated based on the final bupivacaine PK model (excluding the  residual  error.  Simulations  were  performed  for  the  inguinal  herniorrhaphy  (300  mg  HTX-011), bunionectomy  (60  mg  HTX-011),  augmentation  mammoplasty  (400  mg  HTX-011)  and  total  knee arthroplasty  (400  mg  HTX-011)  surgeries  over  a  range  of  weights  (median  and  2.5th  and  97.5th percentiles: 76, 54 and 118 kg, respectively). The provided simulation for Cmax bupivacaine clearly show that the rate of occurrence of potential CNS effect is low at the 400 mg dose of bupivacaine used for mammoplasty or TKA (respectively 2.2% for overweight and 0.6% for low weight subjects). Evaluation of the effect of HTX-011-056 on QTcF interval ECG-plasma concentration relation from two Phase 2b (Study 209 and Study 211) and two Phase 3 (Study 301 and Study 302) clinical trials of HTX-011 was investigated. For each study HTX-011 plasma concentrations were investigated on four endpoints, QTcF, HR, PR and QRS. No global analysis with all the available PK/PD were performed. Overall the exposure-response modelling appears to demonstrate a shortening of the QTcF interval for both bupivacaine and meloxicam with no discussion by the applicant. Medicinal product no longer authorised

## Exposure-efficacy (Pharmacokinetic/ Pharmacodynamic)

## Exposure-Efficacy

<div style=\"page-break-after: always\"></div>

An exposure-response (ER) model was developed with the objective to describe bupivacaine effect on pain score. The ER include PK/PD data from three surgery type bunionectomy (Study 208 and Study 301), herniorrhaphy (Study 202 and Study 302) and TKA (Study 209). PK/PD data from mammoplasty (Study 211) were excluded since no appropriate placebo comparator was available and PK/PD data from abdominoplasty (Study 203) were also discarded (during the PPK model development).

Given that the analgesic effects of local anesthetics occur locally at the site of administration, systemic bupivacaine plasma concentrations are a surrogate for the local concentration and were used to calculate bupivacaine release rate from HTX-011. Bupivacaine release rate, which was calculated as the combined rate of zero-order and first-order bupivacaine absorption in the population PK model, represents the rate at which bupivacaine is released from the HTX-011 formulation and enters the surgical site to be available for  analgesia.    In  order  to  characterize  the  effect  of  HTX-011  on  pain  score,  separate  models  were developed  for  the  time-dependent  decrease  in  pain  scores  in  subjects  receiving  saline  placebo  (ie, placebo model) and the additional drug-dependent decrease in pain scores in subjects receiving HTX011 ie, ER model). An indirect response model with bupivacaine absorption or release (mg/hr) driving a sigmoid maximum effect of drug exposure (Emax) model of pain relief describes the decreases in pain score. In addition, an exponential decay function (known as the 'narcotic' effect) describes the increase in pain immediately following surgery as the effects of anesthesia and perioperative analgesia (eg. from lidocaine or fentanyl) diminished. First a time-dependent model for pain scores for subject receiving placebo was developed first, then results from this analysis were used to estimate the additional effects of HTX-011 in a separate ER model. Overall for both PD model, PD parameter were estimated with a good precision, however the associated IIV was particularly high from 46.5% to 18583%. In addition, many of the PD parameter were highly correlated questioning the reliability of the developed PK/PD model. Finally, the main result from this analysis is the link between the release rate of bupivacaine (expressed in mg/h) from HTX-011 to the pain score. Therefore, we could not rule out that HTX-002 (bupivacaine alone) produces the same result because it is supposed to be released at the same rate as HTX-011. 2.4.3. Pharmacodynamics Mechanism of action HTX-011-56 is a novel, extended-release, fixed dose combination product that contains bupivacaine, an amide-type  local  anaesthetic,  and  low-dose  meloxicam,  a  nonsteroidal  anti-inflammatory  drug.  The rationale for this combination therapy is that generally analgesic efficacy of local anaesthetics, including bupivacaine, is affected by inflammation which creates a local acidic environment (Hargreaves, 2002; Ueno, 2008). This in turn favours the ionized form of bupivacaine thus limiting its penetration into the nerve membrane. This may be the reason for the reduced analgesic efficacy of bupivacaine alone in inflamed  tissues.  The  addition  of  an  NSAID,  i.e.  meloxicam,  to  bupivacaine  may  reduce  the  local inflammation and normalize the pH at the surgical site. This leads to an increase in the un-ionized lipidsoluble form of bupivacaine able to penetrate the nerve membrane and results in enhanced analgesia. Meloxicam demonstrated the optimal profile of potency (to allow a practical dose for incorporation in the matrix) and other physicochemical properties, such as solubility, for use in combination with bupivacaine formulated with the TEG-POE polymer. Medicinal product no longer authorised

Therefore, in case of Zynrelef, meloxicam is not used for its analgesic properties but is believed to reduce local inflammation and normalize local pH, resulting in a significantly greater analgesic effect at lower bupivacaine doses, and therefore a longer duration of bupivacaine's effect (enhanced penetration into the  nerves).  These  arguments  are  endorsed  even  though  those  did  not  exclude  analgesic  effect  of

<div style=\"page-break-after: always\"></div>

meloxicam. The brand-new polymer developed by the applicant would then constitute also a support to the  increase  duration  of  bupivacaine's  efficacy  allowing  controlled  extended  release  of  the  active substances during 72 hours.

<!-- image -->

The indication claimed by the applicant for the association of bupivacaine and low dose meloxicam is not different from the one associated to bupivacaine alone (relief of post-operative pain) and the distinction is  related to the duration of action: Zynrelef has been developed in order to obtain a longer-lasting postoperative analgesic. This could be considered as the new therapeutic claim. For  fixed  combination  medicinal  product,  Applicants  are  required  to  justify  the  pharmacological  and medical rationale for the particular combination of active substances and for the intended therapeutic indication. Clinical development should correspond to the intended claim. The applicant underlined key elements of the application. Local acidic environment following surgery is believed to contribute to the limited duration of local anesthetic effect even with continued exposure and that increasing the pH favors the nonprotonated form of bupivacaine, permitting more bupivacaine to enter  the  nerve  and  increasing  analgesia.  Therefore,  local  administration  of  nonsteroidal  antiinflammatory drugs (NSAIDs) would be expected to limit the local inflammatory response and inhibit the production of tissue prostaglandins, thereby reducing the local inflammatory-mediated tissue pH drop and peripheral sensitization. This is endorsed. According to the applicant, Zynrelef meets the criteria of a fixed combination product in that it offers greater (in magnitude and duration) overall effect in postoperative analgesia compared to monotherapy with  bupivacaine  HCl,  the  current  standard  of  care.  This  was  overall  shown  in  phase  3  studies  in bunionectomy with osteotomy (301) and open inguinal herniorrhaphy (302). However, the bupivacaine doses (standard of care) were inferior to the doses of bupivacaine contained in the FDC Zynrelef and used  for  comparison.  As  a  consequence,  it  was  not  possible  to  formally  assess  the  contribution  of meloxicam in the proposed FDC Zynrelef in those phase 3 studies. Nonclinical data in domestic piglet are suggested by the applicant to confirm that a surgical incision in results in rapid local tissue acidosis, which is reversed with meloxicam in HTX-011. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 10: Change in Incision Site Intra-Dermal pH Over Time in the Domestic Piglet Postoperative Pain Model

<!-- image -->

Regarding the claim of synergy between meloxicam and bupivacaine, meloxicam alone having no to minimal analgesic activity, the applicant proposes a rational for the FDC based on section 4.3. 'Initial combination  treatment'  of  the  'Guideline  on  clinical  development  of  fixed  combination  medicinal products' (EMA/CHMP/158268/2017) […] ' The design of clinical efficacy/safety studies to support a fixed combination medicinal product application for initial treatment will depend on its rationale, specifically to achieve superior efficacy or improved safety compared to use of the single active substances ' […] Option C ' One (or more) active substance has no individual efficacy in the targeted indication ' : ' If one (or more) of the active substances has no efficacy in the targeted indication by itself and compelling mechanistic data (e.g. using biomarkers) would suggest a synergistic effect, mechanistic data (e.g. in vitro data), preclinical and human PD data may be sufficient to support a claim of improved efficacy of the fixed combination medicinal product instead of (stepwise) up-titration or addition of those active substances  in  a  clinical  efficacy/safety  study.  Still,  improved  efficacy  over  (an)  individual  active substance(s) that have established efficacy in the targeted indication needs to be shown as usual. The design of the pivotal clinical studies should be according to specific clinical guidance, where placebo or standard of care - instead of these individual active substances - may be acceptable as comparators. A direct comparison against individual active substances with established efficacy in the targeted indication would still be expected '. Clinical evidence of the role of meloxicam in the FDC came from two phase 2 studies. Study 202 and study 208 were phase 2, randomized, pilot studies to investigate the safety, efficacy, pharmacokinetics and bioavailability of HTX-011, HTX-002, or HTX-009 administered via injection and/or topical application following unilateral open inguinal herniorrhaphy and bunionectomy with osteotomy, respectively. Several formulations, administrations technics, and doses of the FDC were tested. In addition, formulations of the polymer with respectively bupivacaine (HTX-002) or meloxicam (HTX-009) alone were also tested. The analgesic synergy of the combined active substances was suggested by the following: 1. Prolonged-release meloxicam (HTX-009) had negligible effect on postoperative pain Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Figure 11

<!-- image -->

<!-- image -->

These studies presented several limitations that led to question the exact role of meloxicam in the FDC. Indeed, an assessment of the contribution of each of the substances of the FDC in the indication based on  a  comparison  on  small  effective  at  a  non-optimal  dose  and  including  not  just  only  the  claimed administration method (instillation) raises uncertainties. It is endorsed that study 202 and 208 suggest efficacy  of  the  FDC  in  postoperative  pain.  However,  these  studies  were  not  designed  to  formally demonstrate synergy between bupivacaine and meloxicam.

2. The efficacy of Zynrelef was superior to that of prolonged-release bupivacaine (HTX 002) at the same bupivacaine doses. Figure 12 Medicinal product no longer authorised

The  applicant  acknowledged  that  neither  Study  202  nor  Study  208  formally  demonstrated  synergy between meloxicam and bupivacaine or negligible inherent analgesic effect of meloxicam. However, the applicant  stated  that  'the  replicated  evidence  of  the  superior  efficacy  of  HTX-011  compared  with

<div style=\"page-break-after: always\"></div>

prolonged-release bupivacaine, demonstrated using the same endpoint and analysis method as in the Phase 3 studies, supports the potentiating effect of meloxicam on the activity of bupivacaine, justifying the role of meloxicam in the FDC'. This was considered acceptable.

<!-- image -->

<!-- image -->

Figure 13 Furthermore, the choice of meloxicam (active ingredient) rather than another substance (excipient) has been adequately justified by the applicant after an initial concern raised. Similarly, the rationale for the selection of meloxicam over another NSAID been adequately justified by the applicant Primary and Secondary pharmacology Proof-of-Concept Study in Healthy Volunteers Study 02 Study 02 was a phase 1, first-in-human, proof-of-concept study used to demonstrate dose-dependent, antinociceptive effects of earlier formulations, HTX-011-19 and HTX-011-49, with extended duration in a human pain model. Study Design and Objectives : Open-label,  saline  placebo-controlled,  single-ascending  dose  study  investigating  the  PK,  safety, tolerability,  and  PD  of  2  earlier  clinical  formulations  (HTX-011-19  and  HTX-011-49)  in  healthy  adult volunteers. The study was conducted in 3 parts. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Table 7

<!-- image -->

| Study Part   | Objectives                                                                                                                                                                                                                                                                                      | Treatments                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Part I       | Primary: assess PK of bupivacaine and meloxicam after single ascending subcutaneous doses of HTX-011-19. Secondary: • assess safety and local tolerability after single ascending subcutaneous doses of HTX-011-19. • assess PDafter single ascending subcutaneous doses of HTX-011-19.         | Subjects (N=18) received single, ascending doses of HTX-011-19 (100 mg/3 mg, 200 mg/6 mg, or 400 mg/12 mg) or saline placebo via subcutaneous, divided injections in the upper part of the right leg. authorised                                                                                                                                                                                                                                      |
| Part II      | Primary: assess and compare the analgesic and anesthetic effects of three different, single, subcutaneous doses of HTX-011-19. Secondary: • assess PK, safety and local tolerability of three different single, subcutaneous doses of HTX-011-19. no                                            | Subjects (N=16) were randomized to either HTX-011-19 (100 mg/3 mg or 400 mg/12 mg) or saline placebo. The Minimal Erythema Dose (MED) of UVB light was determined for each subject during the screening period. Twenty hours prior to dosing, each subject was exposed to 3 times the MED of UVB light on the upper part the right leg, which was followed by study drug administration via subcutaneous, divided injections in the same area. longer |
| Part III     | Primary: assess PK of bupivacaine and meloxicam after single ascending subcutaneous doses of HTX-011-49. Secondary: • assess safety and local tolerability after single ascending subcutaneous doses of HTX-011-49. • assess PDafter single ascending subcutaneous doses of HTX-011-49. product | Subjects (N=12) were randomized to receive either HTX-011-49 (100 mg/3 mg or 200 mg/6 mg) or saline placebo via subcutaneous, divided injections in the upper part of the right leg.                                                                                                                                                                                                                                                                  |

Safety and tolerability parameters assessed throughout the study included adverse events (AEs), local tolerability, vital signs, ECG recordings, and clinical safety laboratory findings. A follow-up examination was conducted on Day 12, and all treatment-emergent AEs (TEAEs) were followed to resolution or Day 28 after dosing.

Criteria: The mechanical detection threshold (MDT), mechanical pain threshold (MPT), cold pain threshold (Part II only), and heat pain threshold (Part II only) were assessed for PD effects of HTX-011-19 or HTX 01149 at pre-dose on Day 1 and at specified time-points through Day 7 on the area where study drug was administered.  For  all  study  parts,  blood  samples  were  collected  from  each  subject  at  prespecified timepoints through Day 7 for the determination of bupivacaine and meloxicam PK in plasma. Medicinal product no longer authorised

## Subject Population :

A total of 46 subjects were randomized and received study drug:

<div style=\"page-break-after: always\"></div>

27 received HTX-011-19 (100 mg/3 mg (N=11), 200 mg/6 mg (N=5), or 400 mg/12 mg (N=11)) via subcutaneous injection, 10 received HTX-011-49 (100 mg/3 mg (N=5) or 200 mg/6 mg (N=5)) via subcutaneous injection and 9 received saline placebo. The majority of subjects were male (56.5%) and White (97.8%) with a 100 mg/3 mg (N=5) or 200 mg/6 mg (N=5) via subcutaneous injection mean (SD) age of 27.9 (9.3) years.

<!-- image -->

Generally,  based  on  the  validation  reports,  the  used  bioanalytical  methods  developed  for  the quantification of bupivacaine, meloxicam in human plasma and the end-products of the TEG-POE polymer in both plasma and urine, comply with acceptance criteria. Analytical validation reports were provided with satisfactory results.

Forty-five subjects completed study assessments through the Follow-up Visit. Pharmacodynamic Results : In Part I, the mechanical thresholds for detection and pain increased with dose, with maximum MDT values obtained at 6 hours (100 mg/3 mg dose level), 12 hours (200 mg/6 mg dose level), and 24 hours (400 mg/12 mg dose level). In Part II, there were trends for dose-dependent effects on mechanical thresholds for detection and pain on skin irradiated with ultraviolet B light. The maximum effect on MDT at HTX-011-19 400 mg/12 mg dosing was approximately 2.5 times higher than at 100 mg/3 mg dosing. The duration of maximum effect was also longer at 400 mg/12 mg dosing (24 hours post-dose) compared with 100 mg/3 mg (4 hours post-dose). In Part III, there was faster onset of the effects on the mechanical thresholds for detection and pain observed with HTX-011-49 as compared with HTX-011-19 in Parts I and II. The duration of effects, however, was also shorter lasting for HTX-011-49 as compared with HTX-011-19. In study 02, dose-dependent effects on MDT and MPT were observed with HTX-011-19 and HTX-01149. PD data are indicative of a dose-dependent, antinociceptive effect with extended duration in a human pain model. The  formulations  of  HTX-011-19  and  HTX-011-49  do  not  correspond  to  the  finished  product (Zynrelef/HTX-011) and were administrated by subcutaneous injection whereas Zynrelef/HTX-011 is intended to be administrated by instillation. Finally, it is difficult to consider this study as a 'proof of concept' study because exact role of meloxicam and polymer has not been assessed. 2.4.4. Discussion on clinical pharmacology The clinical pharmacology data of HTX-011 are supported by 7 clinical studies in adult patients (Study 202, 203, 208, 209, 211, 301 and 302) and one clinical study in healthy volunteers (Study 102). The clinical development program covers 5 different type of surgery (bunionectomy, herniorrhaphy, total knew arthroplasty, abdominoplasty and mammoplasty) from which several administration techniques were tested (injection, instillation, combination of injection and instillation). Rich sampling was performed in all clinical studies, except those associated to the pivotal studies (Study 301  and  302)  where  sparse  PK  sampling  was  performed.  Therefore,  summary  of  the  PK  exposure parameters provided in the dossier came from results from the developed PPK analysis for bupivacaine and meloxicam. Medicinal product no longer authorised

The PK of both bupivacaine and meloxicam is considered well known, therefore the applicant relies upon the prescribing information for approved products for distribution, DDI and elimination.

<div style=\"page-break-after: always\"></div>

In general, following instillation of HTX-011:

- -bupivacaine  Tmax  ranged  from  3h  (bunionectomy)  to  18.22-20.87  h  (herniorrhaphy-TKA) whereas for meloxicam Tmax ranged 18h (bunionectomy) to 36.2-53.7h (TKA-herniorrhaphy) suggesting that meloxicam released from the polymer is delayed. This is confirmed by the release rate of each compound (36.2 to 45.3% at 24h for bupivacaine and 22.3% to 30% for meloxicam).

Overall, the PPK model for bupivacaine fits for purpose when all PK data were pooled. ETA-shrinkage for PK parameters associated to the absorption process were particularly high. This suggest that available PK data from certain surgery type does not provide sufficient information to derive reliable individual PK parameters. Finally, results from the developed PPK model were used in a simulation exercise for a safety

-Apparent volume of distribution of bupivacaine Vz/F estimated by NCA, and across surgery type ranged  from  218  L  to  1430  L  (herniorrhaphy  to  bunionectomy)  suggesting  strong  tissue distribution.  This  finding  was  not  confirmed  by  PPK  analysis  where  an  apparent  central  and peripheral distribution volume were estimated at 12.2 L and 29.3 L. Similar discrepancies were observed for meloxicam and both are attributable to flip flop kinetics. However, a concern remain with regards to the discrepancy between the estimated value of apparent distribution volume of both compounds from the PPK analysis and the value reported in the SmPC suggesting an update of the developed PPK models. -Mean  terminal  half-life  for  bupivacaine  ranged  from  9.11  h  to  14  h  (herniorrhaphy  to bunionectomy) whereas for meloxicam the mean terminal half-life  and  across  surgery  type, ranged from 17.8 h to 28.8 h (herniorrhaphy to bunionectomy). Dose proportionality was claimed for both bupivacaine and meloxicam from 30 mg /0.9 mg to 400 mg / 12 mg whatever the administration technique and the surgery type. However the claimed administration technique  is  instillation  and  the  claimed  indication  is  not  endorsed  since  several  surgery  type  are investigated where ' extrapolation of safety and efficacy from local application at one surgical site to another surgical site is difficult due to different anatomical conditions such as magnitude of the surgical area and vascularization '. Consequently, it should be noted that the results presented by the applicant cover all surgical procedure tested  in  clinical  trials  (bunionectomy,  herniorrhaphy,  TKA,  abdominosplasty,  mammoplasty)  and  all administration techniques (injection, instillation and combination) used in these trials whereas it was expected, at this stage, a demonstration of dose linearity with the claimed administration technique (instillation) for a specific surgery type. Based on the individual reports and Applicants methodology 'Dose proportionality was concluded if the 90% CI for the slope was completely contained within the pre-specified  acceptance  range  for  Cmax  and  AUC  values  [0.8-1.25]',  dose  proportionality  is  not demonstrated whatever the surgery type with the instillation technique. The issue will not be pursued since dose proportionality is not claimed by the applicant in the SmPC, and to note based on the Table 2 provided in the SmPC for both bupivacaine and meloxicam, it remains obvious that dose proportionality is not demonstrated. A separate PPK model was developed for bupivacaine and meloxicam. The PPK model for bupivacaine was developed sequentially with first PK data from Studies 202 and 203, then after discarding PK data from Study 203, with PK data from Studies 202 and 208. Then predictive performance of the build base PK model was evaluated using NPDE with PK data from Studies 209 and 211, and finally PK data from Studies 301 and 302 were added. Overall, the applicant PK model building process remain unclear. Particularly the evaluation of predictive performance of the base PK model using only graphical evaluation with NPDE without computing the associated statistics of interest (mean, variance, skewness, kurtosis…) instead of using metrics to evaluate bias and imprecision would have been useful for the purpose. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

purpose and for the description of the release of bupivacaine and meloxicam; and as input to the PK/PD analysis for bupivacaine.

A PK/PD model was developed from which results should be interpreted with cautions, since to note individual PK parameters used as input to estimate the release rate have a high shrinkage, and the final PD  parameters  are  associated  to  a  huge  IIV  from  46.5%  to  18583%  with  PD  parameters  highly correlated. The main result is the link between bupivacaine released from the polymer (expressed in mg/h) associated to the decrease of the pain score. This suggest that we could not rule out that HTX002 (bupivacaine alone) produces the same result because it is supposed to be released at the same rate than HTX-011. 2.4.5. Conclusions on clinical pharmacology Pharmacokinetics  is  considered  adequately  characterized  in  terms  of  absorption,  distribution  and elimination. However a issue was raised with regards to the estimate value of the apparent distribution volume  for  both  compounds  and  that  suggest  a  refinement  of  the  PPK  model.  Nevertheless,  such refinement will not be needed as unreliable Vds do not have an influence on the absorption process. Demonstration  of  synergy  between  meloxicam  and  bupivacaine  has  been  demonstrated  sufficiently, despite a number of limitations of the clinical development. 2.5. Clinical efficacy Table 8: Overview of HTX-011 Studies Supporting the Proposed Indication Medicinal product no longer authorised

<!-- image -->

| Study No. (Region)   | Study Design                                                                                      | Surgical Procedure   | Treatment Groups (ITT/mITT Population)                                                       | Analysis                        | Type of Model   | Anatomic Space   |
|----------------------|---------------------------------------------------------------------------------------------------|----------------------|----------------------------------------------------------------------------------------------|---------------------------------|-----------------|------------------|
| Pivotal Studies      | Pivotal Studies                                                                                   | Pivotal Studies      | Pivotal Studies                                                                              | Pivotal Studies                 | Pivotal Studies | Pivotal Studies  |
| Phase 3              | Phase 3                                                                                           | Phase 3              | Phase 3                                                                                      | Phase 3                         | Phase 3         | Phase 3          |
| 301 (US)             | Randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study product   | Bunionectomy         | • HTX-011 60 mg/1.8 mg (N=157) • Saline placebo (N=100) • Bupivacaine HCl 0.5% 50 mg (N=155) | • Efficacy • Exposure- response | Bony            | Small            |
| 302 (US and Europe)  | Randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study Medicinal | Herniorrhaphy        | • HTX-011 300 mg/9 mg (N=164) • Saline placebo (N=82) • Bupivacaine HCl 0.25% 75 mg (N=172)  | • Efficacy • Exposure- response | Soft tissue     | Medium           |
| Phase 2b             | Phase 2b                                                                                          | Phase 2b             | Phase 2b                                                                                     | Phase 2b                        | Phase 2b        | Phase 2b         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study No. (Region)   | Study Design                                                                                           | Surgical Procedure               | Treatment Groups (ITT/mITT Population)                                                                                                             | Analysis                                   | Type of Model   | Anatomic Space   |
|----------------------|--------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------|------------------|
| 209 a Cohort 2 (US)  | Randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study                | Total knee arthroplasty          | • HTX-011 400 mg/12 mg + ropivacaine 0.5% 50 mg (N=56) • HTX-011 400 mg/12 mg (N=58) • Saline placebo (N=53) • Bupivacaine HCl 0.25% 125 mg (N=55) | • Efficacy • Exposure- response authorised | Bony            | Large            |
| Supportive Studies   | Supportive Studies                                                                                     | Supportive Studies               | Supportive Studies                                                                                                                                 |                                            |                 |                  |
| Phase 2b             | Phase 2b                                                                                               | Phase 2b                         | Phase 2b                                                                                                                                           | Phase 2b                                   |                 |                  |
| 209 a Cohort 1 (US)  | Randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study                | Total knee arthroplasty          | • HTX-011 200 mg/6 mg (N=20) • Saline placebo (N=11) • Bupivacaine HCl 0.25% 125 mg (N=10) longer                                                  | • Efficacy • Exposure- response            | Bony            | Large            |
| 211 b (US)           | Randomized, double-blind, placebo- and active-controlled efficacy, safety, and PK study                | Augmentation mammoplasty product | • HTX-011 400 mg/12 mg (N=50) • Saline placebo (N=41) • Bupivacaine HCl 0.25% 50 mg (N=41) no                                                      | • Efficacy                                 | Soft tissue     | Large            |
| Phase 2a             | Phase 2a                                                                                               | Phase 2a                         | Phase 2a                                                                                                                                           | Phase 2a                                   |                 |                  |
| 208 c (US)           | Phase 2a, randomized, blinded, placebo- and active-controlled safety, efficacy, and PK study Medicinal | Bunionectomy                     | • HTX-011 60 mg/1.8 mg* (N=17) • HTX-011 120 mg/3.6 mg (N=37) • Saline placebo (N=103) • Bupivacaine HCl 0.5% 50 mg (N=25)                         | • Efficacy • Exposure- response            | Bony            | Small            |

<div style=\"page-break-after: always\"></div>

| Study No. (Region)   | Study Design                                                                                 | Surgical Procedure   | Treatment Groups (ITT/mITT Population)                                                                                                                | Analysis                                   | Type of Model   | Anatomic Space   |
|----------------------|----------------------------------------------------------------------------------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------|------------------|
| 202 c (US)           | Phase 2a, randomized, blinded, placebo- and active-controlled safety, efficacy, and PK study | Herniorrhaphy        | • HTX-011 200 mg/6 mg (N=16) • HTX-011 300 mg/9 mg* (N=16) • HTX-011 400 mg/12 mg (N=21) • Saline placebo (N=83) • Bupivacaine HCl 0.25% 75 mg (N=32) | • Efficacy • Exposure- response authorised | Soft tissue     | Medium           |

-

Abbreviations: ITT, Intent-to-Treat; mITT, modified Intent-to-Treat; PK, pharmacokinetics; US, United States. Notes: HTX-011 (also referred to as HTX-011-56) is the intended commercial formulation and was the only formulation evaluated in the Phase 3 and Phase 2b studies.  The  ITT  Population  included  all  subjects  who  were  randomized  and received study drug (Studies 301, 302, and 209). The mITT Population included all subjects in the ITT Population who had at least 1 postdose scheduled pain intensity score (Studies 211, 208, and 202). *   Doses selected for Phase 3. a  Study 209 included 2 sequential cohorts. Cohort 1 was a dose-finding cohort. Cohort 2 was adequate and well-controlled. b  Study 211 was a Phase 2b nerve block study that included 1 treatment group of  HTX-011  administered  via  instillation.  Only  HTX-011  administered  via instillation  (intended commercial route of administration) and the 2 controls (saline placebo and bupivacaine HCl) administered via nerve block and pooled across cohorts are presented. c  Only the intended commercial formulation of HTX-011 (also referred to as HTX011-56) and doses of HTX-011 administered via the intended commercial route of administration (instillation) are presented (pooled across cohorts). Bupivacaine dose is mentioned first then the meloxicam dose in HTX-011 2.5.1. Dose response study(ies) The applicant did not conduct any dose response studies. The clinical development was focused on the different types of surgeries (bunionectomy and herniorrhaphy in particular). Phase II studies were design to lead the applicant, for each type of surgery on the selection of: -The optimal formulation; -The optimal administration technique; The optimal doses of the fixed dose combination. Bunionectomy: Study 208 Medicinal product no longer authorised

'A  Phase  2,  Randomized,  Controlled,  Multicenter,  Evaluation  of  the  Efficacy  and  Safety  of  Locally Administered HTX-011, HTX-002, or HTX-009 for Postoperative Analgesia Following Bunionectomy'.

<div style=\"page-break-after: always\"></div>

This study was designed to evaluate the safety, efficacy, and PK of 2 HTX-011 formulations (HTX-01149 and HTX-011-56) administered as a single dose via local administration into the surgical site via different techniques in adult subjects undergoing unilateral simple bunionectomy.

<!-- image -->

<!-- image -->

Saline placebo and bupivacaine HCl 0.5% without epinephrine were employed as controls. Two HTX011-56 comparators, HTX-002 (bupivacaine only) and HTX-009 (meloxicam only), were also included to evaluate the contribution of the APIs to the effects of HTX-011-56. The primary efficacy endpoint was the summed pain intensity score (SPI) over the first 24 hours (SPI024). A total of 430 subjects were randomized and received study drug. 423 (98.4%) completed the study. 17 subjects were randomized in HTX-011 60 mg / 1.8 mg administered by instillation with a Luer-Lock applicator group (the selected dose and administration technique for the phase 3 study). HTX-011-49 formulation was discontinued during the course of this study due to preliminary PK data. The minimum effective dose that produced statistically significant reductions in SPI0-24 compared with bupivacaine HCl was HTX-011-56 60 mg/1.8 mg (primary endpoint). All administration techniques were effective at reducing pain. Systemic exposures (bupivacaine and meloxicam) were higher with injection techniques compared to instillation techniques. There appeared to be a dose-dependent increase in the incidence of overall TEAEs. Thus, the optimal HTX-011 formulation, dose, and administration technique to reduce postoperative pain with a favourable safety profile in subjects undergoing bunionectomy was determined by the applicant to be HTX-011-56 60 mg/1.8 mg via instillation using a Luer-lock applicator. This dose was selected for the phase 3 study in bunionectomy. Table 9: Primary Endpoint: Mean SPI0-24 by HTX-011-56 Dose Group vs. Saline Placebo and Bupivacaine HCl (LOCF, mITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 14: Mean Pain Intensity Scores over time by HTX-011-56 Dose Group vs. Saline Placebo and Bupivacaine HCl (LOCF, mITT Population)

<!-- image -->

<!-- image -->

Contribution of HTX-011 components to the reduction in mean AUC of pain intensity scores was assessed using least squares mean difference with HTX-011-56 120 mg/3.6 mg, HTX-002 120 mg and HTX-009 3.6 mg compared to placebo. HTX-011-56 120 mg/3.6 mg reduced pain more effectively than equivalent doses of either comparator: HTX-002 120 mg or HTX-009 3.6 mg. Furthermore, the reduction in pain intensity was more than the sum of the 2 comparators. In addition, an assessment of reduction in pain intensity was performed comparing HTX-011-56 against extended-release bupivacaine (HTX-002) and immediate-release bupivacaine (bupivacaine HCl). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 10: Mean AUC of Pain intensity Score for HTX-011-56 vs. HTX-002 (wWOCF, mITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 15: Contribution of HTX-011 Components to the Reduction in Mean AUC of Pain Intensity Scores: HTX-011-56 120 mg/3.6 mg vs. HTX-002 120 mg and HTX-009 3.6 mg (wWOCF, mITT Population)

<!-- image -->

| Mean AUC of pain intensity scores   | Placebo (N=103) Injection with or without a Mayo block Medicinal   | Bupivacaine HCl (50 mg) (N=25) Injection with or without a Mayo block   | HTX-002 (bupivacaine 120 mg) (N=30) Injection with or without a Mayo block   | HTX-009 (meloxicam 3.6 mg) (N=30) Injection with or without a Mayo block   | HTX-011-56 (bupivacaine 120 mg / meloxicam 3.6 mg) (N=74) Injection with or without a Mayo block + instillation with or without a Luer-lock applicator   |
|-------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

Table 11: Mean AUC of pain intensity scores for placebo, bupivacaine HCl, HTX-002, HTX-009 and HTX-011-56 (wWOCF, mITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| AUC 0-24 (SD)   | 154.66 (49.168)   | 143.02 (53.864)   | 147.84 (51.103)   | 152.94 (52.829)   | 99.22 (50.476)   |
|-----------------|-------------------|-------------------|-------------------|-------------------|------------------|
| AUC 0-48 (SD)   | 309.26 (105.542)  | 306.54 (114.674)  | 322.48 (101.045)  | 309.77 (103.511)  | 236.28 (97.872)  |
| AUC 0-72 (SD)   | 434.05 (167.930)  | 430.11 (183.942)  | 460.17 (144.577)  | 428.15 (160.301)  | 351.46 (152.177) |

<!-- image -->

(SD) (105.542) AUC 0-72 (SD) 434.05 (167.930) Overall, these results suggest that bupivacaine HCl (50 mg), HTX-009 (3.6 mg of meloxicam alone) and HTX-002 (120 mg of bupivacaine alone) administered by injection have no or little  analgesic effect according to mean AUC of pain intensity scores (AUC 0-24; AUC 0-48 and AUC 0-72) compared to placebo. Only HTX-011-56 (bupivacaine 120 mg / meloxicam 3.6 mg), all administration techniques combined, shows consistent numerical decrease of mean AUC of pain intensity scores (AUC 0-24; AUC 0-48 and AUC 0-72) compared to placebo. Assessment and extrapolation of these data seems difficult considering  that  administration  techniques  were  pooled,  effectives  are  relatively  small,  standard deviations are important and AUC for pain intensity scores collected over various time intervals was only included as an exploratory endpoint.  In addition, it should be noted that HTX-011-56 (120 mg / 3.6 mg) is not the dose selected for the phase 3 study in bunionectomy. The demonstration of the contribution of bupivacaine and meloxicam to the efficacy of Zynrelef (HTX011) as, respectively, the active substance and the enhancer of activity without analgesic properties itself based on these data considered to be sufficient. Herniorrhaphy: Study 202 'A  Phase  2,  Randomized,  Pilot  Study  to  Investigate  the  Safety,  Efficacy,  Pharmacokinetics  and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy'. This study was designed to evaluate the safety, efficacy, and PK of 3 HTX-011 formulations (HTX-01119, HTX-011-49, and HTX-011-56) administered as a single dose via local administration into the surgical site  using  different  administration  techniques  in  adult  subjects  undergoing  unilateral  open  inguinal herniorrhaphy. Saline placebo and bupivacaine HCl 0.25% without epinephrine were used as controls. Two HTX-011-56 comparators, HTX-002 and HTX-009, were also included to evaluate the contribution of the APIs to the effects of HTX-011-56. This  study  was  used  to  determine  the  optimal  formulation,  dose,  and  method  of  administration  for herniorrhaphy in phase 3. The primary efficacy endpoint was the summed pain intensity score (SPI) over the first 24 hours (SPI024). A total of 463 subjects were randomized and received study drug. 11 subjects did not complete the study. The main reason was lost to follow up. 16 subjects were randomized in HTX-011 300 mg / 9 mg administered by instillation group (the selected dose and administration technique for the phase 3 study). Medicinal product no longer authorised

Development of HTX-011-19 and HTX-011-49 was discontinued during the course of this study due to high viscosity for HTX-011-19 and to preliminary PK data for HTX-011-49.

<div style=\"page-break-after: always\"></div>

The minimum effective dose that produced statistically significant reductions in SPI0-24 compared with bupivacaine HCl was HTX-011-56 300 mg/9 mg (primary endpoint). Moreover, the mean SPI0-24 was the lowest for HTX-011-56 300 mg/9 mg.

<!-- image -->

| no   |
|------|

<!-- image -->

Administration of HTX-011-56 via injection generally did not result in improved mean pain intensity scores compared with saline placebo and bupivacaine HCl. Mean plasma exposures of bupivacaine were generally similar across all administration techniques and no  significant  differences  in  plasma  exposures  of  meloxicam  were  observed  across  the  different administration techniques. In order to select the phase 3 dose and formulation of HTX-011, the applicant has taken into account the formulation, dose, together with the administration technique to reduce postoperative pain with a favourable safety profile in subjects undergoing herniorrhaphy. As instillation is considered to be less invasive technique, the applicant determined that HTX-011-56 300 mg/9 mg via instillation using a Luerlock applicator should be used for further clinical trial. Table 12: Primary Efficacy Endpoint: Mean SPI0-24 for HTX-011-56 vs Saline Placebo and Bupivacaine HCl (LOCF, mITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 16: Mean Pain Intensity Scores over time for HTX-011-56 vs Saline Placebo and Bupivacaine HCl (LOCF, mITT Population)

<!-- image -->

<!-- image -->

Contribution of HTX-011 components to the reduction in mean AUC of pain Intensity Scores was assessed using least squares mean difference with HTX-011-56 400 mg/12 mg, HTX-002 400 mg and HTX-009 12 mg compared to placebo. HTX-011-56 400 mg/12 mg (administrated via instillation) reduced mean AUC of pain intensity scores more effectively than equivalent doses of either comparator: HTX-002 400 mg (administrated via instillation) or HTX-009 12 mg (administrated by a combination of injection and instillation). The reduction in pain intensity was more than the sum of the 2 comparators. According to the applicant, these findings show that the analgesic efficacy of HTX-011-56, a fixed-ratio combination product, is not the sole result of the disease-active component, bupivacaine. An assessment of reduction in pain intensity was performed comparing HTX-011-56 against extendedrelease bupivacaine (HTX-002) and immediate-release bupivacaine (bupivacaine HCl). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 13: Mean AUC of Pain Intensity Scores for HTX-011-56 vs HTX-002 (wWOCF, mITT Population)

<!-- image -->

<!-- image -->

Overall, these results mostly suggest that the difference on mean AUC of pain intensity scores between HTX-011-56 (bupivacaine and meloxicam) and HTX-002 (bupivacaine only) is not obvious. The difference is statistically significant when HTX-011-56 200 mg/6 mg (N=16) is compared to HTX-002 200 mg (N=13) on mean AUC0-72 (both products were administrated by instillation). Although results may suggest a trend, the other differences are only numerical. Moreover, the effectives are too small and standard deviations are too high to draw firm conclusion. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 17: Contribution of HTX-011 Components to the Reduction in Mean AUC of Pain Intensity Scores: HTX-011-56 400 mg/12 mg vs HTX-002 400 mg and HTX-009 12 mg (wWOCF, mITT Population)

<!-- image -->

| Mean AUC of pain intensity scores   | Placebo (N=60) Injection + instillation   | Bupivacaine HCl (50 mg) (N=15) Injection   | HTX-002 (bupivacaine 400 mg) (N=15) Instillation   | HTX-009 (meloxicam 12 mg) (N=18) Injection + instillation   | HTX-011-56 (bupivacaine 400 mg / meloxicam 12 mg) (N=16) Instillation   |
|-------------------------------------|-------------------------------------------|--------------------------------------------|----------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------------------|
| AUC 0-24 (SD) Medicinal             | 152.02 (54.284)                           | 135.19 (56.062)                            | 117.79 (63.243)                                    | 146.19 (35.860)                                             | 110.11 (65.379)                                                         |
| AUC 0-48 (SD)                       | 289.81 (120.347)                          | 272.41 (116.176)                           | 250.36 (118.770)                                   | 291.19 (83.162)                                             | 220.10 (125.896)                                                        |
| AUC 0-72 (SD)                       | 393.45 (184.664)                          | 381.41 (175.658)                           | 366.26 (171.896)                                   | 406.92 (137.347)                                            | 317.66 (189.382)                                                        |

Table 14: Mean AUC of pain intensity scores for placebo, bupivacaine HCl, HTX-002, HTX-009 and HTX-011-56 (wWOCF, mITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

According  to  mean  AUC  of  pain  intensity  scores  (AUC  0-24;  AUC  0-48  and  AUC  0-72),  HTX-009 (meloxicam 12 mg) shows no analgesic effect with numerical results close to placebo. Bupivacaine HCl (50 mg) presents very modest to no reduction of mean AUC of pain intensity scores (AUC 0-24; AUC 048 and AUC 0-72) compared to placebo. HTX-002 (bupivacaine 400 mg) reduces mean AUC of pain intensity scores (AUC 0-24; AUC 0-48 and AUC 0-72) compared to placebo. It should be noted that bupivacaine dose is 4 times higher in HTX-002 compared to bupivacaine HCl.

<!-- image -->

HTX-011-56 (bupivacaine 400 mg / meloxicam 12 mg) presents the higher reduction of mean AUC of pain intensity scores (AUC 0-24; AUC 0-48 and AUC 0-72) compared to placebo. The interpretation of these results is limited due to small effect, high standard deviation, and the use of HTX-011-56 (bupivacaine 400 mg / meloxicam 12 mg) which is not the selected dose for the phase 3 study in herniorrhaphy. In addition, HTX-009 effect was assessed with pooled administration techniques. It is also difficult to understand how these differences on mean AUC of pain intensity scores (AUC 0-24; AUC 0-48 and AUC 0-72) will translate on patients pain experience. The demonstration of the contribution of bupivacaine and meloxicam to the efficacy of Zynrelef (HTX011) as, respectively, the active substance and the enhancer of activity without analgesic properties itself based on these data is endorsed, despite the study limitations. Total Knee Arthroplasty: Study 209 'Phase 2b, Randomized, Double Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX011 via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty'. Study design This study was designed to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX011 administered as a single dose into the surgical site in subjects undergoing primary unilateral total knee arthroplasty (TKA). The study included 2 sequential cohorts. Cohort 1 was a dose- and administration technique-finding cohort  and  evaluated  HTX-011  200  mg/6  mg  administered  via  2  different  techniques  (periarticular instillation or a combination of periarticular injection and instillation) compared with saline placebo and bupivacaine HCl 0.25% 125 mg. Cohort 2 evaluated HTX-011 400 mg/12 mg via periarticular instillation with or without a low-dose of ropivacaine (50 mg of a 0.5% solution) injected into the posterior capsule of the knee compared with saline placebo and bupivacaine HCl 0.25% 125 mg. Cohort 2 was initiated after an interim review of Cohort 1 results by an unblinded internal Interim Review Committee (IRC). Study drug was administered prior to the completion of surgery. The study consisted in the following phases: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 18

<!-- image -->

Study assessment Efficacy  assessments  included  evaluations  of  pain  intensity  using  the  Numeric  Rating  Scale  of  pain intensity  score  (NRS)  at  rest  and  with  activity  (NRS-R  and  NRS-A,  respectively);  use  of  opioid medication;  the  Patient  Global  Assessment  (PGA)  of  pain  control;  assessments  of  rehabilitation, ambulation, and discharge readiness; the subject's satisfaction with postoperative pain control; and the subject's assessment of overall benefit of analgesia. Safety assessments included adverse event (AE) recording, local anesthetic systemic toxicity (LAST) assessments,  physical  examinations,  vital  signs,  electrocardiograms  (ECGs)  and  Holter  monitoring, motor function assessments, hematology and serum chemistry, and wound healing assessments. PK assessments included the collection of blood samples at scheduled timepoints for bupivacaine and meloxicam PK analysis. Main inclusion criteria Subjects  were  male  or  female  with  scheduled  unilateral  TKA  under  general  anesthesia  and  had  not previously undergone TKA in either knee. Main exclusion criteria Subjects  had  another  pre-existing  painful  condition  that  could  confound  pain  assessments  or  were currently taking analgesics for a chronically painful condition, or had taken long-acting opioids within 3 days of surgery, or had taken any opioids within 24 hours of scheduled surgery for this study. Subjects had a known or suspected history of alcohol or drug abuse, or a positive drug screen. Subjects had clinically significant cardiac, renal or hepatic abnormalities. Treatments Cohort 1 : Up to approximately 60 subjects were to be randomized to 1 of the following 4 treatment groups in a 2:2:1:1 ratio: -HTX-011, 200 mg/6 mg (bupivacaine/meloxicam doses), 6.8 mL, via periarticular instillation into the surgical site HTX-011,  200  mg/6  mg  (bupivacaine/meloxicam  doses),  6.8  mL,  via  a  combination  of periarticular injection and instillation into the surgical site Medicinal product no longer authorised

- -Saline placebo, 6.8 mL, via periarticular injection into the surgical site
- -Bupivacaine HCl without epinephrine 0.25%, 125 mg (50 mL), via periarticular injection into the surgical site

<div style=\"page-break-after: always\"></div>

Cohort 2 : Up to approximately 200 subjects were to be randomized to 1 of the following 4 treatment groups in a 1:1:1:1 ratio:

- -HTX-011, 400 mg/12 mg (bupivacaine/meloxicam doses), 13.7 mL, via periarticular instillation into the surgical site

-

-HTX-011, 400 mg/12 mg (bupivacaine/meloxicam doses), 13.7 mL, via periarticular instillation into the surgical site, and ropivacaine 0.5% (50 mg, 10 mL) via periarticular injection into the surgical site (posterior capsule) -Saline placebo, 13.7 mL, via periarticular injection into the surgical site -Bupivacaine HCl without epinephrine 0.25%, 125 mg (50 mL), via periarticular injection into the surgical site The surgical procedure was conducted under general anesthesia or spinal anesthesia. In cohort 1, subjects received a standardized 50 μg of IV fentanyl after study drug administration and before wound closure to minimize the inherent variability of intraoperative pain control on immediate postoperative pain. After an amendment, the amount of IV fentanyl administered intraoperatively was increased to 75 μg . In  cohort  2,  all  subjects  were  administered  pregabalin  orally  (PO;  150  mg)  and  acetaminophen intravenously (IV; ≤ 1,000 mg in a 6-hour window, as per the approved prescribing information) just prior to surgery to reduce initial postoperative pain. The subjects also received a standardized 75 μg of IV fentanyl after study drug administration and before wound closure Rescue  medication  during  72  hours  after  study  drug  administration  was  allowed  to  subjects  with inadequately controlled pain symptoms. The rescue medications were the following: -Morphine up to 15 mg IV for the first 2 hours; -Thereafter, morphine up to 10 mg IV in a 2-hour period; -Oral oxycodone up to 10 mg within any 4-hour period as needed After  72  hours,  the  analgesic  regimen  could  be  adjusted  for  each  subject  individually  as  deemed appropriate by the physician responsible for the postoperative care. Main study objectives Primary: to compare the efficacy and duration of analgesia achieved following periarticular infiltration of HTX-011 with that of saline placebo in subjects undergoing unilateral TKA. Main secondary objectives: -To compare the efficacy and duration of analgesia for HTX-011 with that of bupivacaine HCl without epinephrine in this study population; -To evaluate additional efficacy parameters, including opioid load, in this study population; To evaluate the efficacy  and duration of analgesia for  HTX-011 administered using different techniques in this study population. Medicinal product no longer authorised

## Main efficacy endpoints

The primary efficacy endpoint was the mean AUC of the NRS-R pain intensity scores through 48 hours (AUC0-48).

<div style=\"page-break-after: always\"></div>

The key secondary endpoint was the mean AUC of the NRS-R pain intensity scores through 72 hours (AUC0-72).

Main  secondary  endpoints  included  mean  total  postoperative  opioid  consumption  (in  morphine equivalents) through 24, 48, and 72 hours, median time in hours to first opioid rescue administration and mean NRS-R and mean NRS-A pain intensity scores at each assessed timepoint.

<!-- image -->

Study subjects A total of 285 subjects were randomized and received study drug, 63 in Cohort 1 and 222 in Cohort 2. The numbers of male and female subjects within each cohort were evenly distributed. The mean age was 61.9 (8.06) years in Cohort 1 and 62.1 (8.90) years in Cohort 2. Over 98% of subjects in each cohort completed the study. Main Results in cohort 1 Efficacy appeared to be similar for both HTX-011 200 mg/6 mg groups, instillation and combination of instillation and injection. Both HTX-011 200 mg/6 mg groups had numerically lower mean AUC0-48 of NRS-R pain intensity scores (primary endpoint) and mean AUC0-72 of NRS-R pain intensity scores (key secondary  endpoint)  compared  with  saline  placebo  (primary  comparison),  but  the  treatment  group differences did not reach statistical significance. In addition, total opioid consumption was lower in both HTX-011 200 mg/6 mg groups through 24, 48, and 72 hours (other secondary endpoints) compared with saline placebo. Both  HTX-011  200  mg/6  mg  groups  had  higher  mean  pain  intensity  scores  compared  with  the bupivacaine HCl group; however, the treatment differences in the mean NRS-R scores at 24, 48, and 72 hours, as well as the mean AUC0-48 and AUC0-72 of NRS-R pain intensity scores, were not statistically significant. Total opioid consumption for the bupivacaine HCl group was lower than or similar to the HTX011 groups through 24, 48, and 72 hours. These results suggested there was some clinical activity with HTX-011, but that the dose, 200 mg/6 mg, was likely not high enough. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 19: Mean NRS-R Pain Intensity Scores over Time for Cohort 1 (wWOCF, ITT Population)

<!-- image -->

<!-- image -->

<!-- image -->

Table 15: Mean AUC0-48 and AUC0-72 of NRS-R Pain Intensity Scores (wWOCF, ITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 16: Total Postoperative Opioid Consumption (MME) From 0 through 24, 48, and 72 Hours in Cohort 1 (ITT Population)

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

The result for TKA study for cohort 1 was negative regarding the selected primary endpoint. HTX-011 200  mg/6  mg  did  not  produce  significantly  superior  pain  relief  compared  with  the  control  groups. However, the applicant considered that there was an indication of activity, based only on numerically lower NRS-S pain intensity scores and total opioid consumption compared with saline placebo. In  that  context,  the  applicant  decided  to  proceed  to  Cohort  2  with  a  higher  dose  level  of  HTX-011 (400mg/12mg), based on the hypothesis that the dose of 200mg/6mg was not high enough. The applicant chose the method of administration for HTX-011 in Cohort 2 to parallel the administration technique in the phase 3 studies. Instillation was therefore adopted for Cohort 2. 2.5.2. Main study(ies) A Phase 3, Randomized, Double-Blind, Saline Placebo- and ActiveControlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Simple Bunionectomy The study consisted in the following phases: Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Figure 20

<!-- image -->

6.  Had taken NSAIDs (including meloxicam) within 10 days prior to the scheduled surgery with the exception of subjects on l ow dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.

Study Participants Main inclusion criteria Each subject had to meet all of the following criteria to be enrolled in this study: 1. Was male or female, an d ≥18 years of age at screen ing. 2. Was scheduled to undergo a primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia. 3. Had an American Society of Anesthesiologists Physical Status of I, II, or III. Main exclusion criteria Subjects who met any of the following criteria were excluded from the study: 1. Had a contralateral foot bunionectomy in the past 3 months. 2. Had a planned concurrent surgical procedure (e.g., bilateral bunionectomy or collateral procedures on the surgical foot). 3.  Had  a  pre-existing  concurrent  acute  or  chronic  painful  physical/restrictive  condition  expected  to require  analgesic  treatment  in  the  postoperative  period  for  pain  that  was  not  strictly  related  to  the bunionectomy and which may confound the postoperative assessments. 4. Had a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic  reaction  to  bupivacaine  (or  other  local  anesthetics),  meloxicam  (or  other  NSAIDs), oxycodone, morphine, or acetaminophen. 5. Had known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months. Medicinal product no longer authorised

7. Had taken long-acting opioids within 3 days prior to the scheduled surgery.
8. Had taken any opioids within 24 hours prior to the scheduled surgery.

<div style=\"page-break-after: always\"></div>

9. Had been administered bupivacaine within 5 days prior to the scheduled surgery.

10. Had been administered any local anesthetic within 72 hours prior to the scheduled surgery, other than for pretreatment prior to a needle placement, to treat an AE that occurs after signing the ICF, or to decrease venous irritation (e.g., caused by propofol, in which case no more than a single administration of lidocaine 1% 20 mg IV could be administered).

<!-- image -->

11. Had initiated treatment with any of the following medications within 1 month prior to study drug administration  or  was  taking  any  of  these  medications  to  control  pain:  selective  serotonin  reuptake inhibitors  (SSRIs),  selective  norepinephrine  reuptake  inhibitors  (SNRIs),  gabapentin,  pregabalin,  or cyclooxygenase-2 (COX-2) inhibitors. Anxiolytics prior to surgery were permitted, if necessary. 12. Had been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug (whichever was longer). 13. Had a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments. 14. Had a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Overall, inclusion and exclusion criteria are adequate. However, the study population does not represent target population where pre-existing concurrent acute or chronic painful conditions, opioid medication use and/or drug abuse (opioids) could be rather common. These excluded conditions represent patients with risk factors that could be more difficult to treat. This should be kept in mind for the analysis of the effect size. Treatments The study population was randomized into three treatment groups in a 3:3:2 pattern generated by computer as follows: -HTX-011, 60 mg/1.8 mg (2.1 mL) via instillation into the surgical site using a Luer lock applicator. -Bupivacaine HCl without epinephrine 0.5%, 50 mg (10 mL), via injection into the surgical site. -Saline placebo (2.1 mL) via instillation into the surgical site using a Luer lock applicator. The  surgical  procedure  was  performed  under  regional  anesthesia  with  no  more  than  20  mL  of  1% lidocaine without epinephrine administered as a Mayo block. During surgery, the use of intravenous (IV) fentanyl up to 4 μg/kg was permitted for intraoperative pain control. Rescue medication Postoperative rescue medication consisted of oral (PO) immediate-release oxycodone (no more than 10 mg within a 4-hour period as needed), IV morphine (no more than 10 mg within a 2-hour period as needed), and/or oral acetaminophen (no more than 1,000 mg in a 6-hour period). Rescue medication was administrated upon request. At discharge, subjects were to be provided a daily diary to record if they took any opioid medication from 72 hours through Day 28 (yes or no). Medicinal product no longer authorised

## Objectives

Primary objective:

<div style=\"page-break-after: always\"></div>

To compare the efficacy and duration of analgesia following local administration of HTX-011 with saline placebo during the first 72 hours following unilateral simple bunionectomy.

Secondary objectives:

-

-

- -Proportion of subjects who first achieve an MPADSS score ≥ 9 at 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours.

-To compare the efficacy and duration of analgesia for HTX-011 with bupivacaine HCl without epinephrine during the first 72 hours following surgery. -To compare the effect of HTX-011 with saline placebo and bupivacaine HCl without epinephrine on opioid load during the first 72 hours following surgery. -To assess the safety and tolerability of HTX-011. -To further establish the PK parameters of bupivacaine and meloxicam in HTX-011. Outcomes/endpoints Primary Endpoint Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRSA) through 72 hours (AUC0-72) for HTX-011 compared with saline placebo. Key secondary endpoints -Mean AUC0-72 of the NRS-A pain intensity scores for HTX-011 compared with bupivacaine HCl. -Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with saline placebo. -Proportion  of  subjects  who  are  opioid-free  through  72  hours  for  HTX-011  compared  with bupivacaine HCl. -Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with bupivacaine HCl. Other secondary endpoints -Proportion of subjects who are opioid-free through 72 hours compared with saline placebo. -Proportion of subjects who are opioid-free from 72 hours through Day 10 and Day 28. -Median time in hours to first opioid rescue medication up to 72 hours. -Mean AUC0-72 of the NRS-R pain intensity scores. -Integrated Rank Analysis of Silverman using the NRS-A pain intensity AUC scores and total opioid consumption through 72 hours. -Proportion of subjects who are pain-free with activity (defined as an NRS-A pain intensity score of 0 or 1) at each assessed timepoint through Day 28. Proportion of subjects with an NRS-A pain intensity score ≥ 4 at any timepoint through 72 hours. Proportion of subjects with an NRS-A pain intensity score ≥ 7 at any timepoint through 72 hours. Medicinal product no longer authorised

- -Proportion of subjects achieving a score of 'good' or better (&gt;1) pain control based on PGA at 24, 48, 72 hours, and on Day 28.

<div style=\"page-break-after: always\"></div>

## Pain intensity assessments

Subjects were asked to evaluate their current pain level at scheduled timepoints after surgery. Pain intensity scores were assessed using an 11-point NRS (0-10) where 0 represented 'no pain' and 10 represented 'worst pain imaginable' (Breivik 2008). NRS scores were recorded first at rest (NRS-R) and then with activity (NRS-A).

Approximately 400 subjects (150 subjects in the HTX-011 group, 150 subjects in the bupivacaine HCl active  control  group,  and  100  subjects  in  the  saline  placebo  control  group)  were  planned  to  be randomized  to  provide  at  least  90%  power  to  detect  a  statistically  significant  difference  (2-sided alpha=0.05) between the HTX-011 group and each of the control groups for each of the primary and key secondary endpoints.

For NRS-R assessments, subjects were seated/recumbent with the surgically attended leg elevated or lying supine. Measurements were obtained after the subject was in the resting position for at least 5 minutes. For  NRS-A  assessments,  subjects  were  seated  with  the  plantar  surface  of  the  ball  of  the  surgically attended foot touching the floor (no weight-bearing). Pain intensity assessments were scheduled at 1, 2, 4, 8, 12, 24, 36, 48, 60, 72 hours and at D10 and D28 post-dose. Patient global assessment of pain control Subjects were asked to evaluate their pain control over the preceding 24 hours using a 4-point PGA scale where 0 represented 'poor' and 3 represented 'excellent' (Rothman 2009). Scheduled timepoints were: 24, 48, 72 hours and D28 post-dose. NRS-A was selected for the primary and first key secondary endpoints because NRS is known to be a sensitive  measure  of  pain  control  after  surgery,  and  effective  relief  of  acute  pain  with  activity  is considered  clinically  meaningful  as  it  facilitates  mobilization  and  may  therefore  improve  long-term outcome after surgery. The prescribed activity reflects a simple daily activity for patients: sitting with the plantar surface of the ball of the surgically attended foot touching the floor (no weight-bearing). The  timepoint  of  72  hours  selected  for  the  primary  and  key  secondary  endpoints  in  this  study  is considered by the applicant clinically  relevant  for  patients  as  literature  shows  that  the  most  severe postoperative pain occurs within the first 72 hours after surgery. Sample size Sample size was determined by the applicant based on the estimate of the following parameters from a previous phase 2 study in subjects undergoing unilateral simple bunionectomy: Table 17 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Randomisation and blinding (masking)

The  study  population  was  randomized  into  three  treatment  groups  in  a  3:3:2  pattern.  The  site's pharmacy  and  surgical  staff  were  not  blinded  to  the  treatment  assignments  because  HTX-011  is  a colored, viscous substance and is therefore distinguishable from both bupivacaine HCl and saline placebo. However, subjects were not aware of the study drug they received, and once surgery was completed and the subject was transferred to the PACU, the Investigator and all site staff involved in safety and efficacy assessments were blinded to the treatment assignment until after database lock.

<!-- image -->

Statistical methods Analysis populations · Intent-to-Treat (ITT) Population: All subjects who were randomized and received study drug were included in the ITT Population. · Per Protocol Population: All subjects in the ITT Population who did not receive a prohibited rescue medication prior to 72 hours and who had no important protocol violations prior to 72 hours were included in the Per Protocol Population. · Safety Population: All subjects who received study drug were included in the Safety Population. The primary and first key secondary endpoints were analysed using analysis of variance with treatment group as the main effect, together with pairwise t tests to analyse differences between treatment groups. Missing data, which were expected to be very low due to the 72 hours hospitalization following surgery, were imputed via last observation carried forward for interval censored pain intensity scores and worst observation carried forward (WOCF) for right-censored pain intensity scores in the intent-to-treat (ITT) population. To adjust for the analgesic effect of opioid rescue medication, the windowed WOCF method was implemented as the primary analysis method in which pain intensity scores observed during the analgesic window of any opioid rescue medication were replaced with the worst post-dose, non-missing NRS pain intensity score observed prior to the rescue medication window. A sensitivity analysis of the primary endpoint was performed with no adjustment for opioid usage. The total postoperative opioid consumption through 72 hours was analyzed using a Wilcoxon rank-sum test. The proportion of subjects who were opioid free through 72 hours was analyzed using Fisher's exact test. In order to account for multiple hypothesis testing on the primary endpoint and on each of the 4 key secondary endpoints, a testing hierarchy was applied to control study-wise alpha level at 0.05. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Figure 21: Hierarchical Test Procedure for Primary and Key Secondary Endpoints

<!-- image -->

<!-- image -->

Windowed worst observation carried forward (wWOCF) was used to adjust the NRS-A through 72 hours scores for the duration effect of opioid rescue medications. However, wWOCF was not used to adjust scores for the duration of effect of non-opioid recue medications (acetaminophen). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Results

Figure 22: Participant flow

<!-- image -->

<!-- image -->

Baseline data The overall study population was predominantly female (86.4%). The mean (SD) age was 46.9 (14.22) years, ranging from 18 to 77 years, and the mean BMI (SD) was 27.4 (4.70) kg/m2. The study subjects were overall well balanced across treatment's groups. The etiology of hallux valgus may be multifactorial. Main risk factors are: age, heredity, wearing of high heel and narrow shoes. In about 90% of cases, hallux valgus began between 40 and 50 years old and affects women. Regarding median age and sex ratio, it is considered that study population correctly reflects general population affected by hallux valgus. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 18: Number of Subjects per Analysis Population

<!-- image -->

| product   |
|-----------|

Outcomes and estimation Primary endpoint and first secondary endpoint: Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC0-72) Table 19: Mean AUC0-72 of the NRS-A Pain Intensity Scores for HTX-011 vs Saline Placebo and Bupivacaine HCl (wWOCF, ITT Population) The mean AUC0-72 of the NRS-A pain intensity score was lower in the HTX-011 group compared with saline placebo (primary endpoint) and compared with bupivacaine HCl (first key secondary endpoint) and the differences are statistically significant. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 23: Mean NRS-A Pain Intensity Scores over time (wWOCF, ITT Population)

<!-- image -->

With the exception of the first 2 hours after study drug administration, where mean NRS-A pain intensity scores is lower in the bupivacaine group, HTX-011 presents lower NRS-A pain intensity scores compared with saline placebo and bupivacaine groups through 72 hours. As surgery was performed under regional anesthesia with a lidocaine Mayo block, which provides several hours of analgesia, this explains the low pain scores across groups in this first hours post-dose in this study. These results show a statistically significant reduction of mean AUC0-72 of the NRS-A pain intensity score in the HTX-011 group compared with saline placebo and bupivacaine HCl groups. However, the clinically relevant difference for comparing the mean AUC0-72h of pain intensities has not been discussed or justified. As a consequence, clinical translation of obtained results in AUC are difficult to extrapolate and are open to interpretation. The applicant proposed a justification of the clinical significance based on a 10% to 20% reduction in NRS pain intensity scores as a minimal clinically important difference (MCID)  defined  by  The  Initiative  on  Methods,  Measurement,  and  Pain  Assessment  in  Clinical  Trials (IMMPACT) in chronic pain. However, when AUC of pain intensity scores has been X% decreased in the Zynrelef group compared to the 'reference' AUC in the placebo group at a precise time point does not mean that pain has been X% reduced. The minimal decrease in AUC of pain scores that would translate to a minimal decrease in pain that would been considered as clinically significant is not defined. Second  and  fourth  key  secondary  endpoints:  Mean  total  postoperative  opioid  consumption  (in intravenous mg morphine equivalents, MME) through 72 hours Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 20: Total Postoperative Opioid Consumption (MME) through 72 Hours for HTX-011 vs Saline Placebo and Bupivacaine HCl (ITT Population)

| HIX-011   | Bupivacaine HCl   |
|-----------|-------------------|

Total opioid consumption through 72 hours was lower in the HTX-011 group compared with saline placebo and bupivacaine HCl groups. The differences between median consumptions of opioids through 72 hours are statistically significant. However, the intragroup differences between the minimal and the maximal consumption are high and similar between treatment groups (from 0 to 80/90 MME in each group). Numerically, the mean and median differences between the groups, in particular between HTX-011 and bupivacaine HCl groups seem modest. In HTX-011 group, over 72 hours, mean total opioid consumption is reduced by 37% compared with saline placebo and by 25% compared with bupivacaine HCl. The applicant justified the clinical significance of the opioid sparing effect in particular for outcomes in patients, with an overall reduction of prespecified ORAEs with HTX-011 compared to saline placebo and bupivacaine: 43.9% vs 53.5% vs 50.6% respectively. It is endorsed that HTX-011 allowed an opioid sparing effect of about 6 to 7 of morphine mg equivalent in the first 24 hours compared to placebo which is under what seems to be possibly achieved with other analgesics such as paracetamol and NSAIDs. These 6 to 7 morphine mg equivalent sparing achieved in the first 24 hours is the most important sparing effect achieved on the overall interval of 72 hours (about 50% of the total opioid sparing). It could be hypothesized that the opioid sparing effect on the overall interval (0-72 hours) may be mainly driven by the opioid sparing effect on the first day post-dose (0-24 hours). Overall, the applicant successfully justified an opioid sparing effect associated with a decrease in ORAE. The estimation of the effect size is limited by the study design. Indeed, patient controlled analgesia (PCA) appears to be the method of choice to estimate opioid sparing effect because an accurate measure of  postoperative opioids needs should be preferably based on a method where patients can 'freely' access to opioids to relieve pain and accept some degree of undesirable effects. In addition, to a lesser extent, effect is limited by the use of paracetamol but its influence on opioid sparing is considered limited because the proportion of subjects who used paracetamol was overall lower in the HTX-011 group ad mean total use of paracetamol and average daily use were similar or lower in HTX-011 compared to the two other groups. This opioid sparing effect of HTX-011 is considered as modest but clinically significant. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Third key secondary and other endpoint: proportion of subjects who are opioid-free through 72 hours

Table 21: Proportion of Subjects Who are Opioid-Free through 72 Hours for HTX-011 vs Saline Placebo and Bupivacaine HCl (ITT Population)

<!-- image -->

<!-- image -->

The  proportion  of  subjects  who  did  not  require  any  opioid  rescue  medication  over  the  72-hour postoperative  period  was  higher  in  the  HTX-011  group  compared  with  bupivacaine  HCl  (3rd  key secondary endpoint) and compared with saline placebo (other secondary endpoint). The differences are statistically significant. Sensitivity analyses The applicant proposes sensitivity analyses performed on the primary and first key secondary endpoints to support the robustness of the primary analyses. Results of mean AUC0-72 of NRS-A pain intensity scores are presented without adjusting for opioid use and also using adjustment for opioid use in the per protocol population. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 22: Sensitivity Analyses: Mean AUC0-72 of NRS-A Pain Intensity Scores for the Primary and 1st Key Secondary Endpoints

<!-- image -->

<!-- image -->

The results are in line with those observed for the primary analysis and favour HTX-011 compared to saline placebo and bupivacaine HCl. The applicant provided additional analysis of mean pain intensity scores over different time intervals during the 72 hours post-dose (AUC of NRS-A). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 23: Mean AUC of NRS-A Pain Intensity Scores Over Time Intervals Using wWOCF (ITT Population)

<!-- image -->

Sources: Table 14.2.5.1, Post Hoc Table 14.2.3.7, Post Hoc Table 14.2.3.11.

<div style=\"page-break-after: always\"></div>

The  difference  on  mean  AUC0-72  of  the  NRS-A  pain  intensity  scores  between  saline  placebo  and bupivacaine HCl is statistically significant in favour of the active comparator. According to the applicant, this  suggest  a  confirmation  that  bupivacaine  is  active.  However,  this  result  was  not  expected  (cf. determination of sample size) and no discussion about it has been found.

The results concerning the comparison between saline placebo and bupivacaine HCl group in the first hours post-dose (AUC0-8 and AUC0-12) suggest, according to the applicant, that most of the analgesic benefit in this group was observed in the first 8 to 12 hours, which is supported by current scientific literature.  However,  the  fact  that  larger  overall  intervals  (AUC  0-24,  AUC0-48  and  AUC0-72)  are statistically  significant  in  favour  of  bupivacaine  while  the  intermediate  intervals  are  not  (AUC24-48, AUC48-72 and AUC24-72) suggests a limit of the clinical interpretation of the selected endpoint (mean AUC0-72 of NRS-A pain intensity scores). It should be noted that there is no statistically significant difference between HTX-011 and bupivacaine HCl groups from 48 to 72 hours post-dose (AUC48-72). When looking at the respective differences during 72 hours in AUC between placebo and HTX-011 ([AUC 0-72 (PB)] - [AUC 0-72 (ZYN)]), the proportions represented by the first 24 hours ([AUC 0-24 (PB)] - [AUC 0-24 (ZYN)]) are about 50% of the total difference. This is not in contradiction with supposed postoperative pain trajectory, where the first 3 postoperative days is the time period of most severe pain, as mentioned by the applicant, and considering that it has been reported that during these 3 most painful days, the first 24 hours could represent the most painful hours. However, it could not be excluded that the effect size on the overall interval (0-72 hours) may be mainly driven by the effect size on the first day post-dose (0-24 hours). When looking at the differences in mean pain scores (NRS-A), it seems unquestionable that Zynrelef has a clinically significant effect on reduction of pain scores during the first 24 hours post-dose compared to both saline placebo and bupivacaine HCl. After 24 hours, the differences in pain scores are maintained between 1 and 2 (on a 10 points scale, NRS-A) until 60 hours when HTX-011 is compared to saline placebo. When compared to bupivacaine, the differences in pain scores are maintained between 1 and 2 (on a 10 points scale, NRS-A) until 36 hours. At 48 hours, the difference is close to one (bupivacaine HCl vs HTX-011). At 72 hours, there is no clinically significant difference between treatments. According to the applicant, the results for NRS-R were consistent with NRS-A. The HTX-011 group had statistically  significant  reduced  mean  AUCs of NRS-R pain intensity scores using wWOCF on the ITT population compared with both control groups over the first 24, 48, and 72 hours (AUC0-24, AUC0-48 and AUC0-72). However, there is no statistically significant difference between HTX-011 and both control groups over 48 hours (AUC48-72). Mean AUCs of NRS-R pain intensity scores over time were analyzed using LOCF/WOCF as sensitivity analyses. Mean AUCs of NRS-R were lower than saline placebo and bupivacaine HCl with statistically significant treatment group differences noted for 0 to 12 hours, 0 to 24 hours, and 0 to 48 hours (AUC012, AUC0-24 and AUC0-48). The HTX-011 group also had lower mean AUC of pain intensity score over 72 hours with statistically significant difference compared with saline placebo but not compared with bupivacaine HCl for 0 to 72 hours (AUC0-72). Also, there is no statistically significant difference between HTX-011 and both control groups after 24 hours (AUC24-48 and AUC48-72). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 24: Mean (SE) NRS-R Pain Intensity Scores at Each Assessed Timepoint through 72 Hours Using wWOCF ITT Population

<!-- image -->

| product   |
|-----------|

The applicant provided analysis of proportion of subjects with moderate or severe pain intensity: Table 24: Proportion of subjects with NRSA ≥4 or ≥7 at any time through 24, 48, and 72 hours (wWOCF, ITT Population) Based on NRS-A, 53.5% of subjects in the HTX-011 group experienced severe pain at any time over 72 hours compared with 83.0% in the saline placebo group and 75.5% in the bupivacaine HCl group. These results are statistically significant. Based on NRS-R, 37.6% of subjects in the HTX-011 group experienced severe pain at any time over 72 hours compared with 73.0% in the saline placebo group and 60.0% in the bupivacaine HCl group. These results are statistically significant. Medicinal product no longer authorised

Overall, a large majority  of subjects experienced moderate pain whatever the considered treatment group. This proportion was however lower in the HTX-011 group with statistical significance based on NRS-A (but not based on NRS-R). Considering severe pain, the difference in proportion of subjects is

<div style=\"page-break-after: always\"></div>

statistically significant in favor of HTX-011 group but is also numerically significant based on NRS-A and NRS-R. These results suggest that HTX-011 could be an interesting treatment as part of a multimodal approach to manage postoperative pain and to increase probability to avoid severe pain on patients.

<!-- image -->

| no   |
|------|

Applicant was requested to present proportions of patients with a NRS-A&lt;4 at baseline, 12, 24 and 72 hours for studies 209 - cohort 2, 211, 301 and 302, and to consider these results in the discussion of the clinical relevance of treatment effects. Regarding study 301, treatment with HTX-011 results in a significant greater the proportion of patients with NRS-A score ≤ 4 at 12 and 24 hours. However, this was not the case at 72 hours. The justification of Applicant is that pain is expected to decrease for this surgery as it is seen in the placebo group with a proportion of about 40% subjects with NRS-A score ≤ 4 at 72 hours. It could then be questioned the rational of using this surgery models to show significant efficacy for 72 hours even though it is expected that curve of pain scores over time have great probability to cross or to be very close at this time point as it is seen in this application for phase 3 studies (301 and 302). Overall, it seems that no firm conclusion can be drawn with these results at 72 hours (proportion of subjects with NRS-A score ≤ 4). The result at 12 and 24 hours are in line with previous results showing efficacy of Zynrelef the first day post-surgery. Table 25: Incidence of Rescue Medication use through 72 hours (ITT population) These results on incidence of rescue medication confirm the need of a multimodal approach to manage postoperative  pain  as  supported  by  scientific  literature.  More  than  90%  of  subjects  needed  rescue medication whatever the considered treatment group. The proportion of subjects who received any opioid rescue medication through 72 hours is reduce in HTX-011 group (71.3%) compared to saline placebo (98%) and bupivacaine HCl groups (89%). Medicinal product no longer authorised

It should  be  noted  that substantially  more  subjects  used  only  non-opioid  rescue  medication (paracetamol) in the HTX-011 group. It may express, as suggested by Applicant, that subjects could managed their pain only with paracetamol (acetaminophen).

<div style=\"page-break-after: always\"></div>

The median time to the first use of opioid rescue medication during the 72-hour postoperative period was statistically significantly longer in the HTX-011 group compared with saline placebo and bupivacaine HCl (12.18 hours vs 4.90 and 7.60 hours, respectively).

<!-- image -->

| longer   |
|----------|
| no       |

Provided results suggest an opioid sparing effect maintained over time for a sub-group of subjects as a large  majority  of  opioid-free  subjects  during  the  72  hours  post-dose  period,  where  most  severe postoperative pain occurs, do not need opioid to control pain at Day 10 and Day 28 post-dose. However, the number of patients who lost the analgesic effect during the period from 72 hours up to Day 10 and Day 28 was higher in HTX-011, what may indicate that HTX-011 is not superior to Bupivacaine HCl in maintenance of opioid-free status over the time. The applicant was requested to discuss this point. The applicant provided re-analysis on the opioid-free status of participants in Study 301 and Study 302, taking into account major findings during inspection, which revealed a systematic problem regarding

As  requested,  the  applicant  provided  an  analysis  of  time  to  first  rescue  medication  (opioid  and paracetamol). Overall, HTX-011 delayed the time to first use of opioid rescue medication and increased the  proportion  of  subjects  who  did  not  require  opioid  rescue  medication.  However,  as  previously mentioned,  the  applicant  explained  that  surgery  was  performed  under  regional  anaesthesia  with  a lidocaine Mayo block, which provides several hours of analgesia. The low pain scores across groups following a Mayo block in this study likely led to smaller differences between HTX-011 and saline placebo at 2 and 4 hours. Table 26: Proportion of Subjects who are Opioid-Free through Day 10 or through Day 28 (ITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

errors in use of opioid diaries. There were numerous discrepancies between the post discharge opioid use data in patient diaries and data reported in the CSR. The results of re-analysis showed that proportion of subjects who were opioid-free and remained opioid-free through Day 10 was similar and through Day 28 was higher than in Bupivacaine HCl arm. Mean NRS-A Pain Scores at the Day 10 and Day 28 was lower in HTX-011 arm.

<!-- image -->

<!-- image -->

A Phase 3, Randomized, Double-Blind, Saline Placebo- and ActiveControlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy Methods The study consisted in the following phases: Figure 25 The study design is similar to study 301 in bunionectomy. Inguinal herniorrhaphy is not a surgical model cited in the Guideline on the clinical development of medicinal products intended for the treatment of pain but it is one of the most common soft tissue procedures performed in clinical practice. Acute pain after inguinal herniorrhaphy could be considered as generally moderate. Development of chronic pain after inguinal herniorrhaphy is highlighted in the scientific literature as the major complication of this surgical procedure with an estimated incidence of 10%. Postoperative pain is considered chronic if it persists more than 3 months after the intervention. Poor management of acute postoperative pain may be a risk factor of developing chronic pain as intensity of acute postoperative pain has been reported to correlates with the risk of developing a persistent pain. Thus, it would have been interesting to extend the follow up and to check for persistent pain across the different treatment groups. Study Participants Medicinal product no longer authorised

## Main inclusion criteria

Each subject had to meet all of the following criteria to be enrolled in this study:

<div style=\"page-break-after: always\"></div>

1. Was male or female, an d ≥18 years of age at screening.
2.  Was  scheduled  to  undergo  a  unilateral  open  inguinal  herniorrhaphy  with  mesh  under  general anesthesia.

-

-

3. Had an American Society of Anesthesiologists Physical Status of I, II, or III Main exclusion criteria Subjects who met any of the following criteria were not to be enrolled in the study: 1. Had any prior inguinal hernia repair except as a child (less than 6 years of age). 2. Had a planned concurrent surgical procedure (eg, bilateral herniorrhaphy). 3.  Had  a  pre-existing  concurrent  acute  or  chronic  painful  physical/restrictive  condition  expected  to require  analgesic  treatment  in  the  postoperative  period  for  pain  that  was  not  strictly  related  to  the herniorrhaphy and which may confound the postoperative assessments. 4. Had a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic  reaction  to  bupivacaine  (or  other  local  anesthetics),  meloxicam  (or  other  NSAIDs), oxycodone, morphine, acetaminophen/paracetamol, or fentanyl. 5. Had known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months. 6.  Had taken NSAIDs (including meloxicam) within 10 days prior to the scheduled surgery with the exception of subjects on low dose (≤100 mg) daily acetylsalicylic acid for cardioprotection. 7. Had taken long-acting opioids within 3 days prior to the scheduled surgery. 8. Had taken any opioids within 24 hours prior to the scheduled surgery. 9. Had been administered bupivacaine within 5 days prior to the scheduled surgery. 10. Had been administered any local anesthetic within 72 hours prior to the scheduled surgery, other than for pretreatment prior to a needle placement, to treat an AE that occurs after signing the ICF, or to decrease venous irritation (eg, caused by propofol, in which case no more than a single administration of lidocaine 1% 20 mg IV could be administered). Treatments The study population was randomized into three treatment groups in a 2:2:1 pattern generated by computer as follows: -HTX-011, bupivacaine 300 mg / meloxicam 9 mg (10.3 mL) via instillation into the surgical site using a Luer lock applicator. Bupivacaine HCl without epinephrine 0.25%, 75 mg (30 mL), via injection into the surgical site. Saline placebo, 0.9% sodium chloride (10.3 mL) via instillation into the surgical site using a Luer lock applicator. Medicinal product no longer authorised

The surgical procedure was performed under general anesthesia. During surgery, the use of IV fentanyl up to 4 μg/kg was permitted for intraoperative pain control. Just prior to the end of the surgery, all subjects  received  an  additional  50  µg  IV  fentanyl  in  order  to  decrease  the  inherent  variability  of intraoperative pain control on immediate postoperative pain.

<div style=\"page-break-after: always\"></div>

## Rescue medication

Postoperative rescue medication consisted of (PO) immediate-release oxycodone (no more than 10 mg within a 4-hour period as needed), IV morphine (no more than 10 mg within a 2-hour period as needed), and/or  oral  acetaminophen  (no  more  than  1,000  mg  in  a  6-hour  period).  Rescue  medication  was administrated upon request.

At discharge, subjects were to be provided a daily diary to record if they took any opioid medication from 72 hours through Day 28 (yes or no). Procedure  regarding  instillation  of  HTX-011  and  bupivacaine  injection  were  standardized  and  well described. The dose of bupivacaine HCl used in this study is within the range of dosing in bupivacaine labeling provided and, according to the applicant, was based on advice from medical experts who stated that doses commonly used in herniorrhaphy range from approximately 20 to 30 mL using a 0.25% solution. The dose selected for this study, 30 mL of 0.25% solution (75 mg), reflected the maximum dose and maximum concentration recommended. This seems acceptable. However, as a single-dose is used for postoperative  pain  management  in  this  study,  the  selection  of  bupivacaine  dose  is  crucial  and  it  is considered this point should be further justified. Objectives Primary objective: To compare the efficacy and duration of analgesia following local administration of HTX-011 with saline placebo during the first 72 hours following unilateral open inguinal herniorrhaphy. Secondary objectives: -To compare the efficacy and duration of analgesia for HTX-011 with bupivacaine HCl without epinephrine during the first 72 hours following surgery. -To compare the effect of HTX-011 with saline placebo and bupivacaine HCl without epinephrine on opioid load during the first 72 hours following surgery. -To assess the safety and tolerability of HTX-011. -To further establish the PK parameters of bupivacaine and meloxicam in HTX-011. The objectives of this study are identical to those of study 301 in bunionectomy and are appropriate. Outcomes/endpoints Primary Endpoint Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRSA) through 72 hours (AUC0-72) for HTX-011 compared with saline placebo. Key secondary endpoints -Mean AUC0-72 of the NRS-A pain intensity scores for HTX-011 compared with bupivacaine HCl. Medicinal product no longer authorised

- -Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with saline placebo.

<div style=\"page-break-after: always\"></div>

- -Proportion  of  subjects  who  are  opioid-free  through  72  hours  for  HTX-011  compared  with bupivacaine HCl.
- -Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with bupivacaine HCl.

Other secondary efficacy endpoints -Proportion of subjects who are opioid-free through 72 hours compared with saline placebo. -Proportion of subjects who are opioid-free from 72 hours through Day 10 and Day 28. -Median time in hours to first opioid rescue medication up to 72 hours. -Mean AUC0-72 of the NRS-R pain intensity scores. -Integrated Rank Analysis of Silverman using the NRS-A pain intensity AUC scores and total opioid consumption through 72 hours. -Proportion of subjects who are pain-free with activity (defined as an NRS-A pain intensity score of 0 or 1) at each assessed timepoint through Day 28. -Proportion of subjects with an NRS-A pain intensity score ≥ 4 at any timepoint through 72 hours. -Proportion of subjects with an NRS-A pain intensity score ≥ 7 at any timepoint through 72 hours. -Proportion of subjects who first achieve an MPADSS score ≥ 9 at 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours. -Proportion of subjects achieving a score of 'good' or better (&gt;1) pain control based on PGA at 24, 48, 72 hours, and on Day 28. Pain intensity assessments Subjects were asked to evaluate their current pain level at scheduled timepoints after surgery. Pain intensity scores were assessed using an 11-point NRS (0-10) where 0 represented 'no pain' and 10 represented 'worst pain imaginable' (Breivik 2008). NRS scores were recorded first at rest (NRS-R) and then with activity (NRS-A). For NRS-R assessments, subjects were subjects were recumbent or lying supine. Measurements were obtained after the subject was in the resting position for at least 5 minutes. For  NRS-A  assessments,  subjects  were  recumbent  or  lying  supine  and  were  instructed  to  sit  up. Measurements were obtained as soon as the subject sat up from the resting position. Pain intensity assessments were scheduled at 1, 2, 4, 8, 12, 24, 36, 48, 60, 72 hours and at D10 and D28 post-dose. Discharge readiness Discharge readiness was assessed using the MPADSS criteria (Chung 1995). This study instrument was used to assess each subject's potential readiness to be discharged and was repeated at all scheduled timepoints (2, 4, 8, 12, 24, 36, 48, 60 and 72 hours post-dose). It was not intended to be used to decide whether or not to discharge a subject from the hospital/research facility. Subjects were required to remain in the hospital/research facility for 72 hours. Medicinal product no longer authorised

## Patient global assessment of pain control

Subjects were asked to evaluate their pain control over the preceding 24 hours using a 4-point PGA scale where 0 represented 'poor' and 3 represented 'excellent' (Rothman 2009).

<div style=\"page-break-after: always\"></div>

Scheduled timepoints were: 24, 48, 72 hours and D28 post-dose.

Efficacy endpoints are identical to those of pivotal study 301 in bunionectomy. The prescribed activity for NRS-A in subjects undergoing herniorrhaphy was sitting up from a resting position. This is acceptable.

<!-- image -->

<!-- image -->

Sample size Sample size was determined by the applicant based on the estimate of the following parameters from a previous phase 2 study in subjects undergoing unilateral open inguinal herniorrhaphy: Table 27 Approximately 400 subjects (160 subjects in the HTX-011 group, 160 subjects in the bupivacaine HCl active control group, and 80 subjects in the saline placebo control group) were planned to be randomized to  provide  at  least  90%  power  to  detect  a  statistically  significant  difference  (2-sided  alpha=0.05) between the HTX-011 group and each of the control groups for each of the primary and key secondary endpoints. Studies  appear  sufficiently  powered  according  to  the  criteria  selected.  The  clinical  relevance  of  the expected difference in terms of AUC0-72 of the pain intensity score between HTX-011 and bupivacaine HCl/placebo has not been justified. Randomisation and blinding (masking) study population was randomized into three treatment groups in a 2:2:1 pattern. The site's pharmacy and surgical staff were not blinded to the treatment assignments because HTX-011 is a colored, viscous substance  and  is  therefore  distinguishable  from  both  bupivacaine  HCl  and  saline  placebo.  However, subjects were not aware of the study drug they received, and once surgery was completed and the subject was transferred to the PACU, the Investigator and all site staff involved in safety and efficacy assessments were blinded to the treatment assignment until after database lock. The study blind at the site was not to be broken except in medical emergencies when the appropriate management of the subject required knowledge of the study drug he/she received. Statistical methods Analysis populations · Intent-to-Treat (ITT) Population: All subjects who were randomized and received study drug were included in the ITT Population. Medicinal product no longer authorised

- Per Protocol Population: All subjects in the ITT Population who did not receive a prohibited rescue medication prior to 72 hours and who had no important protocol violations prior to 72 hours were included in the Per Protocol Population.
- Safety Population: All subjects who received study drug were included in the Safety Population.

<div style=\"page-break-after: always\"></div>

Overall  the  statistical  methods  is  identical  to  study  301  in  bunionectomy  and  seems  acceptable.  A hierarchically procedure, in a pre-specified order, has been set to handle multiple comparison in primary and key secondary endpoints.

<!-- image -->

## Baseline data

The definitions of ITT, PP and safety populations are appropriate. Windowed worst observation carried forward (wWOCF) was used to adjust the NRS-A through 72 hours scores for the duration effect of opioid rescue medications. However, wWOCF was not used to adjust scores for the duration of effect of non-opiod recue medications (acetaminophen). Results Figure 26: Participant flow Medicinal product no longer authorised

The overall study population was predominantly male (94.5%). The mean (SD) age was 48.9 (12.75) years,  ranging  from  18  to  83  years,  and  the  mean  BMI  (SD)  was  27.21  (4.058)  kg/m2.  The  study subjects were overall well balanced across treatment's groups. Inguinal hernia is a common pathology

<div style=\"page-break-after: always\"></div>

affecting mainly men. It could exist from birth (congenital) and be for example revealed during an effort in the young adult. In the older subject, it results more from a progressive weakness of the muscles and fibrous tissues of the lower abdomen. Regarding median age and sex ratio, it is considered that study population is adequate.

<!-- image -->

<!-- image -->

Numbers analysed Table 28: Number of Subjects per Analysis Population Outcomes and estimation Primary endpoint and first key secondary endpoint: Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC0-72) Table 29: Mean AUC0-72 of the NRS-A Pain Intensity Scores for HTX-011 vs Saline Placebo and Bupivacaine HCl (wWOCF, ITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The mean AUC0-72 of the NRS-A pain intensity score was lower in the HTX-011 group compared with saline placebo (primary endpoint) and compared with bupivacaine HCl (first key secondary endpoint) and the differences are statistically significant.

<!-- image -->

<!-- image -->

Figure 27: Mean NRS-A Pain Intensity Scores over time (wWOCF, ITT Population) With the exception of the first 2 hours after study drug administration, where mean NRS-A pain intensity scores is lower in the bupivacaine group, HTX-011 presents lower NRS-A pain intensity scores compared with saline placebo and bupivacaine groups through 72 hours. It is difficult to appreciate the clinical relevance of these differences. The clinically relevant difference for comparing the mean AUC0-72h of pain intensities has not been initially discussed or justified. As a consequence, clinical translation of obtained results in AUC are difficult to extrapolate and are open to interpretation. The applicant proposed a justification of the clinical significance based on a 10% to 20% reduction in NRS pain intensity scores as a minimal clinically important difference (MCID) defined by The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) in chronic pain that is not considered fully adapted. Graphically, the most important differences in pain scores between HTX-011 and both of the control groups occurred during the first 24 hours. Between 24 and 72 hours post-dose, the curves of pain scores corresponding to placebo, bupivacaine HCl and HTX-011 are practically parallel. The difference in pain scores between groups is close to 1/10. Overall, this may suggest a spontaneous reduction of pain 24 hours after surgery. HTX-011 effect on pain after 24 hours does not appear clearly. Second  and  fourth  key  secondary  endpoints:  Mean  total  postoperative  opioid  consumption  (in  iv morphine equivalents) through 72 hours Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 30: Total Postoperative Opioid Consumption (MME) through 72 hours for HTX-011 vs Saline Placebo and Bupivacaine HCl (ITT Population)

| HIX-011   | Bupivacaine HCl   |
|-----------|-------------------|

These results show an overall lower consumption of opioids in HTX-011 group compared with saline placebo and bupivacaine HCl groups. However, the intragroup differences between the minimal and the maximal  consumption  are  high  and  similar  between  treatment  groups.  Numerically,  the  mean  and median differences between the groups, in particular between HTX-011 and bupivacaine HCl groups, seem modest. In HTX-011 group, over 72 hours, mean total opioid consumption is reduced by 38% compared with saline placebo and by 25% compared with bupivacaine HCl. As requested, the applicant justified the clinical significance of the opioid sparing effect in particular for outcomes in patients, with an overall reduction of prespecified ORAEs with HTX-011 compared to saline placebo and bupivacaine: 32.5% vs 43.9% vs 42.2% respectively. It is endorsed that HTX-011 allowed an opioid sparing effect of about 6 to 7 of morphine mg equivalent in the first 24 hours compared to placebo which is under what seems to be possibly achieved with other analgesics such as paracetamol and NSAIDs. These 6 to 7 morphine mg equivalent sparing achieved in the first 24 hours is the most important sparing effect achieved on the overall interval of 72 hours (about 50% of the total opioid sparing). It could be hypothesized that the opioid sparing effect on the overall interval (0-72 hours) may be mainly driven by the opioid sparing effect on the first day post-dose (0-24 hours). Overall, the applicant successfully justified an opioid sparing effect associated with a decrease in ORAE. The estimation of the effect size is limited by the study design. Indeed, patient controlled analgesia (PCA) appears to be the method of choice to estimate opioid sparing effect because an accurate measure of  postoperative opioids needs should be preferably based on a method where patients can 'freely' access to opioids to relieve pain and accept some degree of undesirable effects. In addition, to a lesser extent, effect is limited by the use of paracetamol but its influence on opioid sparing is considered limited because the proportion of subjects who used paracetamol was overall lower in the HTX-011 group ad mean total use of paracetamol and average daily use were similar or lower in HTX-011 compared to the two other groups. This opioid sparing effect of HTX-011 is considered as modest but clinically significant. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Third key secondary and other endpoint: proportion of subjects who are opioid-free through 72 hours

Table 31: Proportion of Subjects Who are Opioid-Free through 72 Hours for HTX-011 vs Saline Placebo and Bupivacaine HCl (ITT Population)

<!-- image -->

<!-- image -->

These results show a largely higher proportion of opioid-free subjects over 72 hours post-dose in HTX011 group compared to saline placebo. When compared to bupivacaine, the proportion of opioid-free subjects over 72 hours is higher in the HTX-011 group and the difference is at the limit of the statistical significance (p=0.0486). Sensitivity analyses The applicant proposes sensitivity analyses performed on the primary and first key secondary endpoints to support the robustness of the primary analyses. Results of mean AUC0-72 of NRS-A pain intensity scores are presented without adjusting for opioid use and also using adjustment for opioid use in the per protocol population. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 32: Sensitivity Analyses: Mean AUC0-72 of NRS-A Pain Intensity Scores for the Primary and first Key Secondary Endpoints

<!-- image -->

|    |        | authorised   |
|----|--------|--------------|
|    | longer |              |
| no |        |              |

The results point in the same direction than the primary analysis and favour HTX-011 compared to saline placebo and bupivacaine HCl. It  should  however  be  noted  that  the  mean  AUC0-72  of  NRS-A  pain  intensity  score  is  higher  in  the bupivacaine HCl group compared to the saline placebo group in both sensitivity analyses (without wWOCF in the ITT population and with wWOCF in the per protocol population). This was not the case in the primary analysis even though the mean AUC0-72 of NRS-A pain intensity score were numerically close. This suggest that there is no difference between bupivacaine HCl and placebo in this surgical model. According to the applicant, sensitivity analyses using the Per Protocol Population on the 2nd, 3rd, and 4th key secondary endpoints were also consistent with the primary analyses. The HTX-011 group had lower total opioid consumption and more opioid-free subjects over 72 hours group compared with saline placebo and bupivacaine HCl. Medicinal product no longer authorised

The applicant provided additional analysis of mean pain intensity scores over different time intervals during the 72 hours post-dose (AUC of NRS-A).

<div style=\"page-break-after: always\"></div>

Table 33: Mean AUC of NRS-A Pain Intensity Scores over time Intervals Using wWOCF (ITT Population)

<!-- image -->

The difference during the first 8 hours (AUC0-8) in favour of HTX-011 compared with bupivacaine HCl is on the border of statistical significance (p=0.0426).

<div style=\"page-break-after: always\"></div>

It should be noted that HTX-011 did not result in statistically significant decrease of AUC of pain intensity scores from 48 hours to 72 hours compared to both saline placebo and bupivacaine HCl (AUC 48-72). When looking at the respective differences during 72 hours in AUC between placebo and HTX-011 ([AUC 0-72 (PB)] - [AUC 0-72 (ZYN)]), the proportions represented by the first 24 hours ([AUC 0-24 (PB)] [AUC  0-24  (ZYN)])  are  about  50%.  This  is  not  in  contradiction  with  supposed  postoperative  pain trajectory, where the first 3 postoperative days is the time period of most severe pain, as mentioned by the applicant, and considering that it has been reported that during these 3 most painful days, the first 24 hours could represent the most painful hours. However, it could not be excluded that the effect size on the overall interval (0-72 hours) may be mainly driven by the effect size on the first day post-dose (0-24 hours).

<!-- image -->

When looking at the differences in mean pain scores (NRS-A), it seems unquestionable that Zynrelef has a clinically significant effect on reduction of pain scores during the first 24 hours post-dose compared to both saline placebo and bupivacaine HCl. However, after 24 hours, the differences in pain scores between saline placebo and HTX-011 are systematically under 1 (on a 10 points scale, NRS-A). The correlation between decrease in AUC and decrease in pain is not straightforward and the minimal decrease in AUC of pain scores that would translate to a minimal decrease in pain that would been considered as clinically significant is not defined. It could be then considered that Zynrelef effect after 24 hours in open inguinal herniorrhaphy is not clinically significant in this study. According to the applicant, the results for NRS-R were consistent with NRS-A. The HTX-011 group had statistically  significant  reduced  mean  AUCs of NRS-R pain intensity scores using wWOCF on the ITT population compared with both control groups over the first 24, 48, and 72 hours (AUC0-24, AUC0-48 and AUC0-72). However, there is no statistically significant difference between HTX-011 and both control groups over 48 hours (AUC48-72). Mean AUCs of NRS-A and NRS-R pain intensity scores over time were analyzed using LOCF/WOCF as sensitivity analyses. According to the applicant, results were consistent with the primary analyses and although a statistically significant treatment group difference in the AUC of NRS-R pain intensity scores was not achieved for HTX-011 compared with saline placebo for every time period, this is likely due to the smaller sample size of the saline placebo group. It should however be noted that there was no statistically significant difference between HTX-011 and both control groups after 24 hours (AUC24-48 and AUC48-72) and on the overall interval (AUC0-72). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 28: Mean (SE) NRS-R Pain Intensity Scores at Each Assessed Timepoint through 72 Hours Using wWOCF ITT Population

<!-- image -->

<!-- image -->

Regarding mean AUCs of NRS-R pain intensity scores over time analyzed using LOCF/WOCF, mean AUCs of  NRS-R were lower for HTX-011 compared to saline placebo and bupivacaine HCl with statistically significant treatment group differences noted for 0 to 12 hours, 0 to 24 hours, and 0 to 48 hours (AUC012, AUC0-24 and AUC0-48). However, there is no statistically significant difference between HTX-011 and  both  control  groups  after  24  hours  (AUC24-48  and  AUC48-72).  There  is  also  no  statistically significant difference between HTX-011 and both control groups on the overall interval (AUC0-72). The applicant provided analysis of proportion of subjects with moderate or severe pain intensity. Table 34: Proportion of Subjects with NRSA ≥4 or ≥7 at Any Time through 24, 48, and 72 Hours (wWOCF, ITT Population) Medicinal product no longer authorised

| Medicinal   |
|-------------|

Notes: p-values from Fisher's exact test. Exact 95% CI is based on Farrington-Mamning score statistics.

Source: Table 14.2.14.

<div style=\"page-break-after: always\"></div>

Based on NRS-A, fewer than half the subjects in the HTX-011 group (48.8%) experienced severe pain at any timepoint over 72 hours compared with 81.7% in the saline placebo group and 60.5% in the bupivacaine HCl group. These results are statistically significant.

Based on NRS-R, 36.0% of subjects in the HTX-011 group experienced severe pain at any time over 72 hours compared with 65.9% in the saline placebo group and 34.9% in the bupivacaine HCl group. Overall, a large majority of subjects experienced moderate to severe ( ≥ 4) pain throughout 72 hours whatever the considered treatment group. This proportion was however lower in the HTX-011 group with statistical significance based on NRS-A and NRS-R. Considering severe pain ( ≥ 7), the difference in proportion of subjects is statistically significant in favour of HTX-011 group based on NRS-A. However, there is no statistically significant difference between HTX011 and bupivacaine group based on NRS-R and the proportion was slightly lower in the bupivacaine HCl group (36.0% versus 34.9 respectively). Interestingly, it appears that, based on NRS-A and NRS-R, the proportion of subjects experiencing severe pain at any time over 72 hours did not or practically not progress after 24 hours even in the placebo group. This is in accordance with curves of mean NRS-A and NRS-R pain intensity scores over time (072 hours) showing higher pain intensity scores during the first hours post-surgery. At day 28, there was no significant difference in the proportion of subjects with NRS-A or NRS-R ≥ 7 but the proportion is lower in the bupivacaine group. Applicant was requested to present proportions of patients with a NRS-A&lt;4 at baseline, 12, 24 and 72 hours for studies 209 - cohort 2, 211, 301 and 302, and to consider these results in the discussion of the clinical relevance of treatment effects. Regarding study 302, treatment with HTX-011 results in a significant greater the proportion of patients with NRS-A score ≤ 4 at 12 and 24 hours. However, this was not the case at 72 hours. The justification of Applicant is that pain is expected to decrease for this surgery as it is seen in the placebo group with a proportion of about 60 % subjects with NRS-A score ≤ 4 at 72 hours. It could then be questioned the rational of using this surgery models to show significant efficacy for 72 hours even though it is expected that curve of pain scores over time have great probability to cross or to be very close at this time point as it is seen in this application for phase 3 studies (301 and  302).  Overall,  it  seems  that  no  firm  conclusion  can  be  drawn  with  these  results  at  72  hours (proportion of subjects with NRS-A score ≤ 4). The result at 12 and 24 hours are in line with previous results showing efficacy of Zynrelef the first day post-surgery. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 35: Incidence of Rescue Medication Use through 72 Hours (ITT Population)

<!-- image -->

| authorised   |
|--------------|

These results show a reduced proportion of subjects needing rescue medication in the HTX-011 group. There is a trend to higher use of paracetamol in the bupivacaine HCl group. Mean total and average use of paracetamol in HTX-011 and saline placebo groups seem quite similar. The median time to the first use of opioid rescue medication during the 72-hour postoperative period was not evaluable (estimated beyond 72 hours for the HTX-011 group because over 50% of subjects did not require opioid rescue medication). As  requested,  the  applicant  provided  an  analysis  of  time  to  first  rescue  medication  (opioid  and paracetamol). Overall, HTX-011 statistically significantly delayed the time to first use of opioid rescue medication compared to saline placebo and numerically delayed time to first use of rescue medication compared to bupivacaine HCl, which is satisfactory. In addition, proportion of subjects who did not require any rescue medication through 72 hours was significantly increase with HTX-011 treatment compared to both control groups. However, large majority (&gt; 65 %) of subjects required rescue medication which is an indicator that HTX-011 remains a treatment part of multimodal analgesia. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 36: Proportion of Subjects Who are Opioid-Free through Day 10 or Through Day 28 (ITT Population)

<!-- image -->

| authorised   |
|--------------|

A large majority of opioid free subjects at 72 hours remained opioid free at day 10 and day 28. It would have been interesting to know if these subjects consumed others analgesic such as paracetamol or NSAID after discharge. However, the number of patients who lost the analgesic effect during the period from 72 hours up to Day  10  and  Day  28  was  higher  in  HTX-011,  what  may  indicate  that  HTX-011  is  not  superior  to Bupivacaine HCl in maintenance of opioid-free status over the time. The applicant was requested to discuss this point. The applicant provided re-analysis on the opioid-free status of participants in Study 301 and Study 302, taking into account major findings during inspection, which revealed a systematic problem regarding errors in use of opioid diaries. There were numerous discrepancies between the post discharge opioid use data in patient diaries and data reported in the CSR. The results of re-analysis showed that proportion of subjects who were opioid-free and remained opioid-free through Day 10 was similar and through Day 28 was higher than in Bupivacaine HCl arm. Mean NRS-A Pain Scores at the Day 10 and Day 28 was lower in HTX-011 arm. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Phase 2b, Randomized, Double Blind, Saline Placebo- and ActiveControlled, Multicenter Study of HTX-011 via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty

<!-- image -->

<!-- image -->

Methods The study design was described in Section 2.5.1 of this report along with Cohort 1 results. Cohort 2 results The results for the primary and key secondary endpoints were statistically significant in favor of HTX011 in Cohort 2. HTX-011 400 mg/12 mg administered with or without low-dose ropivacaine significantly reduced the mean AUC of NRS-R pain intensity scores over 48 hours (primary endpoint) and over 72 hours (key secondary endpoint) compared with saline placebo (primary comparison). Mean NRS-R pain scores were lower for the HTX-011 400 mg/12 mg group compared with saline placebo at all timepoints through 72 hours, with clear separation of the pain curves. Administration of low-dose ropivacaine into the posterior capsule provided a small additional benefit in postoperative analgesia during the first 8 hours. In addition, HTX-011 400 mg/12 mg with or without low-dose ropivacaine significantly reduced mean AUC of NRS-R pain scores over 24 hours compared with bupivacaine HCl. Mean AUC of NRS-R pain scores over 48 and 72 hours were also lower for both HTX-011 groups compared with bupivacaine HCl, and the differences were statistically significant for the HTX-011 400 mg/12 mg + low-dose ropivacaine group. Figure 29: Mean NRS-R Pain Intensity Scores over time for HTX-011 vs Saline Placebo and Bupivacaine HCl in Cohort 2 (wWOCF, ITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 37: Mean AUC0-48 and AUC0-72 of NRS-R Pain Intensity Scores for HTX-011 compared with saline placebo in cohort 2 (wWOCF, ITT Population)

| Ireatment Group   | N   | Mean (SD)   | p-value vs Saline Placebo   |
|-------------------|-----|-------------|-----------------------------|

<!-- image -->

| no   |
|------|

However, to show significant results on mean AUC0-48 and mean AUC0-72 of NRS-R Pain Intensity Scores for HTX-011 compared to bupivacaine HCl, it was necessary to add 50 mg of ropivacaine. In fact, graphically, the higher difference in pain scores between HTX-011 and saline placebo occurred in the first 8 hours in the HTX-011 + ropivacaine group, when the ropivacaine is active.

Table 38: Mean AUC0-48 and AUC0-72 of NRS-R Pain Intensity Scores for HTX-011 compared with bupivacaine HCl in Cohort 2 (wWOCF, ITT Population) This study in cohort 2 shows positive results on the primary endpoint (mean AUC0-48 of NRS-R Pain Intensity Scores) and on the key secondary endpoint (mean AUC0-72 of NRS-R Pain Intensity Scores) for HTX-011 compared with saline placebo. In terms of pain scores over time, the difference seems close to 2 on 10-point scale. It should be noted that NRS-R was not the criteria selected for the phase 3 studies where NRS-A was utilized. Medicinal product no longer authorised

Pain intensity was also assessed with activity and the results were consistent with the NRS-R results.

<div style=\"page-break-after: always\"></div>

HTX-011  significantly  reduced  mean  AUC  of  NRS-A  pain  intensity  scores  on  every  time  intervals compared to saline placebo (AUC0-24, AUC0-48 and AUC0-72).

HTX-011 significantly reduced mean AUC of NRS-A pain intensity scores over 24 and 48 hours compared to bupivacaine HCl (AUC0-24, AUC0-48).

The difference on mean NRS-A Pain Intensity Scores over time seems close to 1 on 10-point scale. The reduction of pain scores after 24 hours post-dose in HTX-011 group compared to saline placebo seems limited. Overall, pain remains severe ( ≥ 7/10) in all treatment groups. According to the selected criteria (AUC0-48 and AUC0-72 of NRS-R pain intensity scores), over a 72 hours period, HTX-011 does not seem to provide a significant better analgesia than bupivacaine HCl. The applicant was requested to justify the effect of Zynrelef on pain to achieve clinically significant pain reduction for 72 hours. It should be noted that the results provided in the HTX-011 + ropivacaine group were not taken into consideration because ropivacaine has an additional analgesic effect that prevents assessment of HTX-011 analgesic effect considering ropivacaine was not added in the two other groups. The applicant justified that the study was not intended, nor powered, to demonstrate superiority to bupivacaine HCl. However, CHMP disagreed with the applicant's assumption that it is not necessary to formally demonstrate non-inferiority to the active comparator in this particular case. Indeed, in TKA study, the primary and key secondary endpoint only considered a comparison against placebo. This is not considered sufficient as the criteria of AUC of pain intensity scores has no direct clinical translation and the minimum difference that would be considered as clinically significant when comparing AUC has not been justified. All  subjects except 2 (1 in the HTX-011 400 mg/12 mg + low-dose ropivacaine group and 1 in the bupivacaine HCl group) were administered rescue medication during the 72-hour postoperative period. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 39: Total Postoperative Opioid Consumption (MME) From 0 through 24, 48, and 72 Hours in Cohort 2 (ITT Population)

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |

The objective to provide a better pain relief (with a longer-lasting postoperative bupivacain and as a consequence to reduce the need for opioids after surgery) compared to the defined standard of care bupivacaine HCl is not fully achieved.

Overall, opioid sparing effect in this surgical model seems limited. HTX-011 without ropivacaine only reduced  significantly  median  opioid  consumption  over  the  first  24  hours  compared  to  placebo. Numerically, HTX-011 shows an opioid sparing effect of approximately 10 mg/72 hours compared to placebo  (reduction  of  about  12.5  %  on  mean  total  opioid  consumption  through  72  hours).  As  a comparison,  it  has  been  reported  that  analgesic  techniques,  such  as  nonsteroidal  anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 (COX-2) inhibitors, acetaminophen, ketamine, gabapentin and pregabalin,  and  regional  anesthetic  techniques  provide  20-50%  opioid  sparing  in  the  postoperative setting.  In  addition,  no  significant  sparing  effect  of  HTX-011  compared  to  bupivacaine  HCl  can  be highlighted (opioid consumption over 24, 48 and 72 hours). There was also no significant difference in proportion of subjects having used opioids according to the applicant. The applicant was requested to justify clinical significance of the opioid sparing effect and a small opioid sparing effect with a 13.4% greater reduction in opioid use through 72 hours post-dose in HTX-011 compared with saline placebo, and a 9.6% greater reduction compared with bupivacaine HCl. This effect was not associated with a decrease in prespecified ORAEs and is not considered as clinically significant. Medicinal product no longer authorised

A confirmatory phase 3 study in this surgery, using at least a comparison to bupivacaine at a decreased dose (compared to Zynrelef) as a primary or a key secondary endpoint (as what was done in the two phase 3 studies) is regarded as minimally requested.

<div style=\"page-break-after: always\"></div>

Finally,  this  study  in  another  surgical  model  leads  to  not  consider  surgical  models  as  one  entity. Therefore, pain management should be adapted to the type of surgical model, even if the multimodal approach will be the corner stone. Specificities linked to the type of surgical models have to be considered before to claim a broad indication in 'post-operative pain management'.

<!-- image -->

<!-- image -->

| Title:A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Use Following Unilateral Simple Bunionectomy   | Title:A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Use Following Unilateral Simple Bunionectomy   | Title:A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Use Following Unilateral Simple Bunionectomy                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study                                                                                                                                                                                                                | HTX-011-301                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                               | Multicenter (USA), Parallel, Single-dose, Placebo- and Active-Controlled                                                                                                                                             | Randomized, Double-Blind, Saline                                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                               | Duration of surgery phase:                                                                                                                                                                                           | On Day 1, subjects underwent a bunionectomy. The start of study drug administration (intraoperatively) was considered Time 0 (Day 1). longer                                                                                                                           |
| Design                                                                                                                                                                                                               | Duration of postanesthesia phase: no                                                                                                                                                                                 | 72 hours. Postoperative assessments following surgery and immediate postoperative recovery                                                                                                                                                                             |
| Design                                                                                                                                                                                                               | Duration of ambulatory phase: product                                                                                                                                                                                | 38 days After the 72-hour assessments were completed, subjects could be discharged. From discharge through Day 28 : opioid medication recording on daily diary Day 10 and Day 28 : follow-up assessments on study site Day 42 : safety follow-up (X-Ray) on study site |
| Hypothesis Superiority                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                               | Hypothesis Superiority                                                                                                                                                                                                                                                 |
| Treatments groups Medicinal                                                                                                                                                                                          | HTX-011 via instillation into the surgical site (2.1 mL) Bupivacaine 60 mg / Meloxicam 1.8 mg                                                                                                                        | Single dose, Day 1 164 subjects randomized                                                                                                                                                                                                                             |
| Treatments groups Medicinal                                                                                                                                                                                          | Saline Placebo via instillation into the surgical site (2.1 mL)                                                                                                                                                      | Single dose, Day 1 109 subjects randomized                                                                                                                                                                                                                             |
| Treatments groups Medicinal                                                                                                                                                                                          | Bupivacaine HCl 0.5% via injection into the surgical site (50 mg, 10 mL)                                                                                                                                             | Single dose, Day 1 165 subjects randomized                                                                                                                                                                                                                             |

Summary of main studies The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections). Table 40: Summary of efficacy for Study 301 in bunionectomy Medicinal product no longer authorised

a

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                                                                                                       | AUC 0-72 of the NRS-A Pain Intensity Scores                                                                                                                                                                                                                            | Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC 0-72 ) for HTX-011 compared with saline placebo                                                                                       | Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC 0-72 ) for HTX-011 compared with saline placebo                                                                                       |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                       | 1 st Key Secondary endpoint                                                                                                                                                                                                                                            | AUC 0-72 of the NRS-A Pain Intensity Scores                                                                                                                                                                                                                            | Mean AUC 0-72 of the NRS-A pain intensity scores for HTX-011 compared with bupivacaine HCl                                                                                                                                                                             | Mean AUC 0-72 of the NRS-A pain intensity scores for HTX-011 compared with bupivacaine HCl                                                                                                                                                                             |
| Endpoints and definitions                       | 2 nd Key Secondary endpoint                                                                                                                                                                                                                                            | Opioid consumption through 72 hours (MME)                                                                                                                                                                                                                              | Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with saline placebo authorised                                                                                                                             | Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with saline placebo authorised                                                                                                                             |
| Endpoints and definitions                       | 3 nd Key Secondary endpoint                                                                                                                                                                                                                                            | Opioid-free through 72 hours                                                                                                                                                                                                                                           | Proportion of subjects who are opioid- free through 72 hours for HTX-011 compared with bupivacaine HCl                                                                                                                                                                 | Proportion of subjects who are opioid- free through 72 hours for HTX-011 compared with bupivacaine HCl                                                                                                                                                                 |
| Endpoints and definitions                       | 4 th Key Secondary endpoint                                                                                                                                                                                                                                            | Opioid consumption through 72 hours (MME)                                                                                                                                                                                                                              | Mean total postoperative opioid consumption (in morphine milligram equivalents) through 72 hours for HTX-                                                                                                                                                              | Mean total postoperative opioid consumption (in morphine milligram equivalents) through 72 hours for HTX-                                                                                                                                                              |
| 011 compared with bupivacaine HCl Database lock | 011 compared with bupivacaine HCl Database lock                                                                                                                                                                                                                        | 011 compared with bupivacaine HCl Database lock                                                                                                                                                                                                                        | 011 compared with bupivacaine HCl Database lock                                                                                                                                                                                                                        | 011 compared with bupivacaine HCl Database lock                                                                                                                                                                                                                        |
| Results and Analysis longer                     | Results and Analysis longer                                                                                                                                                                                                                                            | Results and Analysis longer                                                                                                                                                                                                                                            | Results and Analysis longer                                                                                                                                                                                                                                            | Results and Analysis longer                                                                                                                                                                                                                                            |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                       |
| Analysis population and time point description  | Intent to treat population: All subjects who were randomized and received study drug (N=412). This population was used as the primary analysis population for all efficacy endpoints. The randomized treatment assignment was used for analysis in this population. no | Intent to treat population: All subjects who were randomized and received study drug (N=412). This population was used as the primary analysis population for all efficacy endpoints. The randomized treatment assignment was used for analysis in this population. no | Intent to treat population: All subjects who were randomized and received study drug (N=412). This population was used as the primary analysis population for all efficacy endpoints. The randomized treatment assignment was used for analysis in this population. no | Intent to treat population: All subjects who were randomized and received study drug (N=412). This population was used as the primary analysis population for all efficacy endpoints. The randomized treatment assignment was used for analysis in this population. no |
| Descriptive statistics and estimate variability |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |
| Medicinal                                       |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |
| Medicinal                                       | Treatment group                                                                                                                                                                                                                                                        | HTX-011                                                                                                                                                                                                                                                                | Placebo                                                                                                                                                                                                                                                                | Bupivacaine HCl                                                                                                                                                                                                                                                        |
| Medicinal                                       | Number of subject AUC 0-72 of the NRS-A Pain Intensity Scores product                                                                                                                                                                                                  | 157                                                                                                                                                                                                                                                                    | 100                                                                                                                                                                                                                                                                    | 155                                                                                                                                                                                                                                                                    |
| Medicinal                                       | Mean (SD)                                                                                                                                                                                                                                                              | 323.29 (182.641)                                                                                                                                                                                                                                                       | 445.34 (155.792)                                                                                                                                                                                                                                                       | 393.5 (153.756)                                                                                                                                                                                                                                                        |
| Medicinal                                       | Opioid consumption through 72 hours (MME)                                                                                                                                                                                                                              | 18.80 (19.801) 12.50                                                                                                                                                                                                                                                   | 30.06 (21.016) 25.00                                                                                                                                                                                                                                                   | 25.09 (21.553) 17.50                                                                                                                                                                                                                                                   |
| Medicinal                                       | Mean (SD) Median (Min, Max)                                                                                                                                                                                                                                            | (0.0, 83.0)                                                                                                                                                                                                                                                            | (0.0, 80.0)                                                                                                                                                                                                                                                            | (0.0, 92.5)                                                                                                                                                                                                                                                            |
| Medicinal                                       | Opioid-free through 72 hours                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |
| Medicinal                                       | N (%)                                                                                                                                                                                                                                                                  | 45 (28.7)                                                                                                                                                                                                                                                              | 2 (2.0)                                                                                                                                                                                                                                                                | 17 (11.0)                                                                                                                                                                                                                                                              |
| Medicinal                                       |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |
| Medicinal                                       |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect estimate per comparison   | AUC 0-72 of the NRS-A Pain Intensity   | Comparison groups                    | HTX-011 vs Placebo   | HTX-011 vs Bupivacaine HCl   |
|----------------------------------|----------------------------------------|--------------------------------------|----------------------|------------------------------|
| Effect estimate per comparison   | Scores                                 | LSMD (SE)                            | -122.05 (21.217)     | -70.16 (18.777)              |
| Effect estimate per comparison   | Scores                                 | [95% CI]                             | [-163.76, -80.34]    | [-107.07, -33.25]            |
| Effect estimate per comparison   | Scores                                 | P-value (ANOVA)                      | <0.0001              | 0.0002                       |
| Effect estimate per comparison   | Opioid consumption through hours (MME) | Comparison groups                    | HTX-011 vs Placebo   | HTX-011 vs Bupivacaine HCl   |
| Effect estimate per comparison   | 72                                     | P-value (Wilcoxon rank sum test)     | <0.0001 authorised   | 0.0022                       |
| Effect estimate per comparison   | Opioid-free through 72 hours           | Comparison groups                    | HTX-011 vs Placebo   | HTX-011 vs Bupivacaine HCl   |
| Effect estimate per comparison   | Opioid-free through 72 hours           | Difference (%)                       | 26.7%                | 17.7%                        |
| Effect estimate per comparison   | Opioid-free through 72 hours           | [95% CI]                             | [18.6%, 34.7%]       | [8.5%, 26.5%]                |
| Effect estimate per comparison   | Opioid-free through 72 hours           | P-value (Fisher's exact test) longer | <0.0001              | 0.0001                       |
| Notes                            |                                        |                                      |                      |                              |

<!-- image -->

| Title: A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy Study identifier product   | Title: A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy Study identifier product   | Title: A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy Study identifier product   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                       | HTX-011-302                                                                                                                                                                                                                                                           | HTX-011-302                                                                                                                                                                                                                                                           |
| Design Medicinal                                                                                                                                                                                                                                                      | Multicenter (USA + Belgium), Parallel, Single-dose, Randomized, Double-Blind, Saline Placebo- and Active-Controlled                                                                                                                                                   | Multicenter (USA + Belgium), Parallel, Single-dose, Randomized, Double-Blind, Saline Placebo- and Active-Controlled                                                                                                                                                   |
| Design Medicinal                                                                                                                                                                                                                                                      | Duration of surgery phase:                                                                                                                                                                                                                                            | On Day 1, subjects underwent a herniorrhaphy. The start of study drug administration (intraoperatively) was considered Time 0 (Day 1).                                                                                                                                |
| Design Medicinal                                                                                                                                                                                                                                                      | Duration of postanesthesia phase:                                                                                                                                                                                                                                     | 72 hours. Postoperative assessments following surgery and immediate postoperative recovery                                                                                                                                                                            |

Table 41: Summary of efficacy for Study 302 in herniorrhaphy Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                      | Duration of ambulatory phase:                                                                                               | Duration of ambulatory phase:                                                                                               | 24 days After the 72-hour assessments were completed, subjects could be discharged. From discharge through Day 28 : opioid medication recording on daily diary Day 10 and Day 28 : follow-up assessments on study site authorised   | 24 days After the 72-hour assessments were completed, subjects could be discharged. From discharge through Day 28 : opioid medication recording on daily diary Day 10 and Day 28 : follow-up assessments on study site authorised   |                                                                                                                             |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                                           | Superiority                                                                                                                 | Superiority                                                                                                                 | Superiority                                                                                                                                                                                                                         |                                                                                                                                                                                                                                     |                                                                                                                             |
| Treatments groups                                                    | HTX-011 via instillation into the surgical site (10.3 mL) Bupivacaine 300 mg / Meloxicam 9 mg                               | HTX-011 via instillation into the surgical site (10.3 mL) Bupivacaine 300 mg / Meloxicam 9 mg                               | Single dose, Day 1 178 subjects randomized                                                                                                                                                                                          | Single dose, Day 1 178 subjects randomized                                                                                                                                                                                          |                                                                                                                             |
| Treatments groups                                                    | Saline Placebo via instillation into the surgical site (10.3 mL)                                                            | Saline Placebo via instillation into the surgical site (10.3 mL)                                                            | Single dose, Day 1 89 subjects randomized                                                                                                                                                                                           | Single dose, Day 1 89 subjects randomized                                                                                                                                                                                           |                                                                                                                             |
| Treatments groups                                                    | Bupivacaine HCl 0.25% via injection into the surgical site (75 mg, 30 mL) Single dose, Day 1 179 subjects randomized longer | Bupivacaine HCl 0.25% via injection into the surgical site (75 mg, 30 mL) Single dose, Day 1 179 subjects randomized longer | Bupivacaine HCl 0.25% via injection into the surgical site (75 mg, 30 mL) Single dose, Day 1 179 subjects randomized longer                                                                                                         | Bupivacaine HCl 0.25% via injection into the surgical site (75 mg, 30 mL) Single dose, Day 1 179 subjects randomized longer                                                                                                         | Bupivacaine HCl 0.25% via injection into the surgical site (75 mg, 30 mL) Single dose, Day 1 179 subjects randomized longer |
| Endpoints and definitions                                            | Primary endpoint                                                                                                            | AUC 0-72 of the NRS-A Pain Intensity Scores                                                                                 | Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC 0-72 ) for HTX-011 compared with saline placebo                                                    | Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) through 72 hours (AUC 0-72 ) for HTX-011 compared with saline placebo                                                    |                                                                                                                             |
| Endpoints and definitions                                            | 1 st Key Secondary endpoint                                                                                                 | AUC 0-72 of the NRS-A Pain Intensity Scores no                                                                              | Mean AUC 0-72 of the NRS-A pain intensity scores for HTX-011 compared with bupivacaine HCl                                                                                                                                          | Mean AUC 0-72 of the NRS-A pain intensity scores for HTX-011 compared with bupivacaine HCl                                                                                                                                          |                                                                                                                             |
| Endpoints and definitions                                            | 2 nd Key Secondary endpoint product                                                                                         | Opioid consumption through 72 hours (MME)                                                                                   | Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with saline placebo                                                                                                     | Mean total postoperative opioid consumption (in morphine equivalents) through 72 hours for HTX-011 compared with saline placebo                                                                                                     |                                                                                                                             |
|                                                                      | 3 nd Key Secondary endpoint                                                                                                 | Opioid-free through 72 hours                                                                                                | Proportion of subjects who are opioid- free through 72 hours for HTX-011 compared with bupivacaine HCl                                                                                                                              | Proportion of subjects who are opioid- free through 72 hours for HTX-011 compared with bupivacaine HCl                                                                                                                              |                                                                                                                             |
|                                                                      | 4 th Key Secondary endpoint                                                                                                 | Opioid consumption through 72 hours (MME)                                                                                   | Mean total postoperative opioid consumption (in morphine milligram equivalents) through 72 hours for HTX- 011 compared with bupivacaine HCl                                                                                         | Mean total postoperative opioid consumption (in morphine milligram equivalents) through 72 hours for HTX- 011 compared with bupivacaine HCl                                                                                         |                                                                                                                             |
| Database lock                                                        | Database lock                                                                                                               | Database lock                                                                                                               | Database lock                                                                                                                                                                                                                       | Database lock                                                                                                                                                                                                                       | Database lock                                                                                                               |
| Results and Analysis Analysis description Primary Analysis Medicinal | Results and Analysis Analysis description Primary Analysis Medicinal                                                        | Results and Analysis Analysis description Primary Analysis Medicinal                                                        | Results and Analysis Analysis description Primary Analysis Medicinal                                                                                                                                                                | Results and Analysis Analysis description Primary Analysis Medicinal                                                                                                                                                                | Results and Analysis Analysis description Primary Analysis Medicinal                                                        |
|                                                                      | Intent to treat population: All subjects who were randomized and received                                                   | Intent to treat population: All subjects who were randomized and received                                                   | Intent to treat population: All subjects who were randomized and received                                                                                                                                                           | Intent to treat population: All subjects who were randomized and received                                                                                                                                                           | Intent to treat population: All subjects who were randomized and received                                                   |
| Descriptive statistics and estimate variability                      | was used for Treatment group                                                                                                | analysis in this population. HTX-011                                                                                        |                                                                                                                                                                                                                                     | Bupivacaine HCl                                                                                                                                                                                                                     |                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                | Number of subject                                                                                        | 164                              | 82                   | 172                        |
|--------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------|----------------------|----------------------------|
|                                | AUC 0-72 of the NRS-A Pain Intensity Scores                                                              |                                  |                      |                            |
|                                | Mean (SD)                                                                                                | 269.39 (173.719)                 | 350.82 (171.224)     | 341.88 (158.303)           |
|                                | Opioid consumption through 72 hours (morphine milligram equivalent)                                      |                                  |                      | authorised                 |
|                                | Mean (SD)                                                                                                | 10.85 (17.062)                   | 17.53 (18.908) 11.25 | 14.51 (18.185) 7.25        |
|                                | Median (Min, Max)                                                                                        | 0.00 (0.0, 103.0)                | (0.0, 73.5)          | (0.0, 87.5)                |
|                                | Opioid-free through 72 hours                                                                             | longer                           |                      |                            |
|                                | N (%)                                                                                                    | 84 (51.2)                        | 18 (22.0)            | 69 (40.1)                  |
| Effect estimate per comparison | AUC 0-72 of the NRS-A Pain Intensity Scores                                                              | Comparison groups                | HTX-011 vs Placebo   | HTX-011 vs Bupivacaine HCl |
| Effect estimate per comparison | AUC 0-72 of the NRS-A Pain Intensity Scores                                                              | LSMD (SE) no                     | -81.43 (22.592)      | -72.49 (18.230)            |
| Effect estimate per comparison | AUC 0-72 of the NRS-A Pain Intensity Scores                                                              | [95% CI]                         | [-125.83, -37.02]    | [-108.32, -36.65]          |
| Effect estimate per comparison | AUC 0-72 of the NRS-A Pain Intensity Scores                                                              | P-value (ANOVA)                  | 0.0004               | <0.0001                    |
| Effect estimate per comparison | Opioid consumption through 72 hours (morphine milligram equivalent) Opioid-free through 72 hours product | Comparison groups                | HTX-011 vs Placebo   | HTX-011 vs Bupivacaine HCl |
| Effect estimate per comparison | Opioid consumption through 72 hours (morphine milligram equivalent) Opioid-free through 72 hours product | P-value (Wilcoxon rank sum test) | 0.0001               | 0.0240                     |
| Effect estimate per comparison | Opioid consumption through 72 hours (morphine milligram equivalent) Opioid-free through 72 hours product | Comparison groups                | HTX-011 vs Placebo   | HTX-011 vs Bupivacaine HCl |
| Effect estimate per comparison | Opioid consumption through 72 hours (morphine milligram equivalent) Opioid-free through 72 hours product | Difference (%)                   | 29.3%                | 11.1%                      |
| Effect estimate per comparison | Opioid consumption through 72 hours (morphine milligram equivalent) Opioid-free through 72 hours product | [95% CI]                         | [15.6%, 40.5%]       | [0.3%, 21.8%]              |
| Effect estimate per comparison | Opioid consumption through 72 hours (morphine milligram equivalent) Opioid-free through 72 hours product | P-value (Fisher's exact test)    | <0.0001              | 0.0486                     |
| Notes Medicinal                |                                                                                                          |                                  |                      |                            |

<div style=\"page-break-after: always\"></div>

## Analysis performed across trials (pooled analyses and meta-analysis)

No pooled analysis and meta-analysis were performed.

Clinical studies in special populations No clinical studies were performed in special population. Supportive study Mammoplasty: study 211 'Phase 2b, Randomized, Controlled Study of HTX-011 Administered Via Pectoral Nerve Block in Subjects Undergoing Upper Extremity Surgery for Augmentation Mammoplasty' This study was designed to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX011  of  HTX-011  administered  as  a  single  dose  via  nerve  block  (NB)  or  via  instillation  in  subjects undergoing augmentation mammoplasty. The study included 4 cohorts. HTX-011 was administered via bilateral ultrasound guided lateral and medial pectoral nerve block (NB) before surgery in Cohorts 1 through 4 and also via instillation into the surgical site prior to the end of surgery in Cohort 4. Increasing doses of HTX-011 were used in each cohort, after review of planned interim analyses of data from the previous cohort. Saline placebo and bupivacaine HCl 0.25% (50 mg) administered via NB were used as control. Study assessments Efficacy was assessed based on pain intensity (NRS-R and NRS-A), use of opioid rescue medication, Patient Global Assessment (PGA) of pain control, discharge readiness per the Modified Postanaesthetic Discharge Scoring System (MPADSS), the subject's satisfaction with pain control, and an overall benefit of analgesia score (OBAS). Safety was assessed based on AEs, clinical laboratory tests, physical examinations, wound healing, vital sign measurements, continuous Holter monitoring, motor function, and sensory function. Serial blood samples were collected for bupivacaine and meloxicam PK analysis. Main inclusion criteria Subjects were adult female with scheduled primary bilateral submuscular augmentation mammoplasty with saline or silicone smooth implants with a volume of 300 to 500 cc, inclusive. Main exclusion criteria Subjects had another planned concurrent surgical procedure (eg, mastopexy) or a planned reconstructive procedure status post breast cancer therapy, a medical condition expected to require analgesic treatment in  the  postoperative  period  or  that  would  confound  postoperative pain assessments, use of NSAIDS within 10 days of surgery or had taken long acting opioids within 3 days of surgery, or had taken any opioids within 24 hours of scheduled surgery for this study. Medicinal product no longer authorised

## Treatments

Cohort 1: approximately 24 subjects were to be randomized to 1 of the following 3 treatment groups in a 2:1:1 ratio:

- -HTX-011 60 mg/1.8 mg (2.1 mL volume administered) via NB.

<!-- image -->

<div style=\"page-break-after: always\"></div>

- -Bupivacaine HCl without epinephrine 0.25% (50 mg, 20 mL) via NB.
- -Saline placebo (2.1 mL) via NB.

Cohort 2: approximately 48 subjects were to be randomized to 1 of the following 3 treatment groups in a 2:1:1 ratio: -HTX-011 (a single dose recommended by the IRC of 120 mg/3.6 mg, 4.1 mL) via NB. -Bupivacaine HCl without epinephrine 0.25% (50 mg, 20 mL) via NB. -Saline placebo (4.1 mL) via NB. Ropivacaine HCl 0.5% 5 mL was administered in each of the surgical incision lines at closure in all treatment groups. Cohort 3: approximately 48 subjects were to be randomized to 1 of the following 3 treatment groups in a 2:1:1 ratio: -HTX-011 (a single dose recommended by the IRC of 240 mg/7.2 mg, 8.2 mL) via NB. -Bupivacaine HCl without epinephrine 0.25% (50 mg, 20 mL) via NB. -Saline placebo (8.2 mL) via NB. Ropivacaine HCl 0.5% 5 mL was administered in each of the surgical incision lines at closure in all treatment groups. Cohort 4: approximately 120 subjects were to be randomized to 1 of the following 4 treatment groups in a 4:4:1:1 ratio: -HTX-011 (a single dose recommended by the IRC of 400 mg/12 mg, 13.7 mL) via NB. -HTX-011 (a single dose recommended by the IRC of 400 mg/12 mg, 13.7 mL) via instillation into the intended space for the implant, with 200 mg/6 mg (6.8 mL) per side; saline placebo (13.7 mL) via NB for masking. -Bupivacaine HCl without epinephrine 0.25% (50 mg, 20 mL) via NB. -Saline placebo (13.7 mL) via NB. Ropivacaine HCl 0.5% 5 mL was administered in each of the surgical incision lines at closure in all treatment groups. The surgical procedure was conducted under general anesthesia. Subjects in Cohorts 2 and 4, and optionally in Cohort 3, received fentanyl 50 μg intravenously (IV) just prior to the end of the surgery in order to decrease the inherent variability of intraoperative pain control on immediate postoperative pain. In Cohorts 2, 3, and 4, subjects were administered 5 mL of 0.5% ropivacaine HCl in each of the surgical incision lines at closure. Medicinal product no longer authorised

Rescue  medication  during  72  hours  after  study  drug  administration  was  allowed  to  subjects  with inadequately controlled pain symptoms. The rescue medications were the following:

- -oral (PO) immediate-release oxycodone ( ≤ 10 mg within a 4-hour period as needed)

<div style=\"page-break-after: always\"></div>

- -IV morphine ( ≤ 10 mg within a 4-hour [Cohort 1] or 2-hour [Cohorts 2, 3, and 4] period)

After  72  hours,  the  analgesic  regimen  could  be  adjusted  for  each  subject  individually  as  deemed appropriate by the physician responsible for the postoperative care.

Main study objectives Primary: to compare the efficacy and duration of analgesia following bilateral ultrasound-guided lateral and medial pectoral nerve block with HTX-011 to bupivacaine HCl without epinephrine and saline placebo in subjects undergoing upper extremity surgery. Main secondary objectives: -To evaluate the efficacy  and duration of analgesia for  HTX-011 administered using different techniques in this study population. -To evaluate additional efficacy parameters in this study population. -To characterize the bupivacaine and meloxicam PK profiles of HTX-011 in this study population. -To determine the optimal administration technique of HTX-011 in this surgical model. -To further assess the safety and tolerability of HTX-011 in this study population. Main efficacy endpoints The primary endpoint was the mean area under the curve (AUC) of the NRS-A pain-intensity scores through 24 hours (AUC0-24). Main  secondary  endpoints  included  mean  total  postoperative  opioid  consumption  (in  morphine equivalents) through 24, 48, and 72 hours, median time in hours to first opioid rescue administration through 72 hours, mean AUC of the NRS-A and NRS-R pain-intensity scores at different intervals (0-6, 0-12, 12-24, 24-48, 0-48, 48-72, and 0-72 hours) and mean NRS-A and NRS-R pain-intensity scores at each assessed timepoint. Study subjects A total of 251 subjects were randomized and 243 received study drug. The majority of the randomized subjects  (88.8%)  were  recruited  at  one  of  the  three  study  sites.  The  demographics  and  baseline characteristics were generally well balanced across treatment groups. The mean (SD) age was 31.2 (8.01). Mean (SD) across treatment groups was 23.66 (3.418). All 243 subjects completed the 72-hour postoperative observation period and 93.8% completed the study. Main results in cohort 1, 2, 3 According to the applicant, the lower HTX-011 doses (60 mg/1.8 mg to 240 mg/7.2 mg) via NB did not significantly reduce postoperative pain compared with either control group. As a consequence, provided results are focused on the cohort 4. Main results in cohort 4 The primary comparison on the primary endpoint for each HTX-011 group was against the pooled saline placebo group. Comparisons of HTX-011 against the pooled bupivacaine HCl were considered secondary comparisons. Medicinal product no longer authorised

Both HTX-011 400 mg/12 mg groups, NB and instillation, had significantly lower mean AUC0-24 of the NRS-A pain-intensity scores compared with saline placebo via NB (primary endpoint, wWOCF). Compared with bupivacaine HCl via NB, both HTX-011 400 mg/12 mg treatment groups had lower mean AUC0-24 of the NRS-A pain-intensity scores but these differences were not statistically significant.

<div style=\"page-break-after: always\"></div>

Figure 30: Mean (SE) AUC0-24 of the NRS-A Pain-Intensity Scores using wWOCF (mITT Population)

<!-- image -->

<!-- image -->

Figure 31: Mean NRS-A of Pain-Intensity Scores at Each Assessed Timepoint through 72 Hours Using LOCF (mITT Population) Medicinal product no longer authorised carried forward.

Source: Table 14.2.5.4.

<div style=\"page-break-after: always\"></div>

Table 42: Mean AUC of NRS-A Pain-Intensity Scores at Each Interval (wWOCF, mITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 32: Mean (SE) NRS-R of Pain-Intensity Scores at each assessed timepoint through 72 hours using LOCF (mITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 43: Mean AUC of NRS-R Pain-Intensity Scores at Each Interval (wWOCF, mITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 44: Total Postoperative Opioid Consumption in Morphine Equivalents through 24, 48, and 72 Hours (mITT Population)

<!-- image -->

This study in cohort 4 shows positive results for HTX-011 400 mg/12 mg, administered as a single dose via nerve block (NB) or via instillation, on the primary endpoint (mean AUC0-24 of the NRS-A painintensity scores) compared with saline placebo. Compared with bupivacaine HCl via NB, both HTX-011 400 mg/12 mg treatment groups had lower mean AUC0-24 of the NRS-A pain-intensity scores but these differences were not statistically significant. After 24 hours post-dose, there is no clinically meaningful difference in pain scores between HTX-011 400 mg/12 mg and both control groups. Medicinal product no longer authorised

Mean and median total opioid consumption in MME over 72 hours were numerically higher in HTX-011 400 mg/12 mg administered via instillation compared to both control groups.

These results seem not sufficient to support an indication to reduce postoperative pain for 72 hours in augmentation mammoplasty.

<div style=\"page-break-after: always\"></div>

The applicant justified that the study was only exploratory and not designed for comparative assessment of HTX-011 administered via instillation as the comparators (saline placebo and bupivacaine HCl) were administered via nerve block but supports the activity of HTX-011 in an additional soft tissue model as reduction in mean AUC of the NRS-A score through 24 hours (NRS-A0-24; primary endpoint) was showed compared with saline placebo (primary analysis).

It  is  expected  that  a  product  containing  a  high-dose  bupivacaine  shows  some  activity  compared  to placebo  but  these  exploratory  results  are  not  considered  sufficient  for  supporting  an  indication  in mammoplasty. 2.5.3. Discussion on clinical efficacy Design and conduct of clinical studies The clinical development of Zynrelef (HTX-011) is based on two phase 3, randomized, double-blind, multicenter, active and placebo-controlled, pivotal studies (study 301 in bunionectomy and study 302 in herniorrhaphy). Overall, the design of these both Phase 3 was adequate. The selection criteria were globally consistent with the target population for each surgical model. Two doses of the fixed dose combination product were tested in phase 3 studies: bupivacaine 60 mg/ meloxicam 1.8 mg in bunionectomy and bupivacaine 300 mg/ meloxicam 9 mg in herniorrhaphy. These doses and the administration technique were selected based on previous results on phase 2 studies (study 208 in bunionectomy and study 202 in herniorrhaphy). The dose to be applied depends upon the size of the surgical site and the volume required to coat the affected tissues. The clinical development program involved two other phase 2 studies in total knee arthroplasty (TKA) and augmentation mammoplasty (study 209 and study 211 respectively). A higher dose of bupivacaine 400 mg/ meloxicam 12 mg was selected in these studies through increasing dose and administration techniques finding cohorts. These surgical models have been selected to provide efficacy data of Zynrelef in bony and soft tissue surgical models with different pain levels, in different anatomic spaces with different vascularities and to support a broad indication in postoperative pain for 72 hours. The active comparator selected for the clinical development was bupivacaine HCl administered as a single dose  via  injection  into  the  surgical  site.  Bupivacaine  solution  for  injection  is  at  present  the  most appropriate active comparator as it is standard of care. However, most of its analgesic benefit occurred in the first 8 to 12 hours. The primary endpoint and the key secondary endpoints were identical in both phase 3 studies. The mean AUC of the Numeric Rating Scale with activity (NRS-A) pain intensity scores through 72 hours (AUC072) for HTX-011 compared with saline placebo and compared with bupivacaine HCl, were primary and first key secondary endpoints respectively. According to CHMP Scientific Advice, the primary endpoint was only partially endorsed. The CHMP Scientific Advice highlight the fact that '[…] it should be discussed and justified in advance which difference can be regarded clinically relevant for comparing the mean AUC0-72h of pain intensities. Statistical significance only does not suffice to demonstrate a clinically relevant  effect.  It  is  furthermore  expected  that  the  complete  course  of  pain  intensities  over  the measurement interval is presented. Taking into consideration the lack of an appropriate comparator with longer duration of effect an earlier time point will also be critical for assessment of efficacy and would usefully be included as co-primary EP, e.g. at least non-inferiority (which of course would not help to justify the addition of the meloxicam component of the combination) and preferably superiority on AUC06h when selecting bupivacaine solution for injection or HTX-002 as active comparator. AUC0-72h could Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

then demonstrate the additional benefit of the new formulation '. This advice was not fully followed by the applicant.

The clinically relevant difference for comparing the mean AUC0-72h of pain intensities has not been justified. As a consequence, clinical translation of obtained results in AUC are difficult to extrapolate and are open to interpretation.

The clinically relevant difference for comparing the mean AUC0-72h of pain intensities has not been justified. As a consequence, clinical translation of obtained results in AUC are difficult to extrapolate and are open to interpretation. In study 301 in bunionectomy, the differences on mean AUC48-72 of the NRS-A  and  NRS-R  pain  intensity  using  wWOCF  on  the  ITT  population  score  between  HTX-011  and bupivacaine HCl are not statistically significant. The difference on mean AUC0-72 of the NRS-R pain intensity using LOCF/WOCF on the ITT population score between HTX-011 and bupivacaine HCl is not

The other key secondary endpoints are thus considered as important to appreciate clinical significance. There  were  mainly  focused  on  opioids  consumption  (mean  total  postoperative  opioid  consumption through 72 hours and proportion of subjects who are opioid-free through 72 hours compared with saline placebo and bupivacaine HCl). This approach is endorsed as the recognized advantages of multimodal analgesia  include  improved  analgesia,  reduced  opioids  requirements  and  reduced  adverse  effects  of opioids. However, it should be noted that 'patient controlled analgesia' (PCA) appears to be the method of choice to estimate opioid sparing effect because an accurate measure of postoperative opioids needs should be preferably based on a method where patients can 'freely' access opioids to relieve pain and accept some degree of undesirable effects. This method was not used to assess opioid sparing effect. Decreased opioid consumption is a legitimate important clinical objective considered that it is achieved through the same level of pain relief. The choice of the time interval of 72 hours based on the assumption that most severe pain occurs within the first 72 hours after surgery is acceptable. The primary and key secondary endpoints were different in TKA (mean AUC0-48 and AUC0-72 of NRSR Pain Intensity Scores for HTX-011) and in augmentation mammoplasty (mean AUC0-24 of NRS-A pain intensity scores and mean total postoperative opioid consumption through 24, 48 and 72 hours) and considered only comparison with saline placebo. This was not considered optimal as Zynrelef is a fixed dose combination. Efficacy data and additional analyses Phase 3 studies in bunionectomy and herniorrhaphy According to the primary analysis, Zynrelef (HTX-011), at the doses of bupivacaine 60 mg / meloxicam 1.8 mg and bupivacaine 300 mg/ meloxicam 9 mg, was superior to placebo and to bupivacaine HCl to manage postoperative  pain  in  bunionectomy  and  herniorrhaphy  (mean  AUC0-72  of  the  NRS-A  pain intensity scores using wWOCF in the defined ITT population). Sensitivity analysis (mean AUC0-72 of NRS-A pain intensity scores using LOCF/WOCF in the ITT population and mean AUC0-72 of NRS-A pain intensity scores using wWOCF in the per protocol population) were consistent with the primary analysis. These results are in accordance with those observed on pain at rest compared with saline placebo (AUC072 of the NRS-R pain intensity scores using wWOCF in the defined ITT population). These outcomes were supported by key secondary endpoints showing a reduced opioid consumption and higher proportion of opioid-free subjects over 72 hours. The  proportion  of  subjects with  severe  pain  (≥7/10) was  significantly  reduced  in  HTX-011  group compared with saline placebo and bupivacaine HCl based on NRS-A (wWOCF, ITT population). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

statistically significant. In study 302 in herniorrhaphy, there was no statistically significant difference between HTX-011 and saline placebo group after 48 hours post-dose (AUC48-72) on NRS-A of the pain intensity  scores  using  wWOCF  in  the  defined  ITT  population.  There  was  no  statistically  significant difference between HTX-011 and both control groups after 48 hours (mean AUC48-72 of NRS-R pain intensity scores using wWOCF on the ITT population). Regarding mean AUCs of NRS-R pain intensity scores over time analyzed using LOCF/WOCF, there was no statistically significant difference between HTX-011  and  both  control  groups  after  24  hours  (AUC24-48  and  AUC48-72).  There  was  also  no statistically  significant  difference  between  HTX-011  and  both  control  groups  on  the  overall  interval (AUC0-72).

Overall, phase 3 studies (301 and 302) showed positive results in favour of HTX-011 based on primary and key secondary endpoints. However, it remains a reasonable doubt that the effect size on the overall interval (AUC 0-72 hours) may be mainly driven by the effect size on the first day post-dose (AUC 0-24 hours) as well as that the opioid sparing effect on the overall interval (0-72 hours) may be mainly driven by the opioid sparing effect on the first day post-dose (0-24 hours). However, it is estimated that Zynrelef has a clinically significant effect on reduction of pain scores at least during the first 24 hours post-dose and the applicant successfully justified an opioid sparing effect associated with a decrease in ORAE in bunionectomy and herniorrhaphy. This opioid sparing effect of Zynrelef is considered as modest but clinically significant. Phase 2 studies in total knee arthroplasty (TKA) and augmentation mammoplasty According to the primary analysis, Zynrelef (HTX-011), at the doses of bupivacaine 400 mg / meloxicam 12 mg was superior to placebo in TKA and augmentation mammoplasty models. In study 209 in TKA, ZYNRELF (HTX-011) bupivacaine 400 mg / meloxicam 12 mg was superior to placebo (mean AUC of NRS-R pain intensity scores using wWOCF in the defined ITT population) over 48 hours (primary endpoint) and over 72 hours (key secondary endpoint) compared with saline placebo. These results are in accordance with those observed on pain with activity compared with saline placebo. HTX-011 significantly reduced mean AUC of NRS-A pain intensity scores (wWOCF, ITT Population) on every time intervals compared to saline placebo (AUC0-24, AUC0-48 and AUC0-72). However, questions were raised as, according to the selected criteria, over a 72 hours period, HTX-011 bupivacaine 400 mg / meloxicam 12 mg does not provide a significant better analgesia than bupivacaine HCl (mean AUC of NRS-R pain intensity scores over time). The reduction of pain scores after 24 hours post-dose in HTX011 group compared to saline placebo and bupivacaine seems limited. Overall, pain remains severe (≥7/10) in all treatment groups. The opioid sparing effect of HTX-011 seems limited in this surgical model and was not associated with a difference in proportion of subjects having used opioids and/or with a decrease in prespecified ORAEs. No significant sparing effect of HTX-011 compared to bupivacaine HCl could be highlighted. It is estimated that phase 3 confirmatory results, including comparison of mean AUC0-72 of pain intensity scores between Zynrelef and bupivacaine HCl as a primary or first key secondary endpoint, would be necessary to include total knee arthroplasty as a therapeutic indication of Zynrelef. Indeed, in TKA study, the primary and key secondary endpoint only considered a comparison against placebo and was not intended, nor powered, to demonstrate superiority to bupivacaine HCl. This is not considered sufficient for the following reasons: Medicinal product no longer authorised

- -The criteria of AUC of pain intensity scores has no direct clinical translation and the minimum difference that would be considered as clinically significant when comparing AUC has not been justified.

<div style=\"page-break-after: always\"></div>

- -The small opioid sparing effect was not associated with a decrease in prespecified ORAEs and is not considered as clinically significant.

Augmentation mammoplasty study (211) was an exploratory study where reduction in mean AUC of the NRS-A score through 24 hours (NRS-A0-24; primary endpoint) was showed for HTX-011 administered via instillation (and via nerve block) compared with saline placebo. However, even if the study was not designed for this purpose, according to the applicant, compared with bupivacaine HCl via NB, both HTX011 400 mg/12 mg treatment groups had lower mean AUC0-24 of the NRS-A pain-intensity scores but these  differences  were  not  statistically  significant.  After  24  hours  post-dose,  there  is  no  clinically meaningful difference in pain scores between HTX-011 400 mg/12 mg and both control groups. Mean and median total opioid consumption in MME over 72 hours were numerically higher in HTX-011 400 mg/12 mg administered via instillation compared to both control groups. These results are not sufficient to assess the B/R in augmentation mammoplasty. Broad indication in postoperative pain Justification for a broad indication and posology cannot be based on regulatory precedence to already approved local anaesthetics. Claimed indication should only be based on evidence from the development programme. Considering the efficacy of the new product in treatment of acute pain, the Guideline on the Clinical Development of Medicinal Products Intended for the Treatment of Pain states, that ' The efficacy profile of a new product should normally be established in separate studies for both somatic and visceral nociceptive pain ' and 'to justify a general indication for the treatment of acute pain, efficacy needs to be demonstrated independently in models of both somatic and visceral pain, or in models of somatic pain and mixed somatic/visceral pain '. In the case of HTX-011 the studied models represent moderate to severe somatic pain model (Bunionectomy study 301, 208; Total knee arthroplasty study 209) and mixed somatic/visceral mild to moderate pain (Herniorrhaphy study 302, 202 and supportive study in augmentation mammoplasty). There was no data provided on the analgaesic effect of HTX-011 in visceral moderate to severe pain models or mixed somatic/visceral moderate to severe pain models, which represents major abdominal, thoracic or vascular surgeries. The applicant's argument to replace missing pain models with the mechanism of action of the fixed combination is not endorsed as justification is only based on an assumption. While evidence of efficacy can be extrapolated to less severe pain categories within the same model, in this case, the applicant did not provide evidence of efficacy in moderate to severe somatic/visceral pain models or visceral moderate to severe pain models. Although the applicant stated during the evaluation that HTX 011 is intended to treat somatic postoperative soft tissue and bony pain, not visceral pain, the proposed indication  was  not  limited  to  surgeries  representing  only  somatic  pain.  The  applicant  also accepted the deletion of the mention 'for up to 72 hours' from the therapeutic indication and proposed the addition of the adjective 'somatic' to the indication wording. The final indication was agreed to be: Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1). Medicinal product no longer authorised

Uncertainties remain on the clinical significance of the effect in tested surgeries because the primary endpoint of phase 3 studies is only partially endorsed in line with the scientific advice and the minimum difference that would be considered as clinically significant when comparing AUC of pain intensity scores has not been justified. It should be moreover considered that intrinsic factors with incidence on pain management should be considered across different types of surgery.

It is estimated that phase 3 confirmatory results, including comparison of mean AUC0-72 of pain intensity scores  between  Zynrelef  and  bupivacaine  HCl  as  a  primary  or  first  key  secondary  endpoint,  will  be

<div style=\"page-break-after: always\"></div>

necessary to include total knee arthroplasty as a therapeutic indication of Zynrelef. Indeed, in TKA study, the primary and key secondary endpoint only considered a comparison against placebo. Augmentation mammoplasty study (211) was an exploratory study where reduction in mean AUC of the NRS-A score through 24 hours (NRS-A0-24; primary endpoint) was showed but does not provide sufficient results to assess the B/R in this surgery.

The proposed posology was also questioned regarding a broad indication in postoperative pain. The current proposed Zynrelef's administration is limited to a 14 mL volume corresponding to the maximum total dose (about 400 mg / 12 mg). It is not known if this volume will be sufficient to coat the affected tissues within others surgical sites that could result in pain generation. Conversely, in case of miniinvasive surgery with very small incision, the use of a small volume of Zynrelef in the wound might be inefficient: Zynrelef is provided in a single concentration solution of 29.25 mg of bupivacaine and 0.88 mg of meloxicam per mL. During bunionectomy study (301), the use of the defined volume of 2.1 mL was associated with difficulty in suturing some patients with leaks of product. Moreover, this surgery is already at risk of impaired wound healing and dehiscence. The physical presence of a viscous solution (Zynrelef) in the wound has been associated with a slight increase of this risk in the study. It could then be questioned how to assess these specific surgery type risks that likely exist in other surgeries. It is endorsed that surgeons routinely determine the dosing requirements for different surgical wounds, based  on  the  maximum  allowable  dose  and  that  it  would  be  impossible  to  provide dosing recommendations for each procedure. Still, from the CHMP's opinion, there is some difference between a  local  injection  of  bupivacaine  and  an  instillation  of  Zynrelef.  Indeed,  when  Zynrelef  has  been administered and surgical wound has been closed, there is no adapting possibility whereas it is possible to inject a second dose of bupivacaine while not exceeding the maximum recommended dose. As a consequence, it was estimated that Zynrelef recommended posology has to be more strictly defined in the SmPC, for efficacy as well as for safety reasons. The applicant was asked to define a range of volume with a reasonable presumption of efficacy/safety (X to Y mL). The applicant justified that a range of doses cannot be determined based on the data from clinical studies. Instructions regarding the use of adequate amount is proposed by the applicant associated with a warning to avoid excess use that could be deleterious for the site closure. Even not entirely satisfactory, the applicant's proposal is considered acceptable. Fixed dose combination considerations The CHMP considered that based on general methodological principles, in order to establish the efficacy and safety of each component of the fixed dose combination, an appropriate phase III design would have been  a  randomized  three-arm  study  of  bupivacaine  +  meloxicam  versus  bupivacaine  and  versus meloxicam. However, despite the fact that such study has not been submitted by the applicant, the efficacy of bupivacaine in the combination can be considered established on the basis of the overall clinical results as well as known efficacy profile of this active substance. Concerning meloxicam, although conclusive clinical trials investigating its activity in the combination in the claimed indication are lacking, the inference of the contribution to efficacy can be considered sufficiently established based on biological and pharmacological rationale, as well as relevant non-clinical and clinical data, most notably from Phase 2 studies. These studies utilised investigational, prolonged-release bupivacaine-only and meloxicam-only comparator formulations prepared in the same polymer as Zynrelef to assess the contribution of each active ingredient to the combination product. The efficacy of Zynrelef was superior to that of prolongedrelease bupivacaine alone, at the same bupivacaine dose, in both study 202 and study 208. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.5.4. Conclusions on the clinical efficacy

Studied models in Zynrelef's development programme represent moderate to severe somatic pain model (Bunionectomy study 301, 208; Total knee arthroplasty study 209) and mixed somatic/visceral mild to moderate pain (Herniorrhaphy study 302, 202 and supportive study in Augmentation mammoplasty). There is no provided data on the analgesic effect of HTX-011 in visceral moderate to severe pain models or mixed somatic/visceral moderate to severe pain models, which represents major abdominal, thoracic or vascular surgeries. The applicant's argument to replace missing pain models with the mechanism of action of the fixed combination is not endorsed as justification is only based on an assumption.

Additional supportive safety data are from one Phase 1 study (in healthy volunteers) and three Phase 2a studies (in herniorrhaphy, mini- or complete abdominoplasty, or bunionectomy).

Considering the efficacy of the new product in treatment of acute pain, the Guideline on the Clinical Development of Medicinal Products Intended for the Treatment of Pain states, that 'The efficacy profile of  a  new  product  should  normally  be  established  in  separate  studies  for  both  somatic  and  visceral nociceptive pain' and 'to justify a general indication for the treatment of acute pain, efficacy needs to be demonstrated independently in models of both somatic and visceral pain, or in models of somatic pain and mixed somatic/visceral pain'. Therefore, based on the clinical efficacy data provided by the applicant, a broad indication is not justified. It also remains uncertainties on the clinical significance of the effect in tested surgeries because the primary endpoint of phase 3 studies is only partially endorsed in line with the scientific advice and the minimum difference  that  would  be  considered  as  clinically  significant  when  comparing  AUC  of  pain intensity  scores  has  not  been  justified.  It  should  be  moreover  considered  that  intrinsic  factors  with incidence on pain management should be considered across different types of surgery. More precisely, in studies 301 and 302, it could not be excluded that the effect size on pain (AUC of NRS scores) and decreased opioid consumption on the overall interval (0-72 hours) may be mainly driven by the effects size on the first day post-dose (0-24 hours). However, it is estimated that Zynrelef has a clinically significant effect on reduction of pain scores during at least the first 24 hours post-dose and the  applicant  successfully  justified  an  opioid  sparing  effect  associated  with  a  decrease  in  ORAE  in bunionectomy and herniorrhaphy. The opioid sparing effect of Zynrelef in these two surgical models is considered as modest but clinically significant. Nevertheless,  further  evidence  of  efficacy  for  other  tested  models  are  lacking  and  cannot  be  also extrapolated. 2.6. Clinical safety The safety data included in the analysis are from 8 studies that evaluated the intended commercial formulation: one Phase 1, three Phase 2a, two Phase 2b and two Phase 3. In  the  Phase  3  studies,  HTX-011  was  evaluated  at  dose  levels  of  60  mg/1.8  mg  or  300  mg/9  mg administered by instillation into the surgical site. The focus of the integrated analysis of safety is on the pooled data from two Phase 3 studies (in bunionectomy or herniorrhaphy) and two Phase 2b studies (in TKA or mammoplasty), which only evaluated HTX-011, the intended commercial formulation. Because the intended administration technique for HTX-011 is instillation, only data for HTX-011 administered by instillation are included in the pooled dataset. Medicinal product no longer authorised

These were not pooled with those from the Phase 3 and Phase 2b studies because of the following reasons:

· They were exploratory formulation-, dose-, and administration technique-finding studies;

<div style=\"page-break-after: always\"></div>

- Safety assessment measures and timepoints were different from those in Phase 3 and Phase 2b studies;
- Small numbers of subjects were administered HTX-011 by instillation and at dose levels common to the Phase 3 and Phase 2b studies.

<!-- image -->

|         | no      |         |
|---------|---------|---------|
| product | product | product |

Overall, studies were conducted in 5 unique surgical procedures (2 different bony models and 3 different soft tissue models) with different anatomic spaces, vascularities, and levels of pain in diverse patient populations, across various populations receiving, for the large majority of the, pain medication (opioids and non-opioids 'on demand' with specific dose regimen for each subject) and with 4 different doses of HTX-011  (ranging  from  60mg/1.8mg  (bupivacaine  meloxicam)  to  400mg/12mg).  Considering  these specificities, the proposed pooling approach is too limited and does not allow to assess precisely HTX011 safety profile. For safety concerns requiring a specific attention (i.e. local treatment adverse events (TEAEs),  LAST-related  TEAEs),  safety  data  detailed  in  each  individual  clinical  study  report  will  be presented. Patient exposure Exposure in Phase 2b and Phase 3 Studies The patient exposure in pooled clinical trials in Phase 2b and 3 studies is summarised in the Table below. Table 45: Treatment groups in pooled analysis of safety of HTX-011. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Exposure in Phase 1 and Phase 2a Studies

In the Phase 1 study, only the intended commercial formulation was evaluated. In Phase 2a studies, earlier formulations and/or formulations containing only bupivacaine and meloxicam were also evaluated. The results for these formulations and saline placebo used as a comparator for these formulations are not included in the analysis of safety of HTX-011.

<!-- image -->

In Phase 3 and 2b studies, the incidences of any TEAE were similar for total HTX-011, pooled saline placebo, and total bupivacaine HCl, and ranged from 81.4% to 84.1%. The majority of TEAEs were mild or moderate in severity. The incidence of severe TEAEs was low and similar for total HTX-011, pooled saline placebo, and total bupivacaine HCl and ranged from 2.4% to 3.2%. The incidence of severe TEAEs did not increase with increasing doses of HTX-011. The incidence of SAEs was low and similar for total

Maximum HTX-011 dose exposure A large number of subjects have been exposed to the proposed maximum recommended dose of 400 mg/12 mg: a total of 364 subjects undergoing various surgical procedures received the 400 mg/12 mg dose  in  clinical  studies,  including  202  subjects  who  received  this  dose  via  instillation  only  and  90 additional subjects who received this dose via a combination of instillation and injection. Demographic and disease characteristics · Phase 3 and Phase 2b Studies In Phase 3 and 2b studies, the demographics and baseline characteristics were generally well balanced for saline placebo, total bupivacaine HCl, and total HTX-011. Approximately half of the subjects were males (ranging from 47.2% to 54.3%) and half females (ranging from 45.7% to 52.8%). The mean age of the subj ects ranged from 50.0 to 51.3 years. The proportion of subjects ≥65 years old was higher for total HTX-011 (19.0%) than for saline placebo (14.5%) and total bupivacaine HCl (12.8%). The race of the majority of the subjects was White. · Phase 1 and Phase 2a Studies The demographic and baseline characteristics were generally similar between HTX-011, bupivacaine HCl and placebo groups in each study. Some differences between the pooled characteristics for HTX-011 groups and specific surgery could be noted: -in study 211, the mean age was low (32 years old) compared to mean age in all HTX-011 groups (32 vs. 46.9 years old) as well as BMI (24 vs. 27.65 kg/m 2 ); -in 209 and 208 (HTX-011 120mg/3.6mg arm) the mean BMI is higher compared to mean BMI in all HTX-011 groups (respectively &gt;31 and &gt;30 kg/m 2  (obesity)); -in study 208 (HTX-011 60mg/1.8mg arm) the mean BMI of HTX-011 group is lower than bupivacaine and placebo groups (respectively 27.6 vs 31.75 and 30.26 kg/m 2 ); -in the HTX-011 groups, in study 203 female and in study 202 male were predominantly enrolled (99%). Adverse events Overview of adverse events Phase 3 and Phase 2b Studies Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

HTX-011,  pooled  saline  placebo,  and  total  bupivacaine  HCl,  and  ranged  from  1.8%  to  2.2%.  The incidence was slightly higher for HTX-011 400 mg/12 mg (3.7%) and bupivacaine HCl 125 mg (4.6%) compared with  pooled  saline  placebo  (2.0%)  and  other  dose  levels  of  HTX-011  or  bupivacaine  HCl (ranging from 0% to 1.9%).

<!-- image -->

Phase 1 and Phase 2a Studies In study 202, for HTX-011 (all doses and administration techniques pooled), the incidence of any TEAE was 73.3% (96 of 131 subjects). Incidences were 65.9% (56 of 85 subjects) for saline placebo and 65.5% (21 of 32 subjects) for bupivacaine HCl 75 mg. The incidence of TEAEs did not increase with increasing doses of HTX-011. The majority of TEAEs were mild or moderate in severity. The incidence of SAEs was lower for HTX-011 (all doses and administration techniques pooled) compared with saline placebo or bupivacaine HCl 75 mg. There were no TEAEs that led to withdrawal from the study. Among subjects administered HTX-011 300 mg/9 mg, 50.0% (8 of 16 subjects) experienced a study drugrelated TEAE. Incidences of study drug-related TEAEs for saline placebo and bupivacaine HCl 75 mg were 28.2% (24 of 85 subjects) and 28.1% (9 of 32 subjects), respectively. In  Study  203  ( complete  abdominoplasty ),  HTX-011  was  administered  as  follows:  300  mg/9  mg  by combination; or 400 mg/12 mg by instillation or combination. The results presented in this section for HTX-011 400 mg/12 mg are pooled across administration techniques. Incidences of any TEAE were similar for HTX-011 (all doses and administration techniques pooled) (89.6%; 69 of 77 subjects), saline placebo (87.5%; 28 of 32 subjects), and bupivacaine HCl 100 mg (88.2%; 15 of 17 subjects). It did not increase with increasing doses of HTX-011. The majority of TEAEs were mild or moderate in severity. Two subjects experienced an SAE: 1 of 17 (5.9%) administered bupivacaine HCl 100 mg and 1 of 35 (2.9%) administered HTX-011 300 mg/9 mg. There were no TEAEs that led to withdrawal from the study. In Study 208, HTX-011 was administered as follows: 30 mg/0.9 mg by injection using a Mayo block; 60 mg/1.8 mg by injection, injection using a Mayo block, or instillation with a Luer lock applicator; 120 mg/3.6  mg  by  injection,  injection  using  a  Mayo  block,  instillation,  or  instillation  with  a  Luer  lock applicator; or 200 mg/6 mg by injection or injection using a Mayo block. The results presented are pooled across administration techniques for each dose level (except for HTX-011 30 mg/0.9 mg). The incidence of any TEAE for HTX-011 (all doses and administration techniques pooled) (72.4%; 126 of 174 subjects) was similar to that for saline placebo (73.1%; 76 of 104 subjects) and lower than that for bupivacaine HCl 50 mg (80.0%; 20 of 25 subjects). Incidences of TEAEs did not increase with increasing doses of HTX-011.  The  majority  of  TEAEs  were  mild  or  moderate  in  severity.  One  of  30  (3.3%)  subjects administered HTX-011 200 mg/6 mg experienced an SAE. One of 104 (1.0%) subjects administered saline placebo experienced a TEAE that led to withdrawal from the study. The incidence of any TEAE was lower for HTX-011 60 mg/1.8 mg (63.5%; 33 of 52 subjects) compared with saline placebo (73.1%; 76 of 104 subjects) and bupivacaine HCl 50 mg (80.0%; 20 of 25 subjects). Similarly, the incidence of study drug-related TEAEs was also lower for HTX-011 60 mg/1.8 mg (19.2%; 10 of 52 subjects) compared with saline placebo (24.0%; 25 of 104 subjects) and bupivacaine HCl 50 mg (28.0%; 7 of 25 subjects). In Study 102 in healthy volunteers, subjects were administered HTX-011 400 mg/12 mg SC divided into 16 total injections. All subjects experienced at least 1 TEAE and at least 1 study drug-related TEAE. All TEAEs were mild or moderate in severity. There were no SAEs. Medicinal product no longer authorised

In a general way, the incidence and severity of TEAEs and the incidence of SAEs reported across placebo, bupivacaine HCl and HTX-011 groups is quite similar, except for local TEAEs. In study 301, the incidence of local inflammatory TEAEs is higher was HTX-011 60mg/1.8mg than placebo and 50mg bupivacaine

<div style=\"page-break-after: always\"></div>

HCl groups (respectively 28.7%, 19.8% and 22.1%). The incidence of local TEAEs seems not increase with increasing doses of HTX-011.

## Most common adverse events

<!-- image -->

<!-- image -->

Overview of most reported adverse events Phase 3 and Phase 2b Studies The TEAEs by PT with an incidence of ≥5% for pooled saline placebo or any dose l evel of HTX-011 or bupivacaine HCl in the Phase 3 and Phase 2b studies are presented in Table 41 and Table 42. For HTX-011 200 mg/6 mg, the number of subjects was small, which limits interpretation of the results for this dose. Table 46: Incidence of the Most Common TEAEs by Preferred Term in Phase 3 and Phase 2b Studies Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Table 47: Incidence of the most common TEAEs in studies 209 and 211. Overview of most reported adverse events Phase 2a and Phase 1 studies In Study 202, the TEAEs with an incidence of &gt;10% (more than 8 subjects) for HTX-011 400 mg/12 mg were  nausea  (27.7%;  23  of  83  subjects),  constipation  (24.1%;  20  of  83  subjects),  and  headache (20.5%; 17 of 82 subjects). These were also the most common TEAEs for saline placebo and bupivacaine HCl 75 mg. Their incidence did not increase with increasing doses of HTX-011. For HTX-011 300 mg/9 mg, constipation was the most common TEAE with the incidence of 37.5% (6 of 16 subjects). Nausea and headache were observed in 1 of 16 subjects (6.3%) administered HTX-011 300 mg/9 mg. Medicinal product no longer authorised

| no   |
|------|

In Study 203 ( complete abdominoplasty ), t he TEAEs observed in ≥5 subjects for HTX -011 400 mg/12 mg were nausea (61.9%; 26 of 42 subjects), constipation (28.6%; 12 of 42 subject), headache (19.0%; 8 of 42 subjects), pruritus (14.3%; 6 of 42 subjects), and tachycardia (11.9%; 5 of 42 subjects). Of these TEAEs, for saline placebo and bupivacaine HCl 100 mg, nausea, constipation, headache, pruritus,

<div style=\"page-break-after: always\"></div>

and tachycardia (bupivacaine HCl 100 mg only) were among the most common TEAEs. There was no apparent dose-response in incidences of these TEAEs. Incidences of headache and pruritus were lower HTX-011 400 mg/12 mg compared with those for saline placebo. For bupivacaine HCl 100 mg, the incidence of nausea was higher than those for HTX-011 400 mg/12 mg and incidences of tachycardia and pruritus were similar to those for HTX-011 400 mg/12 mg.

In Phase 3 Studies 301 and 302 and Phase 2b Studies 209 and 211, symptoms that may be attributed to LAST were reviewed by searching the clinical database for PTs prespecified by the Sponsor based on the published literature (Vasques 2015). These selected PTs are: 'Arrhythmia'; 'Bradycardia'; 'Cardiac arrest';  'Dizziness';  'Dysgeusia';  'Hypotension';  'Muscle  twitching';  'Paraesthesia';  'Paraesthesia oral'; 'Respiratory arrest'; 'Seizure'; 'Tinnitus'; 'Tremor'; 'Vision blurred'; 'Visual impairment'.

In Study 208 , the TEAEs observed in ≥5 subjects for HTX -011 60 mg/1.8 mg were nausea (30.8%; 16 of 52 subjects), vomiting (15.4%; 8 of 52 subjects), and headache (9.6%; 5 of 52 subjects). These were also common TEAEs for saline placebo and bupivacaine HCl 50 mg with incidences higher than those for HTX-011 60 mg/1.8 mg. With the exception of headache, the incidence of these TEAEs did not increase with increasing doses of HTX-011. In  Study  102  in  healthy  volunteers,  the  most frequent TEAEs (with an incidence ≥30%; 3 or more subjects) following SC administration of HTX-011 400 mg/12 mg were injection site bruising (80.0%; 8 of 10 subjects), injection site pain (60.0%; 6 of 10 subjects), injection site warmth (50.0%; 5 of 10 subjects),  injection  site  erythema  (40.0%;  4  of  10  subjects),  injection  site  nodule  (40.0%;  4  of  10 subjects), and injection site swelling (30.0%; 3 of 10 subjects). These TEAEs were attributed to SC route of administration of HTX-011; HTX-011 in this study was administered by 16 SC injections. In general, no dose-dependent incidence in TEAEs onset was identified across the phase 3 and 2 studies, TEAEs onset seems to be specific to each dose and surgery. In Phase 3 and 2b studies, the most TEAEs reported in HTX-011 groups (more than 5% of all subjects receiving HTX-011) and with an slightly higher incidence than placebo are: constipation (17.3% in HTX-011 vs. 14.6% in placebo group), vomiting (16.9%  vs.  15%),  headache  (11.7%  vs.  8.9%),  tachycardia  (6.5%  vs.  5.3%),  bradycardia  (6.0% vs.4.9%). This trend was also identified in Phase 2 studies, and subject local TEAEs were mostly reported in Phase 1 study in subject receiving HTX-011 in subcutaneous. Opioid-Related Adverse Events (ORAEs) For Phase 3, Phase 2b and Phase 2a Studies, ORAEs were pre-specified by the Sponsor as TEAEs that coded to  any  of  the  following  PTs,  regardless  of  whether  subjects  took  opioid  medication: Nausea; Vomiting;  Pruritus;  Pruritus  generalized  (only  for  phase  3  and  2b  studies);  Respiratory  depression; Urinary  retention;  Constipation and Somnolence .  Of  note,  in  Study  209  in  TKA  and  Study  211  in mammoplasty, only opioid rescue medication was available. In general, subjects receiving HTX-011 in Phase 3 studies experienced less OREAs than placebo groups and bupivacaine HCl groups. This is consistent with the proportion of opioids-free subjects in these 2 studies (28.7% in 301 study and 51.5% in 302 study). 'Nausea', 'vomiting' and 'constipation' are less or similarly reported in these studies in HTX groups than placebo and bupivacaine HCl groups. Local Anesthetic Systemic Toxicity (LAST) · Potential LAST-related TEAEs Medicinal product no longer authorised

In studies 301 and 302, dizziness, bradycardia, hypotension, dysguesia, muscle twitching, were reported as more frequent in HTX-011 groups compared to the placebo group, but with a similar frequency than

<div style=\"page-break-after: always\"></div>

the bupivacaine HCl control groups. The frequency of most of potential LAST-related TEAEs is, in most of cases, similar or higher in the HTX-011 low dose group (60mg/1.8mg) compared to the HTX-011 high dose groups (300mg/9mg and 400mg/12mg). Compared to the respective incidence of LAST-related AEs in the placebo groups for each study, no specific trend to an over-represented of these AEs with the 60mg/1.8mg HTX-011 dose is identified.

Taken individually, some of LAST-AEs are identified more frequently in HTX-011 groups than placebo and with a similar or higher frequency than bupivacaine groups (namely 'hypotension', 'bradycardia' and  'tinnitus'  in  study  209  cohort  2;  'hypotension'  in  study  211;  'dizziness',  'bradycardia', 'hypotension'  in  study  301;  'bradycardia',  'dysgeusia',  'paresthesia'/'paresthesia  oral',  'sinus arrhythmia', 'vision blurred', in study 302). As mentioned by Vasques, MD et al. 1  (2015), 'confusion, dizziness, tinnitus, dysgeusia, hallucinations, slurred speech, gait problems, limb twitching, extremity paresthesia, intention tremor, hypotonia, and facial sensorimotor and eye movement abnormalities [are minor central nervous system (CNS) abnormalities] and defined as prodromal manifestations of toxicity when they occurred either alone or before major signs of toxicity'. The authors identified these prodromal signs  as  the  most  frequent  CNS  manifestations  of  LAST.  Similarly,  they  identified  hypotension  and bradycardia as the most frequent signs of cardiovascular toxicity. In 209 study, the potential LAST-related TEAEs identified in cohort 1 and cohort 2 were consistent with those identified in bupivacaine HCl 125mg  and  placebo  groups (2 dizziness on  each  HTX011 120mg/3.6mg and 60mg/1.8mg (by instillation) groups). In  the  study  211,  hypotension  in  the  HTX-011 400mg/12mg  via  instillation  is  reported  with  a  high incidence compared to the placebo and bupivacaine HCl 50mg groups (12% for HTX-011 group, vs. 2.4% for placebo and HCl groups). The applicant considers the AEs of hypotension retrieved in study 211 as non-LAST-related AEs because the bupivacaine plasma concentrations for these 6 subjects prior to the onset of the hypotension TEAE ranged from 118 to 632 ng/mL. Regarding the choice of the applicant to use the threshold plasma concentration of bupivacaine of 2,000 ng/mL as unique criteria to characterize an AE as LAST or not, this approach is questionable. Indeed, regarding this threshold, G.T. Tucker 2 (1986) specifies that 'although these values are useful guidelines, they refer to the mythical \"average subject\" and must be interpreted in the light of a number of considerations (such as, total vs. free Concentrations; ionized vs. un-ionized)'. Hasselstrom, M.D. et al. 3  (1984) reported a relevant case of patient  experienced  convulsions  (serious  LAST  manifestation)  for  which  the  measured  plasma concentration of bupivacaine was considered to be nontoxic (1,100ng/mL). In Phase 2a Studies 202 and 203, the incidence of potential LAST-related TEAEs did not depend on the dose of HTX-011. Plasma concentrations of bupivacaine were not predictable of potential LAST-related TEAEs. The time of onset of potential LAST-related TEAEs did not correlate with maximal concentrations of bupivacaine. In  study  202,  'Dizziness'  and  'hypotension'  were  more  reported  in  HTX-011 300mg/9mg  and 400mg/12mg  groups  than  in  HTX-011 200/6mg.  'Muscle  twitching'  is  more  reported  in  HTX011 200mg/9mg and HTX-011 400mg/12mg than in placebo group (respectively 3.1% and 3.6% vs. 0%)  belong  to  possible  symptom  of  bupivacaine-related  CNS  toxicity  as  mentioned  in  the  current bupivacaine HCl SmPC. In 203 study, 5 subjects reported TEAEs potentially suggestive of LAST in the HTX-011  400mg/12mg  group  by  instillation: 2 subjects experienced 'dizziness', one subject Medicinal product no longer authorised

1  Vasques F, Behr AU, Weinberg G, Ori C,Di Gregorio G. A Review of Local Anesthetic Systemic Toxicity Cases Since Publication of the American Society of Regional Anesthesia Recommendations: To Whom It May Concern. Regional Anesthesia and Pain Medicine 2015; 40(6): 698-705.

2  Tucker GT. Pharmacokinetics of local anaesthetics. Br J Anaesth 1986; 58(7): 717-731.

3 Hasselstrøm  LJ,  Mogensen  T.  Toxic  reaction  of  bupivacaine  at  low  plasma  concentration.  Anesthesiology. 1984;61:99-100.

<div style=\"page-break-after: always\"></div>

'bradycardia', one subject 'paresthesia' and one subject 'tinnitus' (which belong to possible symptom of bupivacaine-related CNS toxicity).

<!-- image -->

· Local Anesthetic Systemic Toxicity Assessment Questionnaire In Studies 301 and 302, a LAST assessment questionnaire was included to standardize the assessment process  for  identifying  subjects  who  may  experience  signs  or  symptoms  of  LAST.  Subjects  were monitored  for  neurological  and  cardiac  signs  and  symptoms  potentially  associated  with  LAST  (e.g., metallic/strange taste, perioral tingling, ringing in ears, visual disturbance, tremors, muscle twitching, dizziness/lightheadedness,  convulsion/seizure,  bradycardia,  arrhythmia,  hypotension,  cardiac  arrest, respiratory arrest ). Subjects were assessed with this questionnaire to identify early stages of toxicity to determine whether treatment of potential LAST-related signs or symptoms should be initiated (Table 48). Signs or symptoms that might be attributed to LAST were to be recorded as AEs and additional safety assessments were to be performed (vital sign measurements, 12-lead ECG, and blood sample collection to measure bupivacaine plasma concentrations). If symptoms were present at a timepoint when 1 of these assessments was not scheduled, an unscheduled assessment was performed. Table 48: Summary of LAST assessment questionnaire results from studies 301 and 302 Some differences in the potential LAST related AEs between male and female population are identified, however the reported differences are not clinically relevant. Medicinal product no longer authorised

<!-- image -->

| no      |
|---------|
| product |

## · Plasma concentration

Bupivacaine  plasma  concentrations  above  2,000  and  4,000  ng/mL  have  been  associated  with neurological  and  CV  effects,  respectively  (Bardsley  1998;  Jorfeldt  1968;  Kastrissios  1993;  Knudsen

<div style=\"page-break-after: always\"></div>

1997;  Tucker  1986).  For  a  comprehensive  analysis,  potential  LAST-related  TEAEs  in  subjects administered HTX-011 were evaluated at concentrations of bupivacaine &gt;800, &gt;1,000, &gt;2,000, and &gt;4,000 ng/mL. Maximum plasma concentrations of bupivacaine following administration of HTX-011 in all subjects and in subjects with potential LAST-related TEAEs across Studies 301, 302, 209, and 211 are presented in Table 49.

<!-- image -->

<!-- image -->

| longer   |
|----------|

<!-- image -->

- -Assessment of signs and symptoms associated with abnormal wound healing.

Table 49: Maximum Concentrations of Bupivacaine Following Administration of HTX-011 and Potential LAST-Related TEAEs in Studies 301, 302, 211, and 209 Three severe dizziness cases were reported from studies 301 and 302; for these subjects, bupivacaine Cmax was reported &lt;500ng/mL. In study 211, one subject experienced tremor and dizziness (plasma concentration  of  bupivacaine  of  bupivacaine  Cmax  &gt;1,000ng/mL)  and  one  experienced  dysgueusie (bupivacaine Cmax &gt;1,000ng/mL). In study 209 study (cohort 2) ventricular tachycardia was reported in  a  subject  receiving  HTX-011  400  mg/12  mg  with  ropivacaine  50  mg  (bupivacaine  Cmax  &gt;2,000 ng/mL), 2 subjects reported diziness (Cmax &lt;1,000ng/mL) and 1 reported bradycardia (bupivacaine Cmax &lt;500ng/mL). In cohort 1, one subject experienced 3 moderate to mild dizziness episodes during 3 days (bupivacaine Cmax=500ng/mL). In study 202 one experienced a potential LAST-related TEAE of dizziness resolved within 5 minutes (Cmax bupivacaine &gt;1000ng/mL). Surgical Wound Healing Assessments Analysis of surgical wound healing in Phase 3 Studies 301 and 302 and Phase 2b Studies 209 and 211 included the following: -Assessment of local inflammatory TEAEs, Medicinal product no longer authorised

In  Phase  2a  Studies  202,  203,  and  208,  surgical  wound  healing  was  assessed  based  on  local inflammatory TEAEs.

<div style=\"page-break-after: always\"></div>

Surgical  wound healing in Studies 302, 209, and 211 was assessed using the Southampton Wound Scoring System. In Study 301, surgical wound healing was assessed based on the presence or absence of the signs and symptoms prespecified by the FDA.

In studies 302, 209 and 211 bruising and erythema were mostly reported. In Study 209 (cohort 1) other sign of inflammation along or around the wound and clear or haemoserous discharge were more reported than other groups, all resolved with a similar frequency than placebo group at day 28. In study 202, all local inflammatory TEAEs, except erythema, were more reported in HTX-011 groups compared to bupivacaine HCl and placebo groups. In  study  203,  in  complete-abdominoplasty,  local  inflammatory  TEAEs  are  similarly  reported  in  HTX011 400mg/12mg via instillation  and  placebo  group  and  less  reported  than  bupivacaine  HCl  100mg group. In study 301, HTX-011 groups are more associated with delayed healing, wound dehiscence, incision site oedema, incision site infection and cellulitis compared to bupivacaine HCl 50mg and placebo groups. Delayed healing remains twice more reported after 42 days in HTX-group. Surgical wound healing was not been graded according to Southampton Wound Scoring System, therefore more accuracy assessment of the wound healing in study 301 is not allowed. The applicant justified the over-representation of local inflammatory AEs in HTX-011 60 mg/1.8 mg HTX-011 group compared to the highest dose of HTX-011 doses by the space limits of wound in bunionectomy. The applicant stated that ' the  lack  of  a  dose response confirms that HTX-011 has a safety profile comparable to saline placebo and bupivacaine HCl ', which is doubtful. In addition, the applicant provided new outcomes regarding bunionectomy through the study 218 (A Phase 2 Open-Label Study of HTX-011 via Individualized Dosing Administration for Postoperative Analgesia Following Unilateral Simple Bunionectomy) specifically designed to assessed the efficacy  and  safety  with  an  individualized  dose  for  each  subject,  precisely  because  in  bunionectomy studies (208 and 301) surgeons noted that amount of HTX-011 drug product was expressed from the surgical site at closure in some subjects and might have resulted in less successful wound closure and/or local inflammatory reactions at the incision site. The mean volume of HTX-011 administered in the 3 studied cohort was 1.62 mL, 1.29 mL, and 1.97 mL (which respectively correspond to 77%, 61% and 94% of the maximum volume recommended in the proposed section 4.2 of Zynrelef SmPC). At any timepoint the number of patients presented 'any abnormal result' corresponds to the expected results following a reduction of the volume administrated, namely a decrease of wound healing events depending on the administrated volume. Indeed, the groups '2.1mL' and '1.97mL' shown similar results and the highest wound healing events (respectively 80.9% and 93.9%), and groups '1.62mL' and '1.29' shown the lowest incidence (respectively 70% and 64.7%). On the contrary, in the specific complications such as 'delayed healing' and 'dehiscence' this trend is not observed and the incidence of these events is more reported in the lowest HTX-011 volume (1.29mL) group following by the '1.97' group and then the 2.1mL group for which the volume appears to be an issue to ensure an optimal wound healing. The administration of HTX-011, regardless of the administrated volume, seems to be a source of complexity for this specific surgery with a restrictive available space. Wound dehiscence and impaired healing were mainly mild in severity, and except one patient with impaired healing, all were resolved without sequalae. The incidence of dehiscence, delayed and impaired healing seems to be correlated with the administration of HTX-011 in bunionectomy. Medicinal product no longer authorised

Regarding  the  seriousness  of  wound  healing  complications  (including  major  complications  such  as infection) graded according to the Southampton Wound Scoring System for the studies 209, 211 and 302. The results of wound healing assessment shown no major complications (grade IV (i.e. pus) and grade V (i.e. deep or severe wound infection with or without tissue breakdown; haematoma requiring aspiration)) in these studies: only 3 AEs related to wound infection were retrieved in HTX-011 groups with a frequency higher or slightly higher compared to placebo: 'incision site cellulitis' (study 209-cohort

<div style=\"page-break-after: always\"></div>

1, 1 AE in HTX-011 200/6mg combination group (4.5%) vs 0% in placebo and bupivacaine groups; study 209-cohort 2, 1 AE in HTX-011+ropivacaine group (1.8%) vs 0% in placebo and bupivacaine groups); 'post procedural cellulitis' (study 209 cohort 2, 1 AE in HTX-011+ropivacaine group (1.8%) vs 0% in placebo and bupivacaine groups).

No wound healing assessment according to the Southampton Wound Scoring System was provided for the study 301 (symptoms associated with abnormal wound healing were evaluated based on the signs and symptoms prespecified by the FDA in this study), whereas the number of wound infections is more reported in this study in HTX-011 groups versus placebo and bupivacaine HCl groups: 'incision site cellulitis'  (7  AEs  in  HTX  60mg/1.8mg  (4.5%)  vs  1  AE  (1%)  in  placebo  group  and  2  AEs  (1.3%)  in bupivacaine group) ; 'incision  site  infection'  (4  AEs  in  HTX  60mg/1.8mg  (2.5%)  vs  1  AE  (0.6%)  in bupivacaine group and 0% in placebo group). In 208 study, the overall local inflammatory TEAEs is more reported in HTX-011 groups than bupivacaine HCl 50mg and placebo groups, especially in HTX-011 120mg/3.6mg group. Individually, except blister, all  identified  PTs  were  more  reported  in  HTX-011  groups  compared to  bupivacaine  HCl  and  placebo groups, and erythema is five times and almost two times more reported in HTX-011 120mg/3.6mg group than, respectively, placebo and bupivacaine HCl 50mg. The applicant stated that 'small amounts of HTX011 drug product were expressed from the surgical site at closure in some subjects potentially impacting the quality of the suturing and causing irritation' and 'the surgical site may have been under increased pressure with postoperative swelling and the application of a pressure bandage after surgery. This could result in an increase in local inflammatory TEAEs, including delayed healing and dehiscence'. Thus, a large volume administrated into the wound can lead to (1) wound complication and compromise healing and/or (2) conduct to completely cover the wound with pressure bandage leading to a risk of infection. In  section  4.2,  examples  (and  no  recommendation)  of  volume  to  administer  are  proposed  by  the applicant for the four surgeries evaluated across Phase 3 and 2b studies; in bunionectomy the dose of 60mg/1.8mg (up to 2.1mL) was given as an example, but surgeons can administer a larger volume. Moreover generally, the sufficient and adequate volume to administer in the surgical site was defined only for 4 surgical procedures, including bunionectomy for which the 120mg/3.6mg was not selected to serve as example of dose to use for this specific surgery. The choice, by surgeons, of the adequate volume to administer to ensure a good wound closure without expressing excess of HTX-011 from the surgical site and with no healing complication in post-surgical period remain difficult to extrapolate for all surgeries as claimed by the applicant (especially those with similar constraints as bunionectomy in terms  of  amount  of  space  available  for  the  product  instillation).  Moreover,  the  selected  populations enrolled in 301, 302 and 209 studies present less risk factors (mainly diabetes) of wound complication in HTX-011 groups than placebo group, this risk could be under-estimated. Study Drug-Related Adverse Events Investigators assessed AEs as possibly related or unlikely related to study drug. Related TEAEs were defined as TEAEs considered possibly related to study drug. The incidence of related TEAEs was higher in the HTX-011 group compared with saline placebo and bupivacaine HCl (25.2% vs 18.3% and 17.9%, respectively). With the exception of skin odour abnormal and dysgeusia, the incidences of related TEAE PTs were similar across treatment groups. A higher incidence of skin odour abnormal (verbatim term of 'body odor') related to study drug was noted in the HTX-011 group compared with the saline placebo and Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) bupivacaine HCl groups (7.4% vs 1.2% and 0.6%, respectively; all reported at 1 site). The incidence of dysgeusia was also higher in the HTX-011 group compared with saline placebo (7.4% vs 2.4%) but was similar to bupivacaine HCl (8.1%). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Phase 3 and Phase 2b Studies

<!-- image -->

In Phase 3 and 2b, the incidence of SAEs was low and similar for total HTX-011, pooled saline placebo, and total bupivacaine HCl, and ranged from 1.8% to 2.2%. The incidence was slightly higher for HTX011 400 mg/12 mg (3.7%) and bupivacaine HCl 125 mg (4.6%) (compared with pooled saline placebo (2.0%) and other dose levels of HTX-011 or bupivacaine HCl (ranging from 0% to 1.9%)). There were a total of 30 SAEs: 14 SAEs in 11 subjects (2.2%) administered HTX-011, 8 SAEs in 7 subjects (1.8%) administered bupivacaine HCl, and 8 SAEs in 5 subjects (2.0%) administered saline placebo. Serious TEAEs are similarly reported between HTX-011, bupivacaine and placebo groups across Phase 3 and 2b studies. Fourteen serious TEAEs were reported, including 3 not related to study drug, 2 of them reported  alternative  explanations  (breast  implant  perforated  during  the  surgery;  thoracic  vertebral fracture after fall at home) or with a reasonable incompatible chronology (diagnosis of bile duct and intestinal  perforation  few  hours  after  receiving  HTX-011).  Two  subjects  experienced  serious  post procedural complication (Incision site haematoma, resolved after 1 day and cellulitis, resolved after 10 days). Phase 2a studies In phase 2a studies, there were a total of 8 SAEs in 8 subjects: 4 SAEs in 4 subjects administered HTX011, 2 SAEs in 2 subjects administered bupivacaine HCl, and 2 SAEs in 2 subjects administered saline placebo. No SAEs occurred in subjects who were administered study drug by instillation only. Death There was 1 death across the entire clinical program, in a subject who had received bupivacaine HCl in Study 301. The cause is unknown, but the death was considered by the Investigator not related to study drug. Laboratory findings Hematology Parameters in Phase 3 and Phase 2b studies Hematology parameters presented in this section were selected based on the proportions of subjects with shifts in values from normal at Baseline to low post-Baseline or from normal at Baseline to high post-Baseline. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## · Shifts from normal at baseline to low post-baseline in hematology parameters

In Phase 3 and 2b studies, the incidences of shifts from normal at Baseline to low at any time postBaseline for RBC count, Hct, Hgb, lymphocyte differential, and lymphocyte count were higher for HTX011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg compared with other treatment groups. HTX-011 200 mg/6 mg and 400 mg/12 mg and bupivacaine HCl 125 mg were used in TKA in Study 209 and HTX-011 400 mg/12 mg was used in mammoplasty in Study 211. However, these changes were driven by TKA; the changes in mammoplasty were similar to those for pooled analysis.

A similar trend was observed for pooled saline placebo. For WBCs, this finding is consistent with a higher incidence of leukocytosis for HTX 400 mg/12 mg compared with pooled saline placebo (6.7% compared with 0.8%). A TEAE of neutrophilia was reported for 1 subject administered HTX-011 400 mg/12 mg. The overall incidence of infections and infestations was similar in all treatment groups. No TEAEs of incision site infection or postoperative wound infection were reported in subjects administered HTX-011 400 mg/12 mg or 200 mg/6 mg or bupivacaine HCl 125 mg. Shifts from normal at Baseline to high postBaseline for HTX-011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg for platelet counts were observed at Day 10 only. A similar trend was observed for pooled saline placebo. There were no

In Study 209, there were no clinically meaningful differences between treatment groups in shifts from normal at Baseline to low post-Baseline in hematology parameters. Incidence of shifts from normal at Baseline to low at post-Baseline for RBC count, Hct, and Hgb for HTX-011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg increased at 72 hours compared with 24 hours and then decreased at Day 10. A similar trend was observed for pooled saline placebo. TKA is associated with a greater blood loss compared with mammoplasty, bunionectomy and herniorrhaphy. Thus, the observed shifts for RBC count, Hct, and Hgb are consistent with those expected after TKA. However, no clinically meaningful differences in incidences of TEAEs of anaemia postoperative, anaemia, red blood cell count decreased, haematocrit  decreased,  and  haemoglobin  decreased  between  treatment  groups  were  observed.  The incidences  of  shifts  from  normal  at  Baseline  to  low  at  post-Baseline  for  lymphocyte  differential  and lymphocyte count for HTX-011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg were the highest at 24 hours and decreased at 72 hours and Day 10. · Shifts from normal at baseline to high post-baseline in hematology parameters The incidences of shifts from normal at Baseline to high at any time post-Baseline for WBCs, neutrophil count, neutrophil differential, and platelet count (on Day 10 only) were higher for HTX-011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg compared with other treatment groups. HTX-011 200 mg/6 mg and 400 mg/12 mg and bupivacaine HCl 125 mg were used in TKA in Study 209 and HTX011 400 mg/12 mg was used in mammoplasty in Study 211. In Studies 209 and 211, there were no clinically  meaningful differences between treatment groups in shifts from normal at Baseline to high post-Baseline in hematology parameters. Incidences of shifts from normal at Baseline to high post-Baseline for WBCs, neutrophil differential, and neutrophil count for HTX-011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg were generally the highest at 24 hours and then decreased at 72 hours and Day 10. The applicant has provided discussion on reported shifts from baseline to high at 24h, 72 h and 10 days timepoints WBC count, neutrophil  differential  and  neutrophil  counts  in  HTX-011  group  compared  to  placebo.  The  applicant argued that, from the one hand these findings are likely related to surgery type, and from the other hand no clinically meaningful related adverse effects were observed (such as infections or infestations). In light of this, it was concluded that these findings do not change the risk/benefit profile for IMP. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

TEAEs  of deep  vein thrombosis, deep  vein thrombosis postoperative, venous  thrombosis, or thrombophlebitis for HTX-011 400 mg/12 mg or 200 mg/6 mg or bupivacaine HCl 125 mg. Incidences of a TEAE of thrombocytosis were similar for all treatment groups.

In Study 209 in TKA in Cohort 2, two subjects administered HTX-011 400 mg/12 mg and 1 subject administered bupivacaine HCl 125 mg experienced TEAEs of pulmonary embolism; they were reported as SAEs. None of these 3 subjects had an elevated platelet count on or near the day of the onset of SAEs; 1 subject administered HTX-011 400 mg/12 mg had a low platelet count (141 × 109/L) at the onset of the pulmonary embolism on Day 3. All 3 SAEs were considered by the Investigator unlikely related to study drug and all resolved. Hematology Parameters in Phase 1 and Phase 2a Studies In Phase 2a Studies (202, 203 and 208), no clinically meaningful changes in mean absolute values or mean changes from Baseline for any hematology parameter were observed. There were no clinically meaningful differences between treatment groups in the proportion of subjects with a shift from Baseline in hematology parameters. In Study 102, no clinically meaningful changes in hematology parameters or shifts from Baseline were observed. Clinical Chemistry Parameters There were no clinically meaningful differences between treatment groups with respect to either mean changes from Baseline in hematology and clinical chemistry parameters, individual subject shifts from Baseline, or associated TEAEs. Observed differences across treatment groups appeared to reflect the different surgical settings (and study populations) in which specific doses were used, rather than being directly related to the dose of HTX-011 or bupivacaine HCl. The  incidence  of  prespecified  liver  function  test  abnormalities  was  similar  across  the  HTX-011, bupivacaine HCl, and saline placebo treatment groups, and no subject met the criteria for Hy's Law. Vital Signs, Physical Findings, and Other Observations Related to Safety In  the  pooled  Phase  3  and  Phase  2b  safety  dataset,  there  were  no  clinically  meaningful  differences between  treatment  groups  with  respect  to  either  mean  changes  from  baseline  in  vital  signs,  the incidences  of  prespecified  clinically  relevant  vital  sign  abnormalities,  or  the  incidences  of  associated TEAEs. To evaluate the effect of HTX-011 on the QTcF interval, multiple regression analyses were performed to evaluate the relationship between derived QTcF interval and plasma concentrations of bupivacaine HCl and meloxicam in Studies 209, 211, 301, and 302. There were no consistent or clinically meaningful differences in ECGs between treatment groups. HTX011  did  not  affect  QTcF  interval,  HR,  PR  interval,  and  QRS  interval  based  on  concentration-effect modeling (Section 3.4.2), central tendency analysis, or outlier categorical frequencies. In Study 209, administration of another local anesthetic, ropivacaine 50 mg, with HTX-011 400 mg/12 mg had no effect on ECG intervals, did not prolong the QTcF interval, nor produce any other adverse ECG effects when compared with HTX-011 400 mg/12 mg administered without ropivacaine. Medicinal product no longer authorised

The applicant report no meaningful ECG findings (heart rate, PR, RR, QRS and change from baseline in QT intervals) between treatment groups in pivotal and supportive studies.

## Bone Healing Assessments

<div style=\"page-break-after: always\"></div>

Bone healing was assessed in Study 301 and Study 208 in bunionectomy.

In study 301, X-rays of the surgical site were performed at the Day 28 and Day 42 Visits to assess bone healing. Bone healing symptoms were recorded as normal, mal-union, or delayed healing. The majority of subjects had normal bone healing on Day 28 (99.0%) and on Day 42 (98.5%).

For the ≥65 years subgroup, the incidence of any potential LAST -related TEAE was highest for the pooled saline placebo group (41.7%) as compared to the total bupivacaine HCl group (36.0%) and total HTX011 group (26.0%) and higher than any HTX-011 dose group (20.0% to 37.5%). The number of subjects with any potential LASTrelated TEAE for the ≥65 years age group was low, with the highest incidence for the bupivacaine HCl 75 mg group (6 of 11, 54.5%) from the herniorrhaphy study.

Mal-union was reported for 3 subjects administered HTX-011 60 mg/1.8 mg; none was reported for subjects  administered  saline  placebo  or  bupivacaine  HCl  50  mg.  Of  the  3  mal-unions  in  subjects administered HTX-011, 2 were reported as TEAEs. Both TEAEs resolved and were considered by the Investigator unlikely related to study drug. Delayed  bone  healing  was  reported  for  4  subjects:  1  administered  saline  placebo,  2  administered bupivacaine HCl 50 mg, and 1 administered HTX-011 60 mg/1.8 mg. Three of the 4 TEAEs, including the TEAE in 1 subject administered HTX-011 60 mg/1.8 mg, were considered by the Investigator unlikely related to study drug and resolved. In Study 208, bone healing was assessed within 4 to 6 weeks following the surgery by X-ray and was evaluated as normal or improper. One subject administered HTX-011 120 mg/3.6 mg had improper bone healing on Day 29. It was reported as mal-union due to non-compliance with postoperative therapy ('premature unprotected weight bearing with rapid return to work'). The abnormal bone healing was considered by the Investigator not related to study drug). No specific safety issue emerged from the reported cases of bone healing impairment in phase 2b and 3 studies in bunionectomy. One improper bone healing (in study 208) and 3 bone mal-union (in study 301) were in HTX-011 groups; all reported noncompliance with postoperative therapy (i.e. premature weight bearing, rapid return to work or activities with no adequate protections) or following an accident. Safety in special populations Effect of age In general, the incidences for any TEAE, any TEAE possibly related to study drug, any SAE, any ORAE, any local inflammatory TEAE, or any potential LAST-related TEAE for the &lt;65 years subgroup were similar to the total population including both age groups for the pooled saline placebo, total bupivacaine HCl, and total HTX-011 groups. The incidences of any TEAE, any SAE, and any ORAE by age subgroup (≥65 years and &lt;65 years) were similar for the total HTX-011 and pooled saline placebo groups. Although similar, the incidences of SAEs were slightly hig her for the ≥65 years age group compared to the &lt;65 years age group for the total HTX-011 (5.2% vs 1.5%) and pooled saline placebo groups (5.6% vs 1.4%). The number of subjects with local inflammatory TEAEs for the ≥65 years age group was low with the highest incidence for the HTX-011 60 mg/1.8 mg group (8 of 24, 33.3%) from the bunionectomy study. Medicinal product no longer authorised

## Effect of Sex

<div style=\"page-break-after: always\"></div>

In general, the incidences for any TEAE for the female subgroup and the male subgroup were similar across the pooled saline placebo, total bupivacaine HCl, and total HTX-011 groups as compared to the total population that included both sexes.

The proportions of subjects in the total HTX-011, pooled saline placebo, and total bupivacaine HCl groups with any TEAE, any ORAE or any local inflammatory TEAE was slightly higher for females compared with males. The incidences of potential LAST-related TEAEs were not consistent and were higher for females for the total HTX-011 group, higher for males for the total bupivacaine HCl group, and similar between females and males for the pooled saline placebo group. The incidence of SAEs was low and similar for females and males across treatment groups. Effect of Race In general, the incidences for any TEAE, any ORAE, any local inflammatory TEAE, and any potential LAST-related  TEAE  for  the  White  subgroup  were  similar  across  the  pooled  saline  placebo,  total bupivacaine HCl, and total HTX-011 groups and for each treatment group by dose as compared to the total population including all races. Safety related to drug-drug interactions and other interactions No drug-drug interaction studies were conducted with HTX-011. The section 4.5 of the Zynrelef SmPC is based on the approved SmPC of each component of the combination. Discontinuation due to adverse events HTX-011  is  intended  for  a  single-dose  application,  therefore  the  large  majority  or  subject  (&gt;95%) completed the studies, and only 3 subjects 'withdrew' from one study (one in the low-dose arm and two in  the  higher-dose  arms)  due  to  safety  reasons.  In  view  of  the  pattern  of  HTX-011  administration (installation in the surgical site prior to closure, which define the Day 0 of the study), no true withdrawal is expected in HTX-011 studies. In the Phase 3 and Phase 2b studies, 3 subjects experienced a TEAE that led to withdrawal from the study  following  the  administration  of  HTX-011  (vs.  one  in  placebo  groups,  withdrew  due  to  an uncontrolled pain after undergoing a unilateral TKA (study 209)). The TEAEs in subjects administered HTX-011 that led to withdrawal from the study were as follows: · In Study 301, one subject administered HTX-011 60 mg/1.8 mg developed a bile duct stone after surgery. The event was serious, and the subject was withdrawn from the study on Day 2. The  subject  underwent  surgery  to  have  the  stone  removed  on  Day  4,  and  the  event  was considered resolved. The event was considered by the Investigator unlikely related to study drug and cited the subject's prior history of gallstones and a gastric ulcer as contributing factors. · In  Study  209,  one  subject  administered  HTX-011  400  mg/12  mg  with  ropivacaine  50  mg experienced an SAE of severe urinary retention on Day 1 that resulted in withdrawal from the study.  The  urinary  retention  resolved  approximately  3  months  after  the  onset  and  was considered by the Investigator unlikely related to study drug. Medicinal product no longer authorised

- In  Study  209,  one  subject  administered  HTX-011  400  mg/12  mg  with  ropivacaine  50  mg experienced an SAE of moderate pulmonary embolism on Day 3 that resulted in withdrawal from the study. The event resolved on Day 9 and was considered by the Investigator unlikely related to study drug.

<div style=\"page-break-after: always\"></div>

There were no TEAEs that led to 'withdrawal' in Phase 2a studies.

## Post marketing experience

HTX-011 is not marketed in any country. Bupivacaine and meloxicam, the active ingredients in HTX-011, are approved in Europe, the US, and other regions, and have a long history of clinical use. An extensive review of clinical literature on toxicities of bupivacaine and meloxicam was conducted by the applicant (searching period: from 1966 to 2018 for bupivacaine and from 1990 to 2018 for meloxicam). Literature Review for Bupivacaine The known toxicities of bupivacaine have been well documented in the literature and mainly consist of clinical neurotoxicity  involving  seizure  activity and  cardiovascular  toxicity  consisting  of  cardiac arrhythmias and cardiac arrest, which is often refractory to standard cardiopulmonary resuscitation but responsive to lipid emulsion therapy. This report found multiple reports of cardiotoxicity, neurotoxicity, chondrolysis, and case reports of dermatologic, allergic, and hepatic toxicities. In this literature review multiple less typical but previously documented adverse effects have been found. Many of these adverse effects are secondary to inadvertent administration of bupivacaine into unintended anatomic areas or spaces or idiosyncratic reactions in the cases of hepatic dysfunction or allergic type reactions. Literature Review for Meloxicam NSAIDs are known for multiple adverse effects, including GI bleeding, cardiovascular side effects, and NSAID-induced nephrotoxicity. Review of the clinical data found clinical reports of meloxicam-related hypertension, drug interactions, and drug intolerance/allergies. This review confirmed the known adverse effects of meloxicam as an NSAID. The majority of the data is supportive of the relative safety of meloxicam as compared to other NSAIDs for cardiovascular and GI adverse effects. The data for allergic reactions to NSAIDs is highly suggestive for a low risk of cross-reactivity in individuals who have a demonstrated reaction to aspirin or other NSAIDs. 2.6.1. Discussion on clinical safety From the safety database all the adverse reactions reported in clinical trials literature have been included in the Summary of Product Characteristics. During Phase 2 and 3 studies, 1067 subjects received a single dose of HTX-011-XX (all formulations and administration techniques). Among them, 504 received HTX-011 via installation in Phase 3 and 2b studies, more than 100 subjects in Phase 2a (considered as supportive) and 20 in Phase 1. The overall number of subjects enrolled in HTX-011 studies is considered sufficient for HTX-011 safety evaluation. Demographic characteristics of the safety population included age, gender, race, ethnicity and BMI. In general, the demographic and baseline characteristics are similar between respective HTX-011, bupivacaine HCl and placebo groups in each study. No subject under 18 years-old and 136 subjects older than 65 years were enrolled in HTX-011 development program. Medicinal product no longer authorised

The population targeted by Zynrelef in the indication claimed by the applicant is broad. In consequence, demographic and baseline characteristics are variable according to the type of surgery (mammoplasty, bunionectomy, TKA and herniorrhaphy). Populations enrolled in each study seem to be representative of each type of surgery. Non-homogeneity in subjects' history have been noted (in 302 study and cohort 1 of 209 study, subjects receiving HTX-011 reported respectively less history of cardiac and cardiovascular disorders than placebo and/or bupivacaine HCl groups; diabetes is less reported in HTX-011 groups than

<div style=\"page-break-after: always\"></div>

bupivacaine HCl and placebo groups in studies 301, 302 and in study 209 cohort 1) and may an impact on under-estimation of cardiovascular events and wound healing.

In general, the incidence and severity of TEAEs and the incidence of SAEs reported across placebo, bupivacaine HCl and HTX-011 groups is quite similar, except for local TEAEs and LAST-related TEAEs.

TEAEs onset seems to be specific to each dose and surgery. In Phase 3 and 2b studies, the most TEAEs reported in HTX-011 groups (more than 5% of all subjects receiving HTX-011) and with an slightly higher incidence than placebo are: constipation (17.3% in HTX-011 vs. 14.6% in placebo group), vomiting (16.9%  vs.  15%),  headache  (11.7%  vs.  8.9%),  tachycardia  (6.5%  vs.  5.3%),  bradycardia  (6.0% vs.4.9%). All subjects in Phase 2b studies (209 and 211), 71.3% of subjects in 301 study and 48.5% in 302 study received rescue medication, upon request, for pain control (mainly oxycodone, morphine, fentanyl) during the 72-hours postoperative period. The role of the systematic use of opioids during the 72-hours postoperative period in these major surgeries (mammoplasty, TKA) cannot be ruled out in 'constipation', 'vomiting' and 'headache' onset. Among opioid-free subjects in study 302, the frequency of local inflammatory AEs is higher in the HTX-011 group than placebo group (6% vs. 0%), as well as the  following  AEs:  'skin  odour  abnormal'  (11.9%  vs.  0%),  'dysgeusia'  (11.9%  vs.  0%)  and 'bradycardia' (9.5% vs. 5.6%). All these AEs are reflected in the proposed section 4.8 of Zynrelef SmPC. The applicant considered the following TEAEs as drug-related, and added these TEAEs to the proposed section 4.8: 'dysgeusia', 'skin odour abnormal', 'dizziness', 'injection site reaction', 'hypotension' and 'bradycardia'.  Regarding  the  potential  gastrointestinal  effect  of  meloxicam,  no  specific  issue  was identified, except 2 cases of haematochezia (in studies 209 and 301) considered unlikely drug-related by the investigator. Regarding LAST-related TEAEs, in studies 301 and 302, dizziness, bradycardia, hypotension, dysgeusia, muscle twitching, were reported as more frequent compared to the placebo group, but with a similar frequency  than  the  bupivacaine  HCl  control  groups.  Taken  individually,  some  of  LAST-TEAEs  are identified more frequently in HTX-011 groups than placebo and with a similar or higher frequency than bupivacaine  groups  (namely  'hypotension',  'bradycardia'  and  'tinnitus'  in  study  209  cohort  2; 'hypotension'  in  study  211;  'dizziness',  'bradycardia',  'hypotension'  in  study  301;  'bradycardia', 'dysgeusia', 'paresthesia'/'paresthesia oral', 'sinus arrhythmia', 'vision blurred', in study 302). As mentioned  by  Vasques,  MD  et  al. 4  (2015),  'confusion,  dizziness,  tinnitus,  dysgeusia,  hallucinations, slurred speech, gait problems, limb twitching, extremity paresthesia, intention tremor, hypotonia, and facial  sensorimotor  and  eye  movement  abnormalities  [are  minor  central  nervous  system  (CNS) abnormalities] and defined as prodromal manifestations of toxicity when they occurred either alone or before major signs of toxicity'. The authors identified these prodromal signs as the most frequent CNS manifestations of LAST. Similarly, they identified hypotension and bradycardia as the most frequent signs of cardiovascular toxicity. In 203 study, 5 subjects reported TEAEs potentially suggestive of LAST in the HTX-011 400mg/12mg group  by  instillation:  2  subjects  experienced  'dizziness',  one  subject  'bradycardia',  one  subject 'paresthesia' and one subject 'tinnitus' (which belong to possible symptom of bupivacaine-related CNS toxicity).    In  study  211,  one  subject  experienced  tremor  and  dizziness  (plasma  concentration  of bupivacaine of bupivacaine Cmax &gt;1,000 ng/mL) and one experienced dysgeusia (bupivacaine Cmax &gt;1,000 ng/mL). In study 209 study (cohort 2) ventricular tachycardia was reported in a subject receiving HTX-011 400 mg/12 mg with ropivacaine 50 mg (bupivacaine Cmax &gt;2,000 ng/mL), 2 subject reported dizziness (Cmax &lt;1,000 ng/mL) and 1 reported bradycardia (bupivacaine Cmax &lt;500 ng/mL). In study 202 one subject experienced a potential LAST-related TEAE of dizziness resolved within 5 minutes (Cmax bupivacaine &gt;1000 ng.mL). As expected, higher plasma concentrations of bupivacaine were associate Medicinal product no longer authorised

4  Vasques F, Behr AU, Weinberg G, Ori C,Di Gregorio G. A Review of Local Anesthetic Systemic Toxicity Cases Since Publication of the American Society of Regional Anesthesia Recommendations: To Whom It May Concern. Regional Anesthesia and Pain Medicine 2015; 40(6): 698-705.

<div style=\"page-break-after: always\"></div>

with the highest incidence of LAST-related TEAEs (30% in subjects for which bupivacaine Cmax &gt; 800 ng/mL; 41% with Cmax &gt; 1000 ng/mL; 100% with Cmax &gt; 2000 ng/mL). Ventricular tachycardia, tremor, severe dizziness pertained to the list of signs or symptoms suggestive of cardiovascular or central nervous system toxicity of bupivacaine. These potential risks are adequately labelled in section 4.4 of the proposed Zynrelef SmPC. The incidences of potential LAST-related TEAEs with rapid onset (less than 1 hour) in HTX-011 groups in Phase 2b and 3 studies were similar to those for bupivacaine HCl. Taking into account that the Tmax of bupivacaine HCl is approximately 1 hour and the Tmax of bupivacaine contained in Zynrelef is 4 hours minimum and the theoretical release of bupivacaine during 72 hours, the similar incidence of the majority of rapid LAST-related AEs, especially in study 302 (HTX-011 300 m/9mg  vs.  bupivacaine  HCl  75  mg  group),  remains  not  fully  explained  and  clarified. The  causal relationship between Cmax and occurrence of LAST-related events is difficult to demonstrate based on the data provided by the applicant. In a general way regarding ALST-related-TEAEs, the applicant use the threshold plasma concentration of bupivacaine of 2,000 ng/mL as unique criteria to characterize an AE as LAST or not, this approach is questionable.

In 208 study, the overall local inflammatory TEAEs is more reported in HTX-011 groups than bupivacaine HCl 50 mg and placebo groups, especially in HTX-011 12 0mg/3.6 mg group. Individually, except blister, all  identified  PTs  were  more  reported  in  HTX-011  groups  compared to  bupivacaine  HCl  and  placebo groups, and erythema is five times and two times more reported in HTX-011 120 mg/3.6 mg group than, respectively, placebo and bupivacaine HCl 50 mg. The applicant states that ' small amounts of HTX-011 drug product were expressed from the surgical site at closure in some subjects potentially impacting the quality of the suturing and causing irritation '  and ' the surgical site may have been under increased pressure with postoperative swelling and the application of a pressure bandage after surgery. This could result in an increase in local inflammatory TEAEs, including delayed healing and dehiscence '. Thus, a large volume administrated into the wound can lead to wound complication and compromise healing and/or conduct to completely cover the wound with pressure bandage leading to a risk of infection. In section 4.2, examples (and no recommendation) of volume to administer are proposed by the applicant for  the  four  surgeries  evaluated  across  Phase  3  and  2b  studies;  in  bunionectomy  the  dose  of  60

Regarding surgical wound healing in bunionectomy studies, in study 301, HTX-011 groups are more associated with delayed healing, wound dehiscence, incision site oedema, incision site infection and cellulitis compared to bupivacaine HCl 50mg and placebo groups. Delayed healing remains twice more reported  after  42  days  in  HTX-group.  Surgical  wound  healing  was  not  been  graded  according  to Southampton Wound Scoring System, whereas the number of wound infections is more reported in this study in HTX-011 groups versus placebo and bupivacaine HCl groups: 'incision site cellulitis' (7 AEs in HTX 60 mg/1.8mg (4.5%) vs 1 AE (1%) in placebo group and 2 AEs (1.3%) in bupivacaine group) ; 'incision site infection' (4 AEs in HTX 60 mg/1.8mg (2.5%) vs 1 AE (0.6%) in bupivacaine group and 0% in placebo group). The applicant provided new outcomes regarding bunionectomy through the study 218 (A Phase 2 Open-Label Study of HTX-011 via Individualized Dosing Administration for Postoperative Analgesia Following Unilateral Simple Bunionectomy) specifically designed to assessed the efficacy and safety with an individualized dose for each subject, precisely because in bunionectomy studies (208 and 301) surgeons noted that amount of HTX-011 drug product was expressed from the surgical site at closure  in  some  subjects  and  might  have  resulted  in  less  successful  wound  closure  and/or  local inflammatory reactions at the incision site. The mean volume of HTX-011 administered in the 3 studied cohort was 1.62 mL, 1.29 mL, and 1.97 mL (which respectively correspond to 77%, 61% and 94% of the maximum volume recommended in the proposed section 4.2 of Zynrelef SmPC). For the specific complications such as 'delayed healing' and 'dehiscence' the incidence of these events is more reported in the lowest HTX-011 volume (1.29 mL) group following by the '1.97 mL' group and then the 2.1 mL group  for  which  the  volume  appears  to  be  an  issue  to  ensure  an  optimal  wound  healing.  The administration of HTX-011, regardless of the administrated volume, seems to be a source of complexity for this specific surgery with a restrictive available space. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

mg/1.8mg (up to 2.1 mL) was given as an example, but surgeons can administer a larger volume. Moreover generally, the sufficient and adequate volume to administer in the surgical site was defined in Phase 3 and 2 studies only for 4 surgical procedures, including bunionectomy for which the 120 mg/3.6 mg was not selected to serve as example of dose to use for this specific surgery. The choice, by surgeons, of the adequate volume to administer to ensure a good wound closure without expressing excess of HTX011 from the surgical site remain difficult to extrapolate for all surgeries as claimed by the applicant, especially those with similar constraints in the available amount of space for the product instillation as bunionectomy. Moreover, the selected populations enrolled in 301, 302 and 209 studies present less risk factors (mainly diabetes) of wound complication in HTX-011 groups than placebo group, this risk could be under-estimated.

In studies 302, 209 and 211 bruising an erythema were mostly reported. In study 209 (cohort 1) other sign of inflammation along or around the wound and clear or haemoserous discharge were more reported than other groups, all resolved with a similar frequency than placebo group at day 28. In study 202, all local  inflammatory  TEAEs,  except  erythema,  were  more  reported  in  HTX-011  groups  compared  to bupivacaine HCl and placebo groups. Wound dehiscence and impaired healing are mainly mild in severity, and except one patient with impaired healing, all were resolved without sequalae. No specific safety issue emerged regarding bone healing impairment. Four subjects experienced bone healing or bone mal-union in study 301 and 208 in bunionectomy, but all reported non-compliance with postoperative therapy or following an accident. Serious TEAEs are similarly reported between HTX-011, bupivacaine and placebo groups across Phase 3 and 2b studies. Fourteen serious TEAEs were reported, including 3 not related to study drug, 2 of them reported  alternative  explanations  (breast  implant  perforated  during  the  surgery;  thoracic  vertebral fracture after fall at home) or with a reasonable incompatible chronology (diagnosis of bile duct and intestinal  perforation  few  hours  after  receiving  HTX-011).  Two  subjects  experienced  serious  post procedural complication (Incision site haematoma, resolved after 1 day and cellulitis, resolved after 10 days). No fatal case was reported in all HTX-011 groups. Anaemia was reported with the higher incidence in the 400 mg/ 12 mg HTX-011 (5.2% v 1.9% in saline group and 0 in bupivacaine HCL group) in phase 3 study. The applicant stated that this AE is more likely associated with the type of the surgery. However, given that meloxicam belongs to NSAID class, possible effects on coagulation processes must considered. Gastrointestinal bleeding was indicated as an AE of special interest by the applicant due to pharmacological effects of meloxicam. Four events of GI bleeding were reported in the HTX-011 group, though all were considered not HTX-011 treatment related by the investigator. Overall significant shifts from baseline to high at 24h, 72 h and 10 days timepoints were reported for WBC count, neutrophil differential and neutrophil counts in HTX-011 group compared to placebo. WBCs, neutrophil differential, and neutrophil counts were the highest at 24 hours and then decreased at 72 hours and Day 10 in both placebo and HTX-011 group. However, difference in shifts from baseline to high for WBC count, neutrophil differential and neutrophil counts reported in HTX-011 group compared to  placebo  was  not  properly  discussed  by  the  applicant.  As  requested,  the  applicant  has  provided discussion on these findings and argues that, from the one hand these findings are likely related to surgery type, and from the other hand no clinically meaningful related adverse effects were observed (such as infections or infestations). In light of this, it was concluded that these findings do not change the risk/benefit profile for Zynrelef. Medicinal product no longer authorised

Evaluation of hepatic function has been performed in line with FDA's Guidance for Industry. Clinical chemistry parameters were evaluated based on proportions of subjects with shifts in values from normal

<div style=\"page-break-after: always\"></div>

at baseline. No clinically meaningful differences were observed comparing pooled HTX-011 group and placebo group, as well as data reported from supportive Phase 1 and 2a studies. Observed deviations from baseline levels in hepatic and renal parameters were not associated with TEAEs.

Higher rates in shift from normal baseline to high was reported for ALP in HTX-011 400 mg/12 mg and 200 mg/6 mg and bupivacaine HCl 125 mg at Day 10 compared with 72 hours. A similar trend was observed also for pooled saline placebo. Increased levels in ALP were observed following TKA. Since ALP is commonly used osteoblast marker these findings were explained by specific type of surgery (TKA), what is generally agreed. The only evaluated parameter characterizing renal function was blood urea nitrogen (BUN). No clinically meaningful differences in shifts from baseline were observed between HTX011 and placebo groups. The provided data do not suggest significant difference in the safety profile depending on patients age. In HTX-011 group any TEAEs were reported with slightly higher incidence in patients &gt; 65 years. Overall incidence of any TEAEs was similar between patients below and above 65 years in total bupivacaine group. Incidence of local inflammatory TEAEs was slightly higher in patients &gt; 65 years in HTX-011 group,  but  significantly  lower  in  total  bupivacaine  HCL  group  and  similar  in  placebo  group.  Lower incidence of any potential LAST related AEs was reported in patients &gt; 65 years. No studies on potential drug-drug interactions were conducted with HTX-011. Safety information relating to drug-drug interactions was based on information provided in the SmPC for already approved products: Marcaine and bupivacaine solution for injection 2.5 mg/mL and 5 mg/mL and and Melox 10 mg/mL solution for injection (Meloxicam Injection SmPC 2017). The potential drug-drug interactions were not evaluated and discussed within the scope of pooled safety assessment provided in support of this MA submission. Although, both active substances are well known with established safety profile, information on potential effects of concomitant use of HTX-011 and other drugs of interest would be valuable for further risk/benefit assessment. As requested, the applicant provided the detail of subjects who were administered a drug that could interfere with hemostasis and a brief analysis of TEAEs occurred in these subjects. Based on the presented data, any specific  safety  risks  were  not  identified  in  subject  with perioperative exposure to drugs that interfere with hemostasis or loop diuretics. The following uncertainties remain: the safety profile seems to be variable depending on the type of surgery and the characteristics of surgical site (systemic exposure to bupivacaine may vary depending on  the  vascularised  area,  size  of  the  wound  and  amount  of  space  available  for  Zynrelef  leading  to complications). 2.6.2. Conclusions on the clinical safety In general, Zynrelef displays a risk profile corresponding to well-known substances used in the fixed combination. In the development program of HTX-011, the safety of the product was evaluated in only 4  surgical  procedures  involving  specific  doses  (ranging  from  60  mg/1.8  mg  to  400  mg/12  mg) corresponding to specific volume to instil directly in the wound before suturing (ranging from 2.1 to 14 mL) in populations mainly receiving rescue medication (opioids). No specific safety issue which can be related  to  meloxicam  was  identified,  but  although  it  seems  that  the  risk  of  AEs  related  to  systemic exposure to meloxicam is rather low, possibility of such risk should not be underestimated, especially in specific subpopulations. Two specific concerns remain as uncertainties. Medicinal product no longer authorised

The first concern is related to the passage of bupivacaine into the bloodstream and compatible with the potential onset of LAST-related TEAEs (CNS and CV). Despite of the fact that Zynrelef allows to avoid the  use  of  inadvertent  intravascular  injection  and  limit  bupivacaine  systemic  exposure,  high  plasma concentrations of bupivacaine associated with LAST-related TEAEs have been identified and the incidence of certain LAST-related and rapid onset (less than 1 hour) LAST TEAEs is quite similar between HTX-011

<div style=\"page-break-after: always\"></div>

and bupivacaine HCl groups. Zynrelef being use in a single administration, the dose cannot be reduced after instillation to better manage AEs.

| Important identified risks   | None                        |
|------------------------------|-----------------------------|
| Important potential risks    | Wound healing impairment no |
| Missing information          | Use in breast feeding women |

<!-- image -->

The second concern is related to the administration of an 'adequate volume' of the product in the surgical site to ensure both a good wound closure with no dehiscence and no expression of an excess of Zynrelef from the surgical site. In a surgery with a restrictive available amount of space for ensuring a complete instillation such as bunionectomy, even a reduction of the volume instilled seems not to ensure conclusive results on wound healing complications. In order to further monitor and characterize this risk, 'wound healing complications' should be included as an 'important potential risk' in the Zynrelef RMP, at least to closely monitor this concern in post-marketing experience in PSURs. The safety profile seems to be variable depending on the type of surgery and the characteristics of surgical site (vascularisation, size of the wound and amount of space available for HTX-011). Risk Management Plan Safety concerns Summary of safety concerns Table 50 Important identified risks None Important potential risks Wound healing impairment Missing information Use in breast feeding women Pharmacovigilance plan Routine pharmacovigilance is considered sufficient to monitor the safety of the product in the approved indication. No additional PV activities are envisaged for bupivacaine / meloxicam. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 51: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

<!-- image -->

Safety concern Risk minimisation measures Pharmacovigilance activities Important identified risks None N/A N/A Important potential risks Wound healing impairment Routine risk minimisation measures: SmPC section 4.2 SmPC section 4.8 PL section 2 Additional risk minimisation measures: None Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Missing information Use in breast feeding women Routine risk minimisation measures: SmPC section 4.6 PL section 2 Additional risk minimisation measures: None Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None Conclusion The CHMP and PRAC considered that the risk management plan version 2.0 is acceptable. 2.7. Pharmacovigilance Pharmacovigilance system Medicinal product no longer authorised

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

<div style=\"page-break-after: always\"></div>

## Periodic Safety Update Reports submission requirements

Based on fact that Zynrelef is a new combination in a new formulation, the CHMP is of the opinion that a separate entry in the EURD list for Zynrelef is needed, as it cannot follow the already existing entry for bupivacaine only. The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did not request the alignment of the new PSUR cycle with the international birth date (IBD). The new EURD list entry will therefore use the EBD to determine the forthcoming Data Lock Points.

Postoperative pain management practice guidelines and clinical studies endorse the use of a multimodal or balanced approach defined as the use of multiple antinociceptive agents with different mechanisms of action. That is, pain is best managed using a combination of methods including regional anesthetic and analgesic  techniques  (e.g.  nerve  blocks,  local  wound  infiltrations,  epidural  catheters)  along  with systemically administered drugs (Schurr 2004). Generally, a systemic opioid is complemented by one or more adjuvant agents (Meissner 2015).

2.8. Product information 2.8.1. User consultation The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. 2.8.2. Labelling exemptions A request to omit certain particulars from the labelling as per Art.63.3 of Directive 2001/83/EC has been submitted by the applicant and has been found acceptable by the QRD Group for the following reasons: Based on a justification mainly relating to the limited space of the immediate container, the Group agreed to allow minimum particulars on the 20 mL vial label. The Group also agreed not to repeat the route of administration provided the final EDQM agreed terms for the pharmaceutical form reflect the route of administration. The latter condition was not fulfilled as the finally agreed terms for the pharmaceutical form ' prolonged-release wound solution ' did not reflect the route of administration (intralesional use). The RoA shall be reflected in the vial label. 3. Benefit-Risk Balance 3.1.1. Disease or condition Zynrelef is intended for treatment of postoperative pain. Up to 70% of patients have moderate to severe pain after surgery and the most severe pain occurs within the first 72 hours. 3.1.2. Available therapies and unmet medical need Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Opioids use is a major element of postoperative pain management. However, as the single therapeutic entity causes significant problems such as ventilatory impairment, sedation, nausea and vomiting, and delayed  recovery  of  bowel  function.  These  adverse  effects  endanger  patient  safety  and/or  impair recovery and rehabilitation and thereby delay discharge from hospital.

The recognised  advantages  of  multimodal  analgesia  are  the  following:  improved  analgesia,  reduced opioids requirements and reduced adverse effects of opioids. Bupivacaine HCl is a common medicine used for post-surgical analgesia as one of the long acting local anaesthetics, but even so it has a limited duration of action after local administration, usually reported as less than 8-12 hours. Alternative  local  anaesthetic  treatment  options  are  needed  as  part  of  multimodal  therapy  to  better manage post-surgical pain that offer extended duration and greater magnitude of analgesic effects. 3.1.3. Main clinical studies The main evidence for efficacy submitted is two phase 3 multicentre, randomized double-blind, placeboand active-controlled comparing: · HTX-011 60 mg / 1.8 mg (2.1 mL) administered via instillation (n=157) vs saline placebo (2.1 mL) administered via instillation (n=100) or bupivacaine 0.5%, 50 mg (10 mL) administered via injection (n=155) in adult subjects undergoing primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation. · HTX-011 300 mg / 9 mg (10.3 mL) administered via instillation (n=164) vs saline placebo (10.3 mL) administered via instillation (n=82) or bupivacaine 0.25%, 75 mg (30 mL) administered via injection (n=172) in adult subjects undergoing unilateral open inguinal herniorrhaphy. In addition, one cohort of a phase 2 study has been classified as pivotal by the applicant. It was a multicentre, randomized double-blind, placebo- and active-controlled study comparing: · HTX-011, 400 mg / 12 mg (13.7 mL) administered via instillation (n=58) or HTX-011, 400 mg / 12 mg (13.7 mL) + ropivacaine administered via instillation (n=56) vs saline placebo administered via periarticular  injection  (n=53)  or  bupivacaine  HCl  0.25%,  125  mg  (50  mL)  administered  via periarticular injection in in adults undergoing total knee arthroplasty (TKA) (n=55). 3.2. Favourable effects According to the primary analysis for phase 3 studies, Zynrelef (HTX-011), at the doses of bupivacaine 60 mg / meloxicam 1.8 mg and bupivacaine 300 mg/ meloxicam 9 mg, was superior to placebo (primary endpoint) and to bupivacaine HCl (first key secondary endpoint) to manage postoperative pain for 72 hours in bunionectomy and herniorrhaphy measured by mean AUC0-72 of the NRS-A pain intensity scores using wWOCF in the ITT population. Medicinal product no longer authorised

These outcomes were supported by key secondary endpoints showing a reduced opioid consumption and higher proportion of opioid-free subjects over 72 hours. It is estimated that Zynrelef has a clinically significant effect on reduction of pain scores during at least the first 24 hours post-dose and the applicant successfully justified an opioid sparing effect associated with a decrease in ORAE in bunionectomy and herniorrhaphy. This opioid sparing effect of Zynrelef is considered as modest but clinically significant.

The  proportion  of  subjects with  severe  pain  (≥7/10) was  significantly  reduced  in  HTX-011  group compared with saline placebo and bupivacaine HCl based on NRS-A (wWOCF, ITT population).

<div style=\"page-break-after: always\"></div>

In study 209 in TKA, Zynrelef (HTX-011) bupivacaine 400 mg / meloxicam 12 mg was superior to placebo (mean AUC of NRS-R pain intensity scores using wWOCF in the defined ITT population over 48 hours (primary endpoint) and over 72 hours (key secondary endpoint) compared with saline placebo.

<!-- image -->

In study 211 in augmentation mammoplasty, HTX-011 400 mg/12 mg, administered as a single dose via nerve block (NB) or via instillation, was superior on the primary endpoint (mean AUC0-24 of the NRS-A pain-intensity scores using wWOCF in mITT Population) compared with saline placebo. 3.3. Uncertainties and limitations about favourable effects · Studied models in Zynrelef's development programme represent moderate to severe somatic pain  model  (Bunionectomy  study  301,  208;  Total  knee  arthroplasty  study  209)  and  mixed somatic/visceral mild to moderate pain (Herniorrhaphy study 302, 202 and supportive study in Augmentation mammoplasty). There is no provided data on the analgesic effect of HTX-011 in visceral  moderate to severe pain models or mixed somatic/visceral moderate to severe pain models,  which  represents  major  abdominal,  thoracic  or  vascular  surgeries. Therefore,  the originally requested broad indication has been restricted . · Uncertainties remain on the clinical significance of the effect in tested surgeries because the  primary  endpoint  of  phase  3  studies  is  only  partially  endorsed in  line  with  the scientific advice, and the minimum difference that would be considered as clinically significant when comparing AUC of pain intensity scores has not been justified. · In studies 301 and 302 (bunionectomy and herniorrhaphy) , it could not be excluded that the effect size on pain (AUC of NRS scores) and decreased opioid consumption on the overall interval (0-72 hours) may be mainly driven by the effects size on the first day post-dose (0-24 hours). In addition, measure of opioid sparing effect is limited by study design (no 'patient controlled  analgesia')  and  to  a  lesser  extent  by  the  concomitant  use  of  paracetamol  rescue medication. · Phase 2 studies in total knee arthroplasty (TKA) and augmentation mammoplasty were not designed or powered to allow a comparison to bupivacaine HCl. · In TKA study , the primary and key secondary endpoint only considered a comparison against placebo. Moreover, the small opioid sparing effect was not associated with a decrease  in  prespecified  ORAEs and  is  not  considered  as  clinically  significant. Phase  3 confirmatory results , including comparison of mean AUC0-72 of pain intensity scores between Zynrelef and bupivacaine HCl as a primary or first key secondary endpoint, would be necessary to include total knee arthroplasty as a therapeutic indication of Zynrelef. · Augmentation mammoplasty study (211) was an exploratory study where reduction in mean AUC of the NRS-A score through 24 hours (NRS-A0-24; primary endpoint) was showed for HTX-011 administered via instillation (and via nerve block) compared with saline placebo. After 24 hours post-dose, there is no clinically meaningful difference in pain scores between HTX-011 400 mg/12 mg and both control groups . Mean and median total opioid consumption in MME over 72 hours were numerically higher in HTX-011 400 mg/12 mg administered via instillation compared to both control groups. These results are not sufficient to assess B/R in augmentation mammoplasty. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

LAST-related (CV and CNS) depend on the passage of bupivacaine into the bloodstream. Despite the fact that Zynrelef allows to avoid the use of inadvertent intravascular injection and limit bupivacaine systemic exposure, high plasma concentrations of bupivacaine associated with LAST-related TEAEs have been identified and the incidence of certain LAST-related and rapid onset (less than 1 hour) LAST TEAEs is quite  similar  between  HTX-011  and  bupivacaine  HCl  groups.  Zynrelef  being  used  in  a  single administration, the dose cannot be reduced after instillation to better manage AEs.

Impaired healing and local application site TEAEs are of particular interest for this product. Impaired healing was reported with slightly higher incidence in pooled HTX-011 group (2.0% versus 1.5% in bupivacaine  HCL  and  0.4%  in  normal  saline  groups).  The  risk  of  local  TEAEs  and  wound  healing complications is not dose-dependent but seems to be related to the surgical site and the volume available to instil the product and suturing. In a surgery with a restrictive available amount of space to ensure a complete instillation as bunionectomy, even a reduction of the volume instilled seems not to ensure conclusive results on wound healing complications. In  conclusion,  the  most  important  identified  risks  of  Zynrelef  are  LAST-related  symptoms  and complications of wound healing in surgery with a small available space to instil the product. Although it seems that the risk of AEs related to systemic exposure to meloxicam is rather low, the possibility of such risk should not be underestimated, especially in specific subpopulations. 3.5. Uncertainties and limitations about unfavourable effects The  safety  data  emerged  from  subjects  undergoing  4  different  surgical  procedures  (bunionectomy, mammoplasty, herniorrhaphy and TKA), in 4 different surgical sites (2 bony models and 2 soft tissue models) each with its own characteristics (specific anatomic spaces, vascularity, post-surgical level of pain) across heterogeneous populations receiving, for the large majority of the pain medication (opioids and non-opioids ' on demand ' with specific dose regimen for each subject) and with different doses of HTX-011 (ranging from 60mg/1.8mg (bupivacaine meloxicam) to 400mg/12mg). These heterogeneous characteristics represent a limit to draw an accurate conclusion regarding the HTX-011 safety profile. Safety issues such as LAST and complications of wound healing seems depend on the type of surgery (which could be explained by the different characteristics of each surgical site, i.e. vascularization, space available to instil the product). In the absence of specific studies, it seems difficult to extrapolate the safety profile in other surgical procedures. Hence, the indication was restricted accordingly. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect      | Short Description Unit                                            | HTX-011          | Placebo          | Bupivacaine HCL   | Uncertainties/ Strength of evidence                                                                                       | References         |
|-------------|-------------------------------------------------------------------|------------------|------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------|--------------------|
|             | Favourable Effects                                                | no               |                  |                   |                                                                                                                           |                    |
| Pain relief | Mean AUC 0-72 of the NRS-A Pain Intensity Scores (SD) AUC         | 323.29 (182.641) | 445.34 (155.792) | 393.5 (153.756)   | HTX-011 vs Placebo : -122.05 [-163.76, - 80.34], p<0.0001 HTX-011 vs Bupivacaine HCl: -70.16 [- 107.07, -33.25], p=0.0022 | 301: bunionectomy  |
| Pain relief | Mean AUC 0-72 of the NRS-A Pain Intensity Scores (SD) AUC product | 269.39 (173.719) | 350.82 (171.224) | 341.88 (158.303)  | HTX-011 vs Placebo: -81.43 [-125.83, - 37.02], p=0.0004 HTX-011 vs Bupivacaine HCl: -72.49 [- 108.32, -36.65], p<0.0001   | 302: Herniorrhaphy |
|             | Unfavourable Effects                                              |                  |                  |                   |                                                                                                                           |                    |

3.6. Effects Table Table 52: Effects Table for Zynrelef. Unfavourable Effects Medicinal product no longer a

<div style=\"page-break-after: always\"></div>

| Effect        | Short Description                                         | Unit   | HTX-011                  | Placebo               | Bupivacaine HCL       | Uncertainties/ Strength of evidence                                                                             | References         |
|---------------|-----------------------------------------------------------|--------|--------------------------|-----------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------|--------------------|
| TEAEs         |                                                           | %      | 84,1                     | 81,4 longer           | 81,4                  | Safety profile is dependent on the type of surgery. Therefore, pooling of the data has significant limitations. | Phase 2b/Phase 3   |
| LAST          | Including Hypotension, Dizziness, Bradycardia, arrhythmia | %      | Female 36.0 Male 32.5 no | Female 30.0 Male 34,4 | Female 41,7 Male 44.1 |                                                                                                                 | Study 301/302      |
| Wound healing | Including delayed healing, dehiscence product             | %      | 2.0                      | 0.4                   | 1.5                   |                                                                                                                 | Pooled safety data |

Medicinal product no longer a

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

3.7.1. Importance of favourable and unfavourable effects Zynrelef has been assessed at different doses and in different types of surgical models (bunionectomy, herniorrhaphy, total knee arthroplasty and augmentation mammoplasty). Considering the efficacy of the new product in treatment of acute pain the Guideline on the Clinical Development of Medicinal Products Intended for the Treatment of Pain states, that ' The efficacy profile of  a  new  product  should  normally  be  established  in  separate  studies  for  both  somatic  and  visceral nociceptive pain ' and 'to justify a general indication for the treatment of acute pain, efficacy needs to be demonstrated independently in models of both somatic and visceral pain, or in models of somatic pain and mixed somatic/visceral pain '. In the case of Zynrelef, the studied models represent moderate to severe somatic pain model (Bunionectomy study 301, 208; Total knee arthroplasty study 209) and mixed somatic/visceral mild to moderate pain (Herniorrhaphy study 302, 202 and supportive study in Augmentation mammoplasty). There is no data provided on the analgaesic effect of HTX-011 in visceral moderate to  severe  pain  models  or  mixed  somatic/visceral  moderate  to  severe  pain  models, which represents major abdominal, thoracic or vascular surgeries .  The applicant argument to replace missing  pain  models  with  the  mechanism  of  action  of  the  fixed  combination  is  not  endorsed  as justification it is based only on an assumption. The current evidence cannot be extrapolated to pain models not studied (e.g. use in thoracic, large abdominal or vascular surgery) and should be limited to pain models studied in phase 3 (bunionectomy, open inguinal herniorrhaphy) with reasonable extrapolation based on those overall positive phase 3 results. In studies 301 and 302 (bunionectomy and herniorrhaphy) , uncertainties remain on the clinical significance of the effect in tested surgeries because the primary endpoint of phase 3 studies is only partially endorsed in line with the scientific advice and the minimum difference that would be considered as clinically significant when comparing AUC of pain intensity scores has not been justified. It should be moreover considered that intrinsic factors with incidence on pain management should be considered across different types of surgery. In addition, it could not be excluded that the effect size on pain (AUC of NRS scores) and decreased opioid consumption on the overall interval (0-72 hours) may be mainly driven by the effects size on the first day post-dose (0-24 hours). However, it is estimated that Zynrelef has a clinically significant effect on reduction of pain scores during at least the first 24 hours post-dose and the applicant successfully justified an opioid sparing effect associated with a decrease in ORAE in bunionectomy and herniorrhaphy. This opioid sparing effect of Zynrelef is considered as modest but clinically significant. Medicinal product no longer authorised

<!-- image -->

Overall, Zynrelef's safety profile is in line with the known safety profile of bupivacaine , no specific safety issue which can be related to meloxicam was identified. However, the safety profile seems to be variable depending  on  the  type  of  surgery and  the characteristics of surgical site (vascularisation, size of the wound and amount of space available for HTX-011). The applicant claimed a  broad  indication  to  reduce  postoperative  pain,  but  to  date,  based  on  safety  data  reviewed  for bunionectomy, mammoplasty, herniorrhaphy and TKA, the extrapolation of Zynrelef safety to other surgical sites seems difficult to determine . Hence, the indication was restricted. Furthermore, two specific concerns remain to consider as uncertainties.

<div style=\"page-break-after: always\"></div>

The first concern is related to the passage of bupivacaine into the bloodstream and compatible with the potential onset of LAST-related AEs (CNS and CV). Despite of the fact that Zynrelef allow to avoid the use  of  inadvertent  intravascular  injection,  the  incidence  of  certain  LAST-related  AEs  is  quite  similar between Zynrelef and bupivacaine HCl groups (especially in study 302). Regarding LAST-related AEs, higher plasma concentrations of bupivacaine were associated with the highest incidence of LAST-related AEs, but a formal causal relationship between these concentrations and the occurrence of LAST-related AEs remain difficult to demonstrate.

The second concern is related to the administration of an 'adequate volume' of the product in the surgical site to ensure both a good wound closure with no dehiscence and no expression of an excess of Zynrelef from the surgical site . In a surgery with a restrictive available amount of space for ensure a  complete  instillation  as  bunionectomy,  even  a  reduction  of  the  volume  instilled  seems  not  ensure conclusive results on the reduction of the major wound healing complications. 3.7.2. Balance of benefits and risks The benefit/risk balance of Zynrelef is considered positive. 3.7.3. Additional considerations on the benefit-risk balance NA 3.8. Conclusions The overall B/R of Zynrelef is positive. 4. Recommendations Outcome Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Zynrelef is favourable in the following indication: Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1). The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions: Conditions or restrictions regarding supply and use Medicinal product subject to restricted medical prescription. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. An updated RMP should be submitted: · At the request of the European Medicines Agency; · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. Additional risk minimisation measures Not applicable Obligation to conduct post-authorisation measures Not applicable Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States Not applicable Medicinal product no longer authorised